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ABSTRACT 
 Parkinson’s disease (PD) is a progressive neurodegenerative disorder 
characterized by loss of dopaminergic function, leading to the classical clinical signs of 
tremor, bradykinesia and loss of postural balance.  These motor symptoms occur late in 
the disease, and since the treatments for late-stage PD are largely ineffective, a better 
understanding of the early stages of PD is needed in order to prevent and treat the 
disease.  The early disease process is still poorly understood, however, and current 
difficulties in diagnosing prodromal or very early-stage PD make clinical studies 
challenging.  Therefore, animal models of early PD are an invaluable resource in 
discovering the neuropathological, behavioral and biochemical features of the early 
stages of neurodegeneration found in PD.  Early PD is associated with non-motor 
clinical signs such as changes to sleep patterns, olfactory functions, cognition and 
mood; while gross motor function is largely compensated for until the later stages of 
dopaminergic neurodegeneration.  The nature of these early clinical signs presents a 
challenge when assessing PD models, however, as subtle sensory and affective 
changes can be difficult to quantify in animals. The goal of this work, therefore, was to 
investigate morphological changes to the dopamine neurons most implicated in the 
development of PD.  Morphological endpoints, which can be robustly quantified using 
unbiased stereological analysis, provide information about the changes occurring to the 
neuronal structure during the neurodegenerative process, and offer promise as an 
objective method to assess the conditions which render dopamine neurons vulnerable 
in PD, as well as to evaluate new neuroprotectants and therapeutic interventions in 
early PD animal models.  A deficiency in n-3 polyunsaturated fatty acids (n-3 PUFAs), 
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which have been shown to be neuroprotective, has been proposed as a potential factor 
in the vulnerability of dopamine neurons to PD.  In order to determine the effects of n-3 
PUFA deficiency on substantia nigra pars compacta (SNpc) dopamine neurons, 
morphological, behavioral and biochemical endpoints were investigated in the unilateral 
intrastriatal 6-hydroxydopamine (6-OHDA) model of early to moderate Parkinson’s 
disease in Aim 1.  In addition, a method was developed to use a novel staining method 
combining tyrosine hydroxylase (TH) staining with silver nucleolar (AgNOR) staining 
and stereological analysis techniques to quantify the morphological changes induced by 
6-OHDA lesion in dopaminergic neurons in Aim 2.  In Aim 3, this method was then 
expanded to investigate morphological changes to the dopaminergic nucleoli stained 
with AgNOR, which may lend valuable insights into the role of the nucleolus in early PD.  
In Aim 4 the cumulative techniques developed in the previous aims were employed to 
determine the differential morphological changes to the dopamine neurons and their 
nucleoli in the A8, A9 and A10 subpopulations of midbrain dopamine neurons, which 
correspond to the retrorubral field (RRF), SNpc, and ventral tegmental area (VTA), 
respectively.  Although the functions of these different neuronal groups is complex and 
still not fully understood, these regions are differentially affected in PD; and in particular 
the A8 and A10 groups have been associated with the early non-motor effects of PD. 
Therefore the characterization of the differential morphological changes to these 
neurons and their nucleoli could provide valuable insights into the structural changes to 
the neurons induced by the neurodegenerative process, and may be useful in assessing 
early PD interventions in the future.  Overall, this dissertation project contributed to a 
v	  
better understanding of the morphological changes to midbrain dopaminergic neurons 
as determined by stereological analysis in an early model of PD.  
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CHAPTER 1 
BACKGROUND AND SIGNIFICANCE 
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1.1 Significance 
Parkinson’s disease (PD) is a progressively debilitating neurodegenerative 
disorder in which the neurons that produce dopamine are destroyed.  Major clinical 
signs of PD are bradykinesia, resting tremor, rigidity and postural instability.  Other 
motor signs of PD are the inability to blink, “masked” facial expression and impaired 
task coordination.   Non-motor signs include autonomic dysfunctions such as 
constipation, hypotension, urinary frequency, sweating and impotence, as well as sleep 
loss, depression, dementia, and disturbances in olfactory function.   Manifestation of 
symptoms as well as progression rate of the disease can vary greatly among patients 
(Zhao et al., 2010).  
The neuropathology of PD is characterized by loss of melanin-pigmented 
neurons in the substantia nigra pars compacta, and the presence of Lewy bodies, which 
are eosinophilic cytoplasmic inclusions, although Lewy bodies may be absent from 
some familial forms of PD (Takahashi et al., 1994).  Neuronal degeneration and Lewy 
bodies are not restricted to the substantia nigra, however, but may be found in a variety 
of other brain regions such as in the peduncular, raphe, and dorsal motor nuclei; the 
locus coeruleus, olfactory bulb, autonomic neurons and others (Levy et al., 2009).  This 
extranigral degeneration likely contributes to many of the non-motor manifestations of 
PD.  
1.1.1 Diagnosis and progression of early PD 
 PD is often clinically detected at a relatively late stage of neuronal loss, at the 
time that severe tremor and motor deficits manifest (Becker et al., 2002).  However, 
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there are a number of early motor and non-motor indicators of developing PD, including 
olfactory deficits, visual disturbances, sleep dysregulation, and mood and cognitive 
disorders (Becker et al., 2002; Claassen et al., 2010).  
The most commonly used clinical scale of PD progression is the Hoehn and Yahr 
scale introduced in 1967.  Many studies have made an effort to correlate each stage 
with an expected time period, although results of these vary greatly (Zhao et al., 2010).  
This tool assigns patients a score from 1-5 based on motor function and bilateralism of 
symptoms.  However, this scale does not address non-motor signs and functioning of 
the patient. Therefore, additional scales have been developed, such as the Unified 
Parkinson Disease Rating Scale, which monitors PD disability and impairment. 
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Table 1. Diagnosis of PD 
Method  Features Assessed 
Hoehn and Yahr Staging 
of Parkinson’s Disease 
 
Stage 0 No signs of disease 
Stage 1 Mild unilateral symptoms 
Stage 1.5 Unilateral symptoms with axial involvement 
Stage 2 Bilateral symptoms with no balance deficit 
Stage 2.5 Bilateral symptoms with recovery on pull test 
Stage 3 Mild to moderate symptoms, some balance disturbances, 
but patient remains independent 
Stage 4 Severe symptoms, but patient can still walk or stand 
unassisted 
Stage 5 Severe symptoms, and patient is usually wheelchair-
bound or bedridden 
Unified Parkinson 
Disease Rating Scale 
 
Part I: Non-motor 
Aspects of Experiences 
of Daily Living 
Cognitive impairment, depressed mood, sleep disorders, 
constipation 
Part II: Motor 
Experiences of Daily 
Living 
Walking problems, drooling, handwriting difficulties, 
chewing problems 
Part III: Motor 
Examination 
Speech, rigidity, finger tapping, postural instability, 
resting tremor  
Part IV: Motor 
Complications 
Time spent with and functional impact of dyskinesias, 
pain of dystonias, functional impact and complexity of 
motor fluctuations 
Sources: (Hoehn and Yahr, 1967; Goetz et al., 2007) 
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1.1.2 Treatment of PD 
There is currently no cure for PD.  Some patients will progress to a late stage 
within a few years of diagnosis, while others can continue to live independently for 
decades (Zhao et al., 2010).  Current treatments include pharmacological management; 
surgical treatment, deep-brain stimulation, and physical and therapy (see Table 2).  All 
current treatments eventually become ineffective at managing symptoms.   Since 
diagnosis often occurs at a late stage in the disease process, current treatments aim to 
maintain sufficient function for independent living. With the increase in lifespan in 
developed countries, the burden of neurological diseases of aging may reach epidemic 
proportions in the near future, especially as there is a notable lack of effective 
treatments for these diseases (Petsko, 2006).  Therefore understanding the foundations 
of PD, including the effects of diet on the etiology and treatment of PD, will be crucial to 
developing treatments to minimize suffering of PD patients. 
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Table 2. Current Treatments for PD 
Treatment Examples  Mechanism/Notes 
Pharmacological 
Measures 
  
Amantadine  Anti-viral drug, alleviates mild 
symptoms 
Anticholinergics Benztropine 
(Cogentin), 
Procyclidine (Kenadrin) 
Eventually limited by side effects, 
including dry mouth and constipation 
Levidopa/Carbidopa  Sinemet Dopamine precursor combined with 
DOPA decarboxylase Inhibitor to 
prevent Levidopa metabolism in the 
periphery 
Dopamine Agonists Bromocriptine, 
Ropinirole, 
Pramipexole 
Act directly on dopamine receptors. 
Impulse control disorders are a 
notable side effect 
Selective Monoamine 
Oxidase Inhibitors 
Rasagaline, Selegiline Inhibit metabolism of dopamine 
COMT Inhibitors Tolcapone, 
Entacapone 
Blocks metabolism of levodopa to 3-
O-methyldopa, resulting in higher 
plasma dopamine levels 
General Measures   
Physical and/or 
Speech Therapy 
--- Helps patients sustain independent 
living 
Surgical Measures   
Deep Brain Stimulation --- For patients resistant to 
pharmacotherapy- may relieve all 
major symptoms 
Source: (Aminoff and Kerchner, 2011)  
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1.2 Etiology and pathogenesis of PD 
The complex etiological processes resulting in the characteristic parkinsonian 
phenotype may actually be a collection of common results from various causes, making 
PD more accurately a syndrome than a disease.  PD is more than simply loss of 
substantia nigra dopamine neurons, since other neuronal systems are also affected.  
The variability in clinical presentation, progression of disease and age of onset of the 
disease also suggest a multifactorial etiology.  
The “multiple hit” theory encompasses the influences of perinatal anomalies and 
insults, genetic polymorphisms, and postnatal environmental factors to propose that 
initial reduction in dopamine neuron numbers or function makes an individual more 
susceptible to consequent stressors, and therefore more likely to develop PD (Holmäng, 
2001; Carvey et al., 2006a; Barlow et al., 2007).  Damage to the nigral neurons in 
idiopathic PD is likely accrued throughout the lifespan, until clinical signs appear when a 
functional threshold of dopamine neuronal loss is reached.  In addition, substantia nigra 
neurons degenerate as a normal function of age.  This process could be hastened by 
abnormalities in dopamine neuron development, number, or function.   Disease could 
also result from reduced survival factors or accumulated environmental insults. The 
principal factors currently involved in the etiology and pathophysiology of PD are 
reviewed here. 
1.2.1 Genetic factors in PD 
As in other neurodegenerative diseases, genetics have been explored as a 
causative factor of PD.  Although most PD cases have not been linked to genetics, a 
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number of studies have shown that PD is more common in relatives of PD patients than 
in matched controls (Payami et al., 1994; Bonifati et al., 1995; Marder et al., 1996).  
Several familial types of PD have been associated with autosomal dominant or 
recessive inheritance patterns (for review see: (Schapira, 2006; Bekris et al., 2010)).  It 
is likely that many cases of so-called idiopathic PD are actually attributable to genetic 
causes, but conclusive evidence to link most PD cases to genetic causes is lacking.   
Each PD gene has been assigned a “Park” name in addition to being referred to 
by its gene name; e.g. the a-synuclein gene causes Park 1 PD, the parkin gene causes 
Park 2 PD, etc.  Several of the Park variants have not yet been conclusively associated 
with a gene.  The known functions of most of the PD gene products involve the 
ubiquitisome and regulation of mitochondrial oxidative stress.   
Park 1 PD is caused by mutations in the α-synuclein gene, a protein found in 
Lewy bodies (Polymeropoulos et al., 1997; Krüger et al., 1998).   Park 2 involves parkin, 
an E3 ligase which ubiquinates proteins tagged for destruction by the proteosome 
(Shimura et al., 2000; Zhang et al., 2000).  Park 2 mutations are associated with 
autosomal recessive juvenile-onset Parkinsonism (Kitada et al., 1998).  Park 6 is 
caused by mutations in PINK1, a gene associated with a familial form of recessive 
early-onset PD, is involved in the mitochondrial localization of parkin among other 
functions in protein folding regulation (Kim et al., 2008).  Park 7 is caused by DJ1, a 
C56 pepsidase thought to be involved in neuroprotection against oxidative stress 
(Bekris et al., 2010).  Park 8 PD is caused by mutations in LRRK2, a gene which 
encodes a multiple-domain 286-kDa cytoplasmic protein widely expressed in the brain.  
Although its function in the brain is not confirmed, it interacts with parkin (Smith et al., 
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2005).  It is also interesting to note that LRRK2 is the most common mutation identified 
in association with PD, with the LRRK2 G2019S mutation found in 2.8 to 6.6% of 
autosomal dominant PD families and 2 to 8% of idiopathic PD patients (Deng et al., 
2005; Di Fonzo et al., 2005; Gilks et al., 2005; Nichols et al., 2005; Zabetian et al., 
2005).  
1.2.2 Environmental risk factors in PD 
Both epidemiological and animal evidence supports the role of environmental risk 
factors in the development of PD.   Among the various risk factors is a theme of 
neurotoxicity causing acute and/or progressive damage to substantia nigra neurons.  
Some lifestyle factors may be neuroprotective against PD.  The main problem in linking 
environmental risk factors with idiopathic PD is that many of the models generated from 
these factors, while often displaying nigral neurodegeneration, rarely show the 
extranigral pathology of clinical PD.  However, the fact that environmental factors, which 
are mostly oxidative stressors, have been linked to PD supports the “multiple hit” 
hypothesis, and undoubtedly contribute to certain cases of the disease. 
1.2.3 Environmental toxins in PD 
Most of the known environmental toxins involved in PD are agricultural agents.  
In addition, occupational exposure to metals such as aluminum and iron has been 
linked to PD in some studies (Gorell et al., 1999), although it is unlikely that this is the 
cause of most idiopathic PD.  In addition, accidental exposure to 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) by recreational meperidine users led to a number of 
cases of parkinsonism, leading to the groundbreaking MPTP model of PD pioneered by 
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Langston (Langston et al., 1983).  In animal models, rotenone and a combination of 
paraquat and maneb have been shown to cause selective nigrostriatal degeneration 
(McCormack et al., 2002; Barlow et al., 2004; Betarbet and Greenamyre, 2004).   
Animal studies confirm epidemiological findings that PD risk is increased with exposure 
to pesticides, along with other risk factors associated with rural living such as drinking 
well water or living in a certain US states, suggesting that geographical factors such as 
soil and water pollutants may have an effect on nigral neurodegeneration.  Interestingly, 
a recent meta-analysis on risks of rural living and PD found that among the studies 
analyzed, the greatest change in risk was for subjects living in rural areas for more than 
40 years, implicating both the importance of early exposure and cumulative damage to 
substantia nigra neurons (Rajput and Uitti, 1987; Betemps and Buncher, 1993; 
Priyadarshi et al., 2001).  While toxins have not been linked to the vast majority of PD 
cases, they have been an indispensable tool in better understanding the etiology of PD.  
1.2.4 Infection in PD 
Infection has also been implicated in the development of PD.   A well-
characterized cohort of encephalitis patients with parkinsonian symptoms resulted from 
the great influenza epidemic of 1918.  Other viral infections have also been linked with 
PD, such as Japanese encephalitis B, and the St. Louis, West Nile and HIV viruses 
(Jang et al., 2009).  Early-life infections may also play a role in development of PD 
much later in life, and lipopolysaccharide injection animal models have shown 
substantia nigra neurodegeneration.  Epidemiological evidence for the influence of 
infection on PD is inconclusive, probably due to the nature of many of the clinical 
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studies being based on recall questionnaires and to the presence of confounding factors 
and post-mortem artifacts (Logroscino, 2005). 
1.2.5 Diet and lifestyle in PD 
Diet is an environmental factor potentially responsible for PD.   A meta-analysis 
on nicotine and caffeine consumption showed that the risk of PD was 60% lower for 
smokers than non-smokers, and 30% lower for coffee drinkers than in non-coffee 
drinkers (Hernán et al., 2002).  In addition, exposure to nicotine and caffeine in animal 
models showed a neuroprotective effect to dopamine neurons (Maggio et al., 1998; 
Chen et al., 2002).  As in many diseases, dietary fat intake has also been considered as 
a risk factor for PD.  A recent study showed that a high-fat diet enhanced dopaminergic 
neurodegeneration in a 6-hyrdoxydopamine (6-OHDA) rat model of PD (Morris et al., 
2010).  Polyunsaturated fatty acids (PUFAs) are of particular interest since they play an 
important role in brain composition and function, and their role in PD is discussed in 
detail in Section 1.7.   
1.3 Pathogenesis of PD 
1.3.1 Evidence of oxidative stress in PD 
Oxidative stress is the central theme common to most theories of PD 
pathogenesis, although it is not clear whether oxidative stress is a cause or effect of PD, 
or both.  Reactive oxygen species (ROS) are a natural product of cellular metabolism.  
When improperly regulated, ROS can react with cell components and initiate apoptosis 
in mitochondria.  Oxidative stress in cells occurs due to excessive production of ROS or 
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decreased antioxidant mechanism functioning.   Aging itself is a risk factor for oxidative 
stress, as more oxidized proteins are found in aging brains, and markers of oxidized 
DNA are detected in nuclear and mitochondrial DNA in the aged brain (Mariani et al., 
2005).  Brain tissue is inherently susceptible to peroxidation due to its high PUFA 
content.  The oxidative metabolism of dopamine can yield hydrogen peroxide and other 
ROS which contribute to lipid peroxidation (Olanow, 1990).  Increased lipid peroxidation 
products malonaldehyde and hydroperoxide have been found in the substantia nigra of 
PD patients (Dexter et al., 1989).  Another cell-damaging product of lipid peroxidation, 
4-hydroxynonenal, has also been detected in PD dopaminergic neurons (Yoritaka et al., 
1996).  
A number of cellular mechanisms have been proposed to account for the 
oxidative damage in PD.   A decrease in the reduced form of glutathione has been found 
in the substantia nigra of PD patients (Sofic et al., 1992), indicating a reduced response 
to oxidative stressors.  NAPDH oxidase (NOX) is another potential source for the 
oxidative damage occurring in PD.  NOX metabolizes molecular oxygen, generating 
superoxide (Wu et al., 2003).  NOX is upregulated in PD patients (Sumimoto et al., 
2004; Li et al., 2005).  NOX has also been implicated in the neurotoxicty of most PD 
models, including MPTP, lipopolysaccharide (LPS), rotenone, paraquat and α-synuclein 
models (Miller et al., 2009).  
An additional candidate stressor is nitric oxide (NO), produced by nitric oxide 
synthase (NOS).  There are several forms of NOS, including an inducible form activated 
by cytokines and LPS (Duval et al., 1996; Ebadi and Sharma, 2003).  NOS is present in 
some neurons, including microglia  (Shih et al., 2001).   Along with is many signaling 
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roles, NO is also involved in neurotransmitter release, reuptake, synaptic plasticity, and 
gene activation.  Increased NO levels have been found to correlate with increased 
mitochondrial cellular oxidation.  Inhibition of NOS activity is protective in MPTP, 
paraquat and LPS models of PD (Miller et al., 2009). 
1.3.2 Oxidative stress and mitochondrial dysfunction in PD 
A discussion of cellular oxidative stress cannot exclude consideration of 
mitochondria, and there is considerable evidence for mitochondrial origins of PD.  
Mitochondria regulate a number of functions crucial to cells, including oxidative 
metabolism and apoptosis (Kroemer and Blomgren, 2007).  Mitochondrial dysregulation 
of oxygen-handling processes can lead to ROS and subsequent cellular damage and 
death.  Since the dopamine-rich substantia nigra is inherently a high-oxygen 
environment, nigral mitochondria may be particularly susceptible to any imbalances in 
oxidative regulation that develop as a function of age or pathology.  
Aside from general oxidative damage to mitochondria from oxidative stress, PD 
has been associated particularly with Complex I dysfunction.  Reduced activity of 
Complex I has been found in the substantia nigra of PD patients, as well as in their 
cerebral cortex and in blood platelets (Schapira et al., 1990; Haas et al., 1995; Keeney 
et al., 2006).  Interestingly, neuroblastoma cells transfected with PD patients’ platelet 
mitochondrial DNA exhibited Complex I deficiency (Swerdlow et al., 1996).  These 
findings suggest a possible systemic deficit in Complex I activity in PD.  
Models of PD can also be attributed to mitochondrial dysfunction. The most 
notable is the MPTP model.  The active metabolite of MPTP, MPP+, is a mitochondrial 
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Complex I inhibitor (Nicklas et al., 1985).  Additional evidence for mitochondrial 
involvement with PD arises from many of the known mutations associated with the 
disease.  Parkin is a mitochondrial protection factor, and upregulates production of 
Complex I subunits (Darios et al., 2003).  PINK 1 aids in the mitochondrial localization of 
parkin, and PINK1 knockout mice develop mitochondrial dysfunction (Kim et al., 2008; 
Wood-Kaczmar et al., 2008).  DJ-1 translocates to the mitochondria in oxidative stress 
conditions, where is regulates antioxidant defense mechanisms (Takahashi et al., 2001; 
Zhang et al., 2005).    
1.3.3 Oxidative stress and PUFA adduct formation in PD 
The substantia nigra, even under ideal conditions, is highly prone to oxidative 
stress, being rich in both reactive dopamine and in peroxidation-prone PUFAs.   
Recently, Liu et al. (2008) synthesized four adducts of dopamine with peroxidation 
products derived from docosahexaenoic acid (DHA) and arachidonic acid (AA), and 
confirmed the presence of all four adducts in rat brain tissue.  Notably, one of the AA-
derived adducts, hexanoyl dopamine (HED), was found to be significantly more 
cytotoxic, in a dose-dependent manner, to human SH-SY5Y neuroblastoma cells 
expressing monoamine transporters.  Cytotoxicity was not apparent in mouse fibroblast 
cells lacking monoamine transporters, suggesting a toxic specificity of HED for cells 
containing the transporters.   A mitochondrial damage mechanism was proposed for 
HED cytoxicity, as HED led to dose-dependent increases in ROS generation, active 
caspase-3, and cytochrome c release.  These findings suggest that HED is a potent 
stressor to mitochondria in vitro (Liu et al., 2008).  It is likely that HED, and perhaps 
other uncharacterized PUFA-dopamine products, play an important role in the 
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pathogenesis of PD.  In addition to potential scope for dietary interventions to prevent 
adduct formation, these detectable novel adducts may also be utilized in the future as 
diagnostic and/or therapeutic molecular targets.  
1.3.4 Oxidative stress and protein dysfunction in PD 
The main protein in the pathogenesis of PD is α-synuclein.   A commonly 
expressed protein in neurons, it makes up to 1% of all cytosolic neuronal proteins, is 
highly expressed in the substantia nigra, and is a main constituent of Lewy bodies (Iwai 
et al., 1995).  These aggregations are believed to play a role in a number of 
synucleinopathies, such as multiple system atrophy and dementia with Lewy bodies, 
and are a defining feature of nearly all forms of PD.  Possible mechanisms for the 
function of α-synuclein include synthesis of dopamine, dopamine transporter (DAT) 
membrane function and synaptic regulation, chaperone functions, and a role in brain 
fatty acid metabolism (Souza et al., 2000; Cabin et al., 2002; Perez et al., 2002; 
Wersinger and Sidhu, 2003; Gorbatyuk et al., 2010).   A30P and A53T mutations in α-
synuclein cause a rare autosomal dominant familial form of the disease, and both 
mutation and overexpression of wild type α-synuclein are associated with clinical PD, as 
well as nigrostriatal degeneration in animal models (Levy et al., 2009).  
The role that α-synuclein may play in PD pathophysiology is still unclear, but it 
appears that aggregation of the protein is necessary to promote its toxicity.  Monomeric 
α-synuclein is soluble, but oligomers have been isolated from PD brains.  These 
oligomers, called protofibrils, can form insoluble fibrils, which aggregate into Lewy 
bodies, along with ubiquitin and other proteins.  However, the evidence indicates that 
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protofibrils are the more toxic species.  Tyrosine nitration is a reaction product of the 
oxidative stressor peroxynitrite with tyrosine residues, and levels of nitrotyrosine are 
commonly used as a measure of peroxyntrite action in cells (Kuhn and Geddes, 2003).  
Tyrosine nitration of α-synuclein in PD patients blocks conversion of protofibrils to fibrils, 
keeping them in the more toxic state.   A30P and A53T mutations in vitro increase the 
rate of protofibril formation in vitro.  Once formed, α-synuclein protofibrils can affect the 
mitochondria by forming ring-like pores in the mitochondrial membrane, leading to 
membrane permeability and an increase in catecholamines in the cytosol.  In addition, 
cytosolic dopamine is known to interact with α-synuclein and slow the conversion of 
protofibrils to fibrils, increasing their toxic potential (Conway et al., 2000; Rochet et al., 
2004; Levy et al., 2009).  Although its function in the pathogenesis of PD is still unclear, 
the fact that α-synuclein plays a role in several neurodegenerative diseases provides an 
intriguing opportunity to uncover commonalities in their etiology.   
1.3.5 Oxidative stress and the role of iron in PD 
 Iron is a vital component of cellular components and enzymes, such as the heme 
components of cytochrome c and hemoglobin, but it also a dangerously reactive 
element that must be highly sequestered by cells.  Normally free iron is tightly bound to 
proteins such as ferritin and transferrin, but at any time, about 5% of the iron is loosely 
bound to ligands which are not clearly understood, in what is known as the labile iron 
pool.   Dysregulation of this iron has been implicated in a host of human diseases, 
including PD (Kruszewski, 2003; Youdim et al., 2004).  Increased oxidative stress may 
result in free iron being released into the cytoplasm.  Free iron contributes to radical 
formation and subsequent oxidative damage via the iron-catalyzed Fenton-like reaction, 
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which produces excess hydroxyl radicals under conditions of high levels of hydrogen 
peroxide and superoxide anions (Chinta and Andersen, 2008).  It is particularly 
interesting to note that Fe3+ is reduced to Fe2+ in the presence of neuromelanin, 
possibly increasing substrate for the dangerous Fenton-like reaction in the 
neuromelanin-enriched substantia nigra (Mizuno et al., 1995).  Other studies have found 
neuromelanin, which accumulates with aging, to be neuroprotective, as it binds iron and 
blocks the oxidation of dopamine and ascorbic acid, preserving precious antioxidant 
content.  These iron-neuromelanin complexes are degraded by hydrogen peroxide to 
release free iron.  Although the actions of neuromelanin and iron in PD are still unclear, 
it seems that they are both potentially contributory to oxidative stress in the substantia 
nigra (Zecca et al., 2008).   
Iron content of the substantia nigra in PD patients is increased compared to age-
matched controls, although whether the accumulation of iron is an early initiation or late 
response event is unclear.  Iron infusion and high-iron diets in animals have shown 
increased hydroxyl radicals in the striatum and brainstems, and the use of iron chelators 
have attenuated MPTP toxicity in animals (Kitada et al., 1998), as well as showing 
promise in human therapeutics with iron chelators such as V-28 (Chinta and Andersen, 
2008).  Although iron obviously plays a role in the pathophysiology of PD, there is still 
much to be discovered about the mechanisms of its actions in the disease.  
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1.4 The nucleolus in the pathogenesis of PD 
 The nucleolus, an organelle housed within the nucleus, is the site of ribosomal 
RNA (rRNA) assembly, and therefore plays a crucial role in the rapid production of 
ribosomal units in response to cellular signaling (Olson et al., 2000; Boulon et al., 2010).  
The nucleolus houses many proteins that are key to neuronal growth regulation, most 
notably the nucleolar-specific rRNA polymerase Pol1 (Grummt, 2003).  In addition to 
rRNA transcription, nucleolar proteins are tied to a number of functions such as cell-
cycle control, DNA repair and apoptosis (Ahmad et al., 2009b).  The nucleolus is also 
involved in directing the cellular response to stress, and is therefore implicated in 
determining the fate of a degenerating neuron.  The nucleolar membrane is disrupted in 
response to a variety of cellular stressors, leading to dysregulation of a host of cellular 
growth and apoptotic effectors (Baltanás et al., 2011; Boyd et al., 2011).  The pro-
apoptotic protein Bax is bound to the nucleolar chaperone protein nucleophosmin/B23 
in a mouse hypoxic model of stroke.  B23 is released from the nucleolus after hypoxia, 
implicating nucleolar regulation of apoptosis in response to stress.  The nucleolus also 
plays an important role in regulating the cellular proliferation factor p53 (Kerr et al., 
2007).  Disruption to the nucleolar membrane, which regulates p53-driven functions by 
nucleolar sequestration of various factors involved in its interactions (Boulon et al., 
2010).  The importance of basic roles of the nucleolus suggest that any dysfunction on 
the nucleolus will have a downstream effect on neuronal function, which could be 
contributing to the neurodegenerative processes found in Parkinson’s disease. 
 The nucleolus is implicated in the etiology of a number of neurodegenerative 
diseases, such as Alzheimers’, Huntington’s, and Parkinson’s diseases, although the 
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full extent of the relationships between the changes in the nucleoli-related factors and 
disease is still unclear (Hetman and Pietrzak, 2012).  There is considerable evidence for 
nucleolar involvement in the etiology and/or effects of Parkinson’s disease.  Nucleolar 
integrity was compromised in human parkinsonian brains, and nucleolar damage was 
found to occur in an MPTP mouse model of Parkinson’s (Rieker et al., 2011).  The 
nucleolus houses several factors that seem to be key in proper functioning of the 
dopaminergic neuron. The transcription initiation factor 1A (TIF1A) regulates Pol1 under 
the influence of growth factors and stressors.  Selective ablation of TIF1A function in 
adult mouse mutants led to oxidative damage, progressive dopaminergic neuron loss 
and motor dysfunction (Kalita et al., 2008; Rieker et al., 2011).  Nucleolar damage in 
Parkinson’s could also be precipitated by DNA damage, as was demonstrated recently 
when the DNA-topoisomerase-2 inhibitor etoposide inhibited Pol1 and induced nucleolar 
stress indicated by staining for B23/nucleophosmin (Pietrzak et al., 2011).  The growing 
evidence for the role of the nucleolus in mature neuronal growth and regeneration 
makes it an attractive potential target for therapeutics in neurodegenerative disease, 
although much remains to be determined about the role of the nucleolus in 
neurodegenerative disease. 
1.5 The midbrain dopamine neurons 
 The midbrain dopamine neurons comprise the majority of dopaminergic neurons 
in the brain (Mai and Paxinos, 2012).  The major subgroups of these neurons include 
the A8, A9 and A10 groups according to the dopaminergic neuron classification scheme 
devised by Dahlstrom and Fuxe in 1964, and these groups roughly correspond to the 
retrorubral field (RRF), substantia nigra (SN) and ventral tegmental area (VTA) regions 
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of the midbrain, respectively (Dahlstrom and Fuxe, 1964).   Apart from classification 
according to the location of the neurons of origin, the midbrain dopamine neurons are 
often classified by their projections into the mesostriatal, mesocortical and mesolimbic 
dopaminergic pathways (Oades and Halliday, 1987; Graybiel, 1991; Tzschentke and 
Schmidt, 2000) (see Figure 1).  The A8, A9 and A10 groups all contribute to the 
pathways to differing degrees, and are all interconnected with each other (Jimenez-
Castellanos and Graybiel, 1987; Oades and Halliday, 1987; Langer and Graybiel, 1989; 
Gasbarri et al., 1997; François et al., 1999).  This suggests that the separate midbrain 
dopaminergic neuronal subpopulations are interdependent, and may therefore all 
contribute to disorders of dopaminergic function, such as PD (Deutch et al., 1988; Arts 
et al., 1996).  Primates have between three to seven times more midbrain dopaminergic 
neurons than do rats, and the proportions of each neuron group and the topography of 
projections varies between primates and rodents (German and Manaye, 1993; Hosp et 
al., 2011), so these differences are important to consider when applying PD models to 
rodents.   
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Figure 1.   
Origin and major projections of the mesocorticolimbic and nigrostriatal DA 
systems. There are three DA midbrain nuclei: the SNc and SNl (=A9), the VTA (=A10), 
and the RRF (=A8). These neurons give rise to the nigrostriatal and mesocorticolimbic 
DA projection systems. PIR, piriform cortex; OTu, olfactory tubercles.  Reprinted from 
Pharmalogical Reviews (Binder et al., 2001), with permission from The American 
Society of Pharmacology and Experimental Therapeutics. 
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1.5.1 The substantia nigra (A9) dopamine neurons 
  The SN contains the A9 group of midbrain dopaminergic neurons.  Because the 
majority of these neurons project to the striatum and are involved in motor dysregulation 
seen in PD, the SN has been the most extensively studied dopaminergic subregion 
involved in the disease.  The SN lies caudally to the cerebral peduncle and anterior to 
the red nucleus and superior cerebellar decussation (Mai and Paxinos, 2012).  The SN 
is comprised of several subclassified nuclei, including the SN pars compacta, the SN 
pars reticulata (SNr), the SN medialis and the SN lateralis.  The pars compacta, which 
is the most densely populated SN subdivision, is itself often divided into dorsal and 
ventral tiers, the SNCd and SNCv, respectively, and even further subdivisions of these 
divisions based on functional and biochemical differences in the cells (Paxinos, 1995).  
Approximately 300,000-550,000 pigmented SN neurons have been found in controls in 
human stereological studies (Pakkenberg et al., 1991; Rudow et al., 2008).  In rodents, 
stereological analysis has determined between 6000-26,000 TH-positive neurons in the 
SN (Giuseppe. Giovanni, 2010).  Proportions of A9 midbrain dopamine neurons to the 
A8 and A10 groups are much higher in primates than in rodents.  It has been proposed 
that the A9 nuclei increases in humans correspond with the increases in the caudate 
and putamen relative to the volume of limbic and cortical regions (German and Manaye, 
1993).   
 
   The SN provides relay and feedback functions to the basal ganglia, limbic 
structures and the cortex.  The substantia nigra pars SNr largely contains GABAnergic 
neurons which receive input from the basal ganglia and project to the thalamus and 
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visual nuclei, while the SNpc contains mostly TH-positive dopamine neurons which 
project to the motor striatum (Mai and Paxinos, 2012).  Each SNpc dopaminergic 
neuron receives input from about 100 striatal neurons, and itself projects back to about 
5% of the striatum (Percheron et al., 1994; Matsuda et al., 2009).  In addition to its 
sensorimotor-associated striatal connections, the SNpc also projects to areas of the 
striatum receiving input from the associative cortex and limbic structures, involving the 
SNpc in the early PD signs of cognitive and affective dysregulation as well as motor 
dysfunction (Becker et al., 2002; Mai and Paxinos, 2012).   Nigrostriatal SN dopamine 
neurons are also involved in learning behaviors and responding to reward, and these 
processes can be affected in PD as well (Kimura, 1995; Kimura and Matsumoto, 1997; 
Horvitz, 2000; Da Cunha et al., 2009; Wise, 2009).  In PD, the SN dopamine neurons 
are reduced by between 66-80% in stereological post-mortem studies and 50-90% in 
other studies (Hirsch et al., 1988; Pakkenberg et al., 1991; Rudow et al., 2008).  
Regardless of the quantitation method used, it is clear that there is massive SN 
dopamine neuron loss in PD.  However, because most studies in humans have been 
done in late-stage patients and in severe PD models, further studies on the SN in early 
PD are needed to better understand the effects of the early disease process on this 
region.  Evidence suggests that although the SN is heavily associated with the late-
stage motor deficits occurring in PD, it is also likely also partially responsible for the 
visual and non-motor cognitive early signs of PD.  
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1.5.2 The ventral tegmental area (A10) dopamine neurons 
 
 The VTA is involved in motivation, reward, emotion, memory and addiction, and 
as such is heavily implicated in the non-motor signs of PD, as well as in other dopamine 
dysfunction associated disorders such as depression, schizophrenia, ADHD and 
addiction (Tzschentke, 2001; Viggiano et al., 2003; Nestler and Carlezon, 2006; 
Laviolette, 2007; Wise, 2009).  The VTA contains the A10 group of midbrain 
dopaminergic neurons, and is a large and diffuse area dorsomedial to the SN and 
medial and both dorsal and ventral to the red nucleus in humans (McRitchie et al., 
1996).  The VTA neurons are smaller than those of the SN, however, and lower in 
degree of pigmentation.  There are approximately 120,000 pigmented neurons in the 
VTA (about 20% of total VTA neurons) (McRitchie et al., 1997), and approximately 
18,000 pigmented VTA neurons in the rat (60% of total VTA neurons) (Halliday and 
Törk, 1986).  The proportion of A10 neurons to the total midbrain dopaminergic neuron 
population is much higher in rodents than in primates (German and Manaye, 1993), 
which is important to keep in mind when performing studies on this region.   
 
 The VTA projects to the structures in the mesocortical and mesolimbic pathways, 
including the prefrontal cortex, hippocampus, nucleus accumbens, amygdala, and the 
olfactory tubercle (Oades and Halliday, 1987; Ikemoto, 2007).  In addition, it also 
projects to the striatum, although to a lesser degree than its cortical and limbic outputs 
(Ferreira et al., 2008).  The VTA receives feedback input from most of the regions it 
innervates, and excitatory glutaminergic projections to the VTA are important in 
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modulating its activity, and are implicated in its role in addictive behaviors (Tzschentke, 
2001).  In early PD, the effects on the VTA as manifested by early loss of olfactory, 
cognitive and affective dysfunction may be an important indicator of the early disease 
(Sharpe, 1990; Aarsland et al., 2005; Lieberman, 2006; Torta and Castelli, 2008; 
Blonder and Slevin, 2011).   In PD, the VTA is (Hirsch, 1994) similarly or less affected 
than A8 neurons in comparative studies of midbrain dopamine neurons (Uhl et al., 1985; 
Deutch et al., 1986; German et al., 1988; Hirsch et al., 1988).  In rodent models of PD, 
the VTA is usually the least affected midbrain dopamine region, with losses of about 30-
50% in moderate 6-OHDA and MPTP PD models (German et al., 1996; Rodríguez et 
al., 2001; Ahmad et al., 2009a).  Although this dopaminergic region has been studied 
extensively in its relevance to other neurological disorders, its role in PD is still not well 
understood, although its potential relevance especially in the early stages of PD 
underscores the importance of better understanding the A10 VTA dopamine neurons in 
PD.  
 
1.5.3 The retrorubral field (A8) neurons 
     The retrorubral field (RRF) is the least understood of the major midbrain 
dopaminergic groups, although the studies that have been performed have shown it to 
be an important component of several dopaminergic circuits.  This region, the dopamine 
neurons of which correspond to the A8 dopamine group (Dahlstrom and Fuxe, 1964), is 
so named because it is caudolateral to the red nucleus in humans (Gibb, 1992; 
McRitchie et al., 1996) and rats (Paxinos, 1995).  In both rodents and primates the RRF 
is located posterior to the SN and lateral to the VTA (Paxinos and Watson, 1998; 
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François et al., 1999).  The RRF in humans contains a heterogeneous population of 
both TH-positive and TH-negative neurons (Mai and Paxinos, 2012).  In both humans 
and rats the RRF A8 neurons make up about 10% of all the midbrain dopaminergic 
neurons (Paxinos, 1995).  There are approximately 10,500 dopaminergic A8 neurons in 
humans (McRitchie et al., 1997), and are approximately 1400-6200 dopaminergic 
neurons on each side in rodents, depending on the quantitation method used (German 
and Manaye, 1993; Paxinos, 1995; German et al., 1996; Nair-Roberts et al., 2008).    
  Apart from its striatal projections, the RRF is also involved in the 
mesocortical and mesolimbic dopaminergic pathways.   The RRF receives reward-
pathway related noradrenergic input from the medulla and locus coeruleus, and largely 
projects to the striatum (Deutch et al., 1988; Mejías-Aponte et al., 2009).   In both 
rodents and in humans, the RRF also projects to the amygdala (Deutch et al., 1986; 
Cho and Fudge, 2010), to the hippocampus (Gasbarri et al., 1997; François et al., 1999; 
Haber et al., 2000), and the prefrontal cortex in primates (Cho and Fudge, 2010).  RRF 
neurons are depleted in PD post-mortem studies by approximately 40-60% (Uhl et al., 
1985; Hirsch et al., 1988), and by approximately 30-70% in rodent 6-OHDA and MPTP 
models (German et al., 1988; Rodríguez et al., 2001); therefore it is likely that the loss 
of these dopamine neurons results in disturbances to the pathways in which these 
neurons normally function. The RRF is implicated in the striatal regulation of orofacial 
movement, and may be involved in the development of the mask-like facies typical of 
advanced PD (Spooren et al., 1993b).   In addition, the RRF appears to be involved in 
the resting tremor found in PD patients, and harmaline-induced tremor in a 6-OHDA rat 
PD model (Hirsch et al., 1992; Kolasiewicz et al., 2012).  The RRF may also be involved 
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with REM Sleep-Behavior Disorder (RBD), which is associated with parkinsonian 
disorders (Dhawan et al., 2006).  Sleep disturbance, mood disorders and resting tremor 
are both early signs of PD, therefore, the RRF may be an important region affected 
early in the disease (Claassen et al., 2010).  
1.6 Models of PD 
Most animal PD models exhibit the destruction or degeneration (not always 
selective) of nigrostriatal neurons.  Although these models usually represent various 
aspects of the clinical disease, there is still no comprehensive PD model showing the 
progressive destruction of nigral neurons with degeneration of other dopaminergic sites, 
decrease in other monoamines, aggregation of Lewy bodies, and the motor and non-
motor signs of PD.  There are three main types of animal PD models: neurotoxin 
models, inflammatory models, and genetic models.  
1.6.1 The 6-hydroxydopamine (6-OHDA) model of PD 
 One of the most commonly used neurotoxic models of PD is a localized infusion of 6-
OHDA. Structurally similar to dopamine and norepinephrine (NE), 6-OHDA is selectively 
transported by monoamine transporters into catecholaminergic neurons, where it is carried by 
retrograde transport into the neuronal bodies and oxidized into damaging hydrogen peroxide 
and paraquinone, leading to cell destruction (Saner and Thoenen, 1971; Kostrzewa and 
Jacobowitz, 1974).  If desired, destruction of noradrenergic neurons can be prevented with 
pretreatment with dismethylimipramine, a selective blocker of the NE transporter, to produce 
specific dopamine neuron destruction (Breese and Traylor, 1971).  6-OHDA  is the preferred 
method of neurotoxic PD lesion in rats, because rats are relatively resistant to MPTP toxicity 
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for unknown reasons, although rat’s low levels of monoamine oxidase B compared to mice 
may play a role (Glover et al., 1986; Tsai and Lee, 1994; Blesa et al., 2012).  In addition, 6-
OHDA does not cross the blood-brain barrier, but must be infused directly into the brain via 
stereotactic surgery methods (Schober, 2004), which are easier to perform on rats than on 
mice.  6-OHDA causes dose-dependent striatal dopamine depletion, with measurable 
behavioral deficits in rodents and primates (Przedborski et al., 1995; Kirik et al., 1998; Bové et 
al., 2005; Blesa et al., 2012).   After the 6-OHDA lesion is induced, behavioral tests are 
commonly performed.  The most common test used is injection of apomorphine (direct agonist) 
or amphetamine (indirect agonist), causing an imbalanced release of dopamine from the 
injured and intact sides and inducing rotation to the contralateral side with dopamine agonists 
and the ipsilateral with dopamine reuptake inhibitors (Lane et al., 2006).  Other effects of 6-
OHDA have been assessed by motor tests designed to have correlates with PD, such as 
deficits in forelimb force, paw-reaching and stepping tests, and pole-climbing tests (Barnéoud 
et al., 2000; Meredith and Kang, 2006; Bethel-Brown et al., 2011); or by increased depressive 
behaviors and anhedonia (Santiago et al., 2010).  
  6-OHDA is often infused unilaterally, as bilaterally infused animals tend to have high 
morbidity and mortality, with severe aphagia and adipsia (Blesa et al., 2012)(cite Cenci 2002).  
However, bilaterally infused animals offer the most complete model of late-stage PD, which is 
bilateral. Unilateral lesions, on the other hand, offer the advantage of modeling the unilateral 
presentation found in early PD (Hoehn and Yahr, 1967).   Also, in unilateral models the 
unlesioned side of the brain is often used as a control for detecting morphological and 
biological changes compared to the ipsilateral lesioned side (Schober, 2004; Blesa et al., 
2012).    
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 There are several modes of administering 6-OHDA.  Injections can be made 
directly into the SN and the medial forebrain bundle (MBF), and these lesions generally 
result in a high degree of neuron loss and striatal depletion (Deumens et al., 2002).  The 
drawback with these targets, however, is that since they are so small, it can be difficult 
to perform the stereotactic surgeries with enough precision to obtain consistent results 
across animals.  In addition, the severe nature of the lesions means that they can only 
be used to model late-stage PD, and are therefore limited in their use for investigation of 
neuroprotective strategies.  The intraventricular model has successfully obtained lower 
levels of neuronal destruction, and has the advantage of less gross destruction of 
dopaminergic tissue from direct needle injection (Rodríguez et al., 2001).  However, this 
model is by nature limited to bilateral application, and therefore is also limited in its use.  
Perhaps the most widely used and versatile 6-OHDA model is the intrastriatal model.  In 
this model, the 6-OHDA toxin is infused, usually unilaterally, into the striatum, where it 
destroys the dopaminergic terminals, and the toxin is carried back to the neuronal 
bodies in the SN, causing destruction there as well (Sauer and Oertel, 1994; Blesa et 
al., 2012).  Dose-dependent effects of this model can be achieved by using multiple 
injections in multiple sites, to achieve a wide variety of states of neurodegeneration 
(Kirik et al., 1998; Deumens et al., 2002).  The unilateral intrastriatal 6-OHDA infusion of 
6-OHDA is a relevant model of early to moderate PD (Przedborski et al., 1995; 
Barnéoud et al., 2000; Deumens et al., 2002).  Using this method, studies have 
achieved SNpc neuronal losses around the 50% thought to be lost at the appearance of 
clinical signs of PD (Marsden, 1990; Kirik et al., 1998; Deumens et al., 2002; Healy-
Stoffel et al., 2012).  This method has also been used to induce behavioral changes, 
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biochemical indices and biomarkers of oxidative stress that can be attenuated with 
various neuroprotective treatments, making this a useful model for development of 
treatments for early PD (Blum et al., 2001; Deumens et al., 2002; Blandini et al., 2007; 
Cansev et al., 2008; Blesa et al., 2012).   
 Like all PD models, 6-OHDA has important similarities with the disease, but does not 
encompass all the features of PD (Potashkin et al., 2010).  There is evidence for the 
endogenous formation of 6-OHDA, suggesting that this toxin could be contributing to the 
naturally occurring disease (Jellinger et al., 1995), although the mode and dosage of the 6-
OHDA model is most certainly more severe than that likely found in idiopathic PD.  Most 
importantly, 6-OHDA causes depletion of midbrain catecholaminergic neurons, as occurs in 
PD, and furthermore, the pattern of loss within the major A8, A9 and A10 dopamine subregions 
after 6-OHDA lesion reflects the losses found in PD (Rodríguez et al., 2001; Kolasiewicz et al., 
2012).  The majority of cell death by striatal infusion will have taken place by one week 
(Meredith et al., 2008), therefore the 6-OHDA lesion method lacks the true progressive nature 
of idiopathic PD.  The neurotoxic effects of 6-OHDA are dose-dependent (Przedborski et al., 
1995; Kirik et al., 1998), however, and therefore various doses and lesion delivery methods 
can be used to create models of various stages of PD progression.  In addition, neurotoxic 
lesion models lack the Lewy body formation found in idiopathic PD (Hirsch et al., 2003; 
Schober, 2004; Blesa et al., 2012), as well as the non-catecholaminergic neurotransmitter 
deficits found in PD.  Although the 6-OHDA PD model is not perfect, it does recreate the most 
drastic and functionally relevant symptoms and pathology of PD, and therefore it is a crucial 
tool in investigating PD.  Due to its overall ease of use and versatility, the 6-OHDA model of PD 
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is one of the most highly-utilized and well-established tools in the study of PD, and will likely 
continue to be well into the future. 
1.6.2 The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of PD 
MPTP is a synthetic opioid, an active metabolite (MPP+) of which is selectively 
transported into substantia nigra dopamine cells, destroying them and causing the 
manifestations of PD.  It is metabolized by monoamine oxidase B (MAO-B) to MPP+, 
which is a potent Complex 1 inhibitor in nigral neurons (Glover et al., 1986; Schober, 
2004).  While this model may not represent the progressive manner in which most 
people develop the disease, it has been a useful tool to investigate the role of 
mitochondrial dysfunction in PD (Dauer and Przedborski, 2003).  While highly toxic in 
primates, it is not effective in rats due to differences in monoamine oxidase expression, 
however, and has variable effects in mice (Hallman et al., 1985).  In mice, the option of 
stereotactic injection is less attractive and the toxin is usually delivered systemically, 
which can lead to high mortality with the does needed to achieve significant dopamine 
neuron destruction, limiting some of the usefulness of this model in rodents (Petroske et 
al., 2001).  MPTP may be either acutely or chronically administered, providing a more 
gradual destruction to mimic the progressive destruction of dopaminergic neurons found 
in idiopathic PD. MPP+, the toxic metabolite of MPTP can be directly infused into the rat 
brain, as MPP+ is a good substrate for DAT.  This model is usually unilaterally 
employed, much like the 6-OHDA model. While not applicable across rodent species 
and often limited by systemic side effects, the MPTP model has proved to be a 
revolutionary factor in our current understanding of PD pathogenesis, and will continue 
to be utilized in the future. 
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1.6.3 Pesticide models of PD 
Paraquat is a commonly used herbicide worldwide.  In cells, paraquat is 
transported into mitochondria by a carrier-mediated process.  Mitochondrial Complex I 
reduces it to a lethal radical species (Cochemé and Murphy, 2008), in contrast to other 
neurotoxins which inhibit Complex I directly.  Although it is capable of producing small 
nigral dopamine neuron losses in rodents (Brooks et al., 1999; Fleming et al., 2004; 
Kuter et al., 2007), paraquat alone has not been shown to instigate progressive loss of 
nigral neurons by itself.  Instead it is usually co-administered with maneb to increase 
toxicity.  Maneb, is a fungicide which disrupts dopamine uptake and release (Vaccari et 
al., 1999).  Administered together, paraquat and maneb lead to progressive loss of 
dopamine neurons (Thiruchelvam et al., 2003), especially in older mice and rats 
(Cicchetti et al., 2005).  The attraction of this model lies in its progressive loss of motor 
neurons, motor function impairment, and induction of microgliosis, all of which are 
features of clinical PD.  However, use of paraquat in rats can be limited by the same 
lung toxicity which makes it a lethal agent to humans (Saint-Pierre et al., 2006). 
Rotenone is another pesticide PD model, and like MPTP, it is a Complex I 
inhibitor.  It is notable that the progressively dying dopaminergic neurons induced by 
rotenone contain Lewy-like cytoplasmic inclusions immunopositive for α-synuclein and 
ubiquitin.  However, the damage caused by rotenone can cause highly variable degrees 
of damage to both dopaminergic and other neuronal cells, limiting the usefulness of this 
model by lack of reproducibility (Meredith et al., 2008).  While pesticide models have 
been useful in exploring the possible environmental etiology of PD, their systemic side 
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effects and incongruity with many of the clinical features of PD in humans may limit their 
usefulness in many cases. 
1.6.4 Inflammatory models of PD 
Inflammation is implicated in neurodegenerative disease due to effects of the 
ROS produced by inflammatory cascades on vulnerable neurons, notably the oxidation-
prone dopamine-enriched nigral neurons.  Inflammatory models of PD rely on the 
activation of microglia, which function as the macrophages of the brain.  When 
activated, microglia produce pro-inflammatory cytokines, NO and ROS.  This function is 
necessary for normal apoptosis that occurs during development and injury, but 
dysfunctional activation and failure to stop the inflammatory cascades are an underlying 
theory for many progressive diseases.  Inflammatory models of PD employ injection of 
LPS, an endotoxic molecule which induces microglial activation.  Microglia density is 4-5 
times higher in the substantia nigra than in other brain regions, leading to selective 
degeneration of nigral neurons with an acute intracerebral dose of 5 or 10 µg of LPS 
(Herrera et al., 2000; Kim et al., 2000; Gao et al., 2003).  Acute LPS administration in 
rats causes permanent lesions and behavior deficits induced by amphetamine rotation, 
but lack of progression, as microglia morphology returns to normal by 30 days post-
injection (Iravani et al., 2005).  However, progressive loss of TH-immunoreactive cells 
has been seen after a single insult (Qin et al., 2007).   Acute systemic LPS injection in 
mice reveals a delayed but progressive degeneration of nigral neurons (Castaño et al., 
1998). 
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Chronic LPS infusion by cannula has been used to create a more progressive PD 
model.  While progressive dopaminergic neuron loss is achieved, this model has yet to 
establish representation of the other cardinal features of PD such as motor dysfunction, 
inclusions, or extranigral degeneration (Gao et al., 2003).  In support of the finding that 
infections in the mother can lead to loss of nigral neurons in the fetus, an intrauterine 
LPS model has shown that prenatal exposure to LPS disrupts normal development, 
resulting in reduced numbers of dopamine neurons.   Acute systemic LPS injection in 
mice reveals a delayed but progressive degeneration of nigral neurons (Castaño et al., 
1998).  Interestingly, rotenone given to 18-month old rats exposed to prenatal LPS 
enhanced the loss of dopamine neurons, supporting the “multiple hit” hypothesis of PD 
(Ling et al., 2004).  With our increasing understanding of the role of inflammation in 
neurodegenerative diseases, the inflammatory model of PD will likely play an even more 
important role in PD studies in the future.    
1.6.5 Genetic models of PD 
Genetic models of PD have become an important tool in understanding the 
etiology of the disease.  Two genetically engineered mouse models which have shown a 
progressive post-natal degeneration of dopamine neurons are Pitx3-null mice and 
Engrailed-null mice.  Pitx3 is a gene crucial to early dopaminergic neuron development, 
and Pitx3-null mice have a rapid post-natal loss of dopamine neurons and behavioral 
deficits alleviated by levodopa (Nunes et al., 2003; van den Munckhof et al., 2003; 
Hwang et al., 2005).  Recent evidence has shown that a polymorphism in the Pitx3 
gene is a risk factor for sporadic PD in humans (Fuchs et al., 2009).  While this model 
does show progressive loss of dopamine neurons, the loss is earlier in life than would 
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be seen in idiopathic PD.  Engrailed knockout mice also show a progressive 
dopaminergic neuron loss, but also show additional cerebellar pathology which limits 
their use in behavioral tests (Sonnier et al., 2007).  
Models of the mutations which have been linked to familial PD have also been 
developed.  The α-synuclein mutant models vary in the promoter used, resulting in 
various mutant and wild-type over-expression models (Chesselet, 2008).  These models 
can be useful for characterizing the effects of overabundant or mutant a-synuclein, but 
many of the behavioral dysfunctions they have do not correspond to PD, and many do 
not demonstrate a nigral neuron loss (Masliah, 2000; Fleming et al., 2005; Hwang et al., 
2005; Tofaris et al., 2006).   A drosophila model of PD has recently been produced to 
express mutant and normal forms of α-synuclein.  These flies showed an age-
dependent loss of TH-positive dorsomedial dopamine neurons.  They also showed α-
synuclein stained inclusions resembling Lewy bodies, and exhibited locomotor 
dysfunction with age, although it could not be shown that the deficits were a function of 
degenerated dopamine neurons (Feany and Bender, 2000).  
Parkin is an important gene in familial PD, encoding an E3 ubiquitin ligase 
involved in proteosomal function.   Although early mutated parkin lines showed mixed or 
absent effects on dopaminergic neuron loss and non-motor and behavioral deficits 
(Goldberg et al., 2003; Perez and Palmiter, 2005; Zhu et al., 2007), a mouse model 
transgenic for Q311X parkin has shown both progressive DA neuron loss and 
progressive motor dysfunction in late adulthood (Lu et al., 2006).  PINK1 knockout mice 
have decreased dopamine release (Kitada et al., 2007), and the DJ1 mutation causes 
diminished resistance to oxidative stress in mice, flies and cultured cells.  DJ1 knockout 
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mice do not develop dopamine neuron loss, however (Dodson and Guo, 2007; 
Yamaguchi and Shen, 2007). 
A comprehensive animal PD model has yet to be developed, although these 
models are useful in representing various aspects of the disease, such as extranigral 
neurodegeneration and Lewy body pathology.  However, the increased knowledge 
about the etiology of PD provided by models of PD will likely lead to the continual 
improvement of PD models in the future.  
1.7 Introduction to PUFAs 
Polyunsaturated fatty acids (PUFAs) are important dietary fats containing more 
than one double bond in their carbon structure.  The different PUFAs are named 
according to the number of carbons they contain, their number of double bonds, and the 
position of the first double bond from the methyl end of the fatty acid.  Thus DHA, a 22-
carbon PUFA with six double bonds and the first double bond at the third carbon from 
the methyl end, is designated as 22:6n-3, and is part of the n-3 class of PUFAs.  PUFAs 
are crucial to brain composition and proper function (Willatts et al., 1998; Birch et al., 
2000).  DHA constitutes approximately 12-15% by weight of the total fatty acids in the 
human brain, while AA makes up 8-11% (Whelan, 2008).  AA (22:4n-6) is distributed 
evenly within the brain, while DHA is highly enriched in neuronal and synaptic 
membranes, suggesting an important role in cell signaling (Farooqui et al., 2000).   
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1.7.1 Dietary PUFAs: synthesis and brain accretion  
Mammals cannot synthesize essential n-3 and n-6 PUFAs de novo.  Instead, 
DHA and AA must be consumed in the diet, or their precursors α-linolenic acid (ALA) 
and linoleic acid (LA) must be provided.   ALA is metabolized by desaturases and 
elongase to form DHA (see Figure 3).  The same enzymes are employed to convert LA 
to AA and ultimately to docosapentaenoic acid (DPA) (Dyall and Michael-Titus, 2008) 
(See Figure 2).    
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Figure 2.  
Summary of omega-3 and omega-6 PUFA biosynthetic pathways. The pathways 
proceed through a series of desaturation and elongation steps in the endoplasmic 
reticulum until 24:5n − 6 and 24:6n − 3, which are translocated to the peroxisome, 
where the chains are shorted by C2 by one cycle of the β-oxidation pathway to form 
22:5n − 6 and 22:6n − 3 (DHA), respectively. These are then translocated back to the 
endoplasmic reticulum for subsequent esterification into aminophospholipids. The 
relative efficiencies of the omega-3 PUFA conversion process are shown to the right of 
the pathways, for further details refer to the text. Reprinted with permission from 
Springer Science and Business Media: NeuroMolecular Medicine (Dyall and Michael-
Titus, 2008) 
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DHA plays an important role in growth and development.  DHA is supplied to the 
fetus by the mothers’ dietary consumption and to infants in breast milk.   In humans, 
most DHA is accumulated in late gestation and early childhood, with lifelong turnover 
(Clandinin et al., 1980a; Clandinin et al., 1980b; Hadley et al., 2009).  Accumulation in 
rats increases later in gestation and most of the DHA is stored from the last three days 
of gestation through weaning (Kishimoto et al., 1965; Green and Yavin, 1996).  Long-
chain PUFAs are sometimes called “conditionally essential” in that no gross deficiency 
disorders are known.  However, possible visual and cognitive deficits in children given a 
low n-3 diet and benefits bestowed by an n-3 supplementation during pregnancy have 
been reported (McNamara and Carlson, 2006).  Dietary DHA deficiency was associated 
with impaired mental and visual performance in otherwise healthy term infants (Willatts 
et al., 1998; Birch et al., 2000).  DHA activates syntaxin-3, a crucial factor in neuron 
growth and regeneration, and which may explain its role in optimal growth and 
development (Whelan, 2008). 
 1.7.2 Influence of dietary PUFAs 
Dietary consumption of PUFAs affects tissue PUFA composition, and an n-3-
PUFA deficient diet in adult rats results in decreased n-3 content of several organs, 
including liver, heart and testes (Bourre et al., 1992).  In addition, previous breeding 
studies in our laboratory have shown that a decrease in n-3 fatty acids in the diet results 
in a decrease of brain DHA, and a concurrent increase in the n-6 fatty acid 
docosapentaenoic acid (DPA), by 32% and 54%, in first litter and second litter pups, 
respectively (Ozias et al., 2007).  Thus brain DHA content is replaced in the Deficient 
rats with the n-6 PUFA DPA, altering the ideal n-6/n-3 PUFA ratio.  Consequent 
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generations do not show marked decreases in percent of brain n-3 PUFAs after the 
second generation, so our study will be limited to two generations.  
Western diets are very low in n-3 fatty acids, and have an n-6/n-3 as high as 
16.7/1 (Simopoulos, 2003).  Importantly, a very high n-6/n-3 ratio has been implicated in 
a variety of human diseases such as coronary artery disease, hypertension, diabetes, 
arthritis, osteoporosis, autoimmune disorders, cancer and mental health disorders 
(Simopoulos, 2008).  Low dietary n-6/n-3 ratios have been shown to favorably alter LDL 
status, improve cardiovascular health, have anti-proliferation effects in colorectal 
cancer, decrease the risk of breast cancer, and decrease inflammation in rheumatoid 
arthritis and asthma (Haworth and Levy, 2007; Calder and Yaqoob, 2009; Fetterman 
and Zdanowicz, 2009; Hartwich et al., 2009; Lavie et al., 2009). 
1.7.3 PUFA metabolism and roles in human health 
PUFAs play a variety of roles in the function of the body, but one of their most 
important effects is their influence on plasma membrane composition.  AA is an 
important signaling molecule in inflammatory cascades, as well as in the D2 receptor 
pathway in the dopaminergic system (Lee et al., 2010).  AA is preferentially cleaved 
from phospholipids in the brain by both cytosolic phospholipase A2 (cPLA2) and 
secretory phospholipase A2 (sPLA2), after which a portion of the released AA can by 
metabolized by cyclooxygenases (COXs) and lipoxygenases (LOXs) to form a class of 
compounds known as the eicosanoids.  Eicosanoids include a variety of mediators of 
cellular activity, including prostaglandins, leukotrienes and lipoxins (see Figure 3).  The 
actions of prostaglandins have a wide range of functions, from smooth muscle 
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contraction to vasodilatation (or vasoconstriction, depending on the particular 
prostaglandin and receptor) and inhibition of platelet aggregation.  Leukotrienes are 
potent vasoconstrictors and leukocyte attractants implicated in immune responses.  
Lipoxins both activate macrophages and monocytes, as well as inhibiting leukocyte 
activation (Brunton et al., 2011).  Most AA-derived metabolites have pro-inflammatory 
functions, although AA contributes to mediators with a broad range of functions in 
signaling and memory and learning modulation (Funk, 2001; Orr and Bazinet, 2008a).  It 
is interesting to note that eicosapentanoic acid (EPA), the 20-carbon n-3 precursor to 
DHA, also forms eicosanoids, most of which are more anti-inflammatory than their AA-
derived counterparts.  EPA competes with AA for the same enzymes, so the n-6/n-3 
ratio influences metabolite production.  Under conditions of cell membrane damage 
(such as oxidative stress), abundant intracellular calcium and inflammatory stimuli, PLA2 
and COX2 transcription is upregulated, leading to increased production of AA 
metabolites (Orr and Bazinet, 2008a). 
DHA is incorporated preferentially into phosphatidylethanolamine and 
phosphatidylserine on the inner membrane layer of synapses and its steric 
incompatibility with cholesterol drives the formation of either DHA- or cholesterol-rich 
lipid rafts.  These rafts serve as protected micro domains and function in 
compartmentalization of various cell signaling molecules (Farooqui et al., 2000).  DHA 
has also been shown to affect membrane fatty acid chain fluidity, ion permeability, 
elasticity, protein function, phase behavior, and fusion (Stillwell and Wassall, 2003; 
Wassall and Stillwell, 2008).  DHA is also cleaved from the phospholipids by 
phospholipase, and evidence indicates that an inducible DHA-selective form of the 
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enzyme, iPLA2, is responsible for its availability.  Once unesterified, DHA goes on to 
perform as a ligand for a variety of receptors, such as peroxisome proliferator-activated 
receptor (PPAR), retinoic acid receptor (RXR) and Toll-like receptor (TLR), as well as 
being metabolized by COX and LOX to form the docosanoids resolvins, neuroprotectin 
D1 (NPD1), and the recently discovered electrophile oxo-derivatives (EFOXs) (Lee et 
al., 2003; Lengqvist et al., 2004; Orr and Bazinet, 2008a; Groeger et al., 2010).  
Resolvins are a class of anti-inflammatory compounds produced by the COX-2 pathway 
in the presence of aspirin (Sharon et al., 2003; Serhan et al., 2004).  Neuroprotectin D-1 
(NPD1) is a peptide that is formed by phosholipase A2 lipooxygenase on free DHA, and 
induces anti-apoptotic Bcl-2 proteins, inhibits pro-apoptotic Bcl-2 proteins, and 
suppresses inflammatory gene expression (Lukiw and Bazan, 2008).  DHA and NPD1 
also affect membrane structure and stability, and alter the balance of n-3 to n-6 PUFAs 
in the membrane, which affects the arachidonic acid cascade by suppression of COX-2.  
Under inflammatory conditions, macrophages were found to produce maresins, DHA-
derived metabolic products with anti-inflammatory properties similar to the resolvins and 
NDP1 (Serhan et al., 2009).  Newly discovered COX-2 EFOX metabolites act as anti-
apoptotic Nrf-2 activators, PPAR-γ agonists, and inhibitors of cytokine and NO 
production (Groeger et al., 2010) (see Figure 3).  DHA also has the ability to inhibit 
TLR4, an important pro-inflammatory factor, and various nuclear receptor initiators of 
the NfκB-mediated anti-inflammatory response (Lee et al., 2003; Weatherill et al., 2005).  
Several studies have documented the ability of n-3 fatty acids to decrease cytokine 
production, and response to COX-2 activity was decreased in a clinical study in which 
patients were supplemented with 15 g/day of fish oil for four weeks (Lee et al., 2003); 
43	  
(Spector, 2001).  Conversely, under oxidative stress, DHA is oxidized into 
neuroprostanes, a class of prostaglandin-like compounds formed without COX.  These 
compounds trigger ROS formation at both sides of the phospholipid membrane 
(Montine et al., 2004).  F4 neuroprostanes, DHA-derived lipid peroxidation products, 
may lead to the formation of further membrane- damaging aminophospholipids (Roberts 
et al., 2005). 
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Figure 3. 
The metabolism of n-3 and n-6 PUFA and the biosynthesis of their respective 
eicosanoid and pro-resolving mediators.  N-3 PUFAs are generally less inflammatory 
than the n-6 PUFA. However, PGE2 derived from n-6 PUFA can have an anti-
inflammatory effect by decreasing LTB4 production by the inhibition of 5-LOX and 
increasing production of LXA4 by stimulating 15-LOX.  N3 PUFA-derived eicosanoids 
have different physiological potencies than n-6 PUFA-derived eicosanoids. 
Abbreviations: HPETE, hydroperoxyeicosatetraenoic acid; LTA4, leukotriene A4; LXA4, 
lipoxin A4. Reprinted from the Journal of Nutritional Biochemistry  (Adkins and Kelley, 
2010),with permission from Elsevier.  
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1.7.4 N-3 PUFAs in PD 
 N-3 PUFAs influence a number of factors that are implicated in the development 
of PD.  In addition, n-3 PUFAs are known to influence several factors implicated in the 
health and maintenance of neurons throughout the lifespan, such as RXR, nuclear 
receptor-related protein 1 (Nurr1) and nerve growth factor-induced Bα (Nur77) 
(Bousquet et al., 2008; Lukiw and Bazan, 2008; Orr and Bazinet, 2008b; Yakunin et al., 
2012).  Thus, dietary n-3 PUFA intake has become an area of interested with regard to 
preventing or slowing the progression of PD. 
1.7.4.1 Dopaminergic developmental factors influenced by n-3 PUFAs 
Several factors influenced by n-3 PUFAs play an important role in dopaminergic 
development, growth and maintenance.  Thus the dysregulation of these factors may 
contribute to the etiology of PD.  RXR is a member of the nuclear hormone family of 
receptors, along with steroid hormone, thyroid hormone, vitamin D receptor, and a host 
of others.  There are three main isotypes: RXR-α, RXR-β and RXR-γ.  RXR-α is 
expressed in liver, kidney, spleen, placenta, epidermis, and visceral tissue; RXR-β is 
expressed in nearly every body tissue; and RXR-γ is mostly in muscle and brain tissue.  
The roles of RXR are complex and not completely understood, but RXR isoforms are 
known to be involved in muscle metabolism, insulin resistance, atherosclerosis and 
cholesterol metabolism, apoptosis, and a variety of differentiation processes, including 
neuronal development (Szanto et al., 2004).  In the dopaminergic system, RXR is a 
crucial developmental and survival factor, in conjunction with its NR4A1 partners Nurr1 
and Nur77 (Lévesque and Rouillard, 2007).   A unique feature of RXR is its ability to 
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form heterodimers with many other nuclear receptors, implicating RXR in the roles of 
multiple transcription pathways.  In particular, RXR heterodimerizes with both Nurr1 and 
Nur77, another member of the NR4A1 orphan nuclear receptor family.  Nurr1 is an 
NR4A1 orphan nuclear receptor crucial to dopaminergic neuronal development, as well 
as regulation of the hypothalamic/pituitary/adrenal axis (Murphy and Conneely, 1997).  
Nurr1 is expressed chiefly in the substantia nigra, ventral tegmental area, midbrain and 
the limbic areas, all areas in which dopamine plays a vital role.  Expression peaks in 
embryo, yet remains high in dopaminergic neurons throughout the lifespan, with Nurr1 
expressed in 96% of adult substantia nigra neurons (Zetterström et al., 1997; Bäckman 
et al., 1999; Le et al., 1999).  Nurr1 regulates the transcription of TH and DAT by binding 
to the NBRE sequence in the 5’-untranslated region, and binds to RXR.  The resulting 
heterodimer plays an important role in the development of neuron cells (Schimmel et al., 
1999; Sacchetti et al., 2002).  
RXR, Nurr1 and Nur77 receptors act as ligand-activated transcription factors with 
three main structural features: (1) DNA binding domains for binding to hormone 
response elements, (2) ligand-binding domains specific for small lipophilic molecules, 
and (3) transactivation domains for activating gene transcription.  There may be several 
endogenous ligands for RXR, but DHA is a known ligand for this receptor (Lengqvist et 
al., 2004), and as such dietary DHA intake may play a role in RXR regulation.  
Target areas of dopaminergic innervation express both RXR-β and RXR-γ 
isoforms.  Mice deficient in these receptors have impaired motor function, and 
decreased mRNA transcription of D1 and D2 receptors in the striatum (Krezel et al., 
1998).  Knockout RXR-γ animals have also been found to have abnormalities in 
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synaptic plasticity and learning (Szanto et al., 2004).  RXR, along with dimerization 
partner Nur77, has been implicated in modulating a number of motor side effects of 
antipsychotic drugs, and decreased Nur77 has been linked to post-mortem brains from 
schizophrenic patients (Lévesque and Rouillard, 2007).  In mice, ablation of RXR-γ 
resulted in depressive behaviors of despair and anhedonia, along with decreased D2 
receptor expression in the nucleus accumbens and changes in serotonin signaling 
(Krzyzosiak et al., 2010).  Knowledge about the roles of RXR and its partners in PD are 
quite limited, although since RXR and Nur77 are implicated in haloperidol-induced 
VCMs and other neuroleptic side effects in antipsychotics, they are likely also involved 
in the dyskinesias associated with L-dopa treatment in PD.  In one recent study, 
activation of RXR by synthetic RXR ligand LG100268 and RXR-Nurr1 ligand 
XCT0139508 in neuronal rat dopaminergic cell cultures was found to protect against 
oxidative stress induced by 6-OHDA and hypoxia.  However, RXR expression alone 
could not protect the cells when treated with kainic acid and hydrogen peroxide; rather, 
neuroprotection against these was selective to Nurr1-expressing cells, still implicating 
RXR as its dimerization partner (Friling et al., 2009).  The apparent complexity of the 
relationships among the nuclear receptors involved in the nigral neurogenesis make it 
difficult to isolate the effects of each, but it is apparent that these development and 
survival factors may play an important role in the susceptibility of adult neurons under 
conditions of neurodegenerative disease. 
1.7.4. Roles of n-3 PUFAs in PD 
Clinical studies on the role of PUFAs in the etiology of PD have generally been 
inconclusive, although there are several studies addressing the role of PUFAs in PD.  
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The prospective cohort Rotterdam study evaluated 5,289 subjects age 55 and older to 
monitor the association between intake of unsaturated fatty acids and the incidence of 
PD.  In this study, a high intake of PUFAs was associated with a decreased risk of PD 
(de Lau et al., 2005).   Since diets vary across cultures, studies could reveal whether 
incidence of PD is altered in populations consuming high amounts of PUFAs 
(particularly n-3 PUFAs).   Although there is an unfortunate lack of studies addressing 
this question to date, one recent case-control study of a Japanese population found that 
n-3 PUFA intake and n-3/n-6 ratio were not associated with an increased risk of PD, 
although increased AA intake, interestingly, was (Miyake et al., 2010).  Additionally, 
PUFA levels measured in post-mortem PD patients were decreased in the substantia 
nigra compared to other brain regions and controls (Dexter et al., 1989), although this 
certainly be an effect rather than a cause of PD.  More clinical studies are needed to 
establish any potential relationships between PUFAs and PD, since these studies could 
reveal important insights about the cause of the disease.  
The roles of n-3 PUFAs in PD have been much more extensively studied in 
animal models of PD, although the question of whether a high n-3 diet is beneficial in 
PD still remains inconclusive.   However, many of the studies in animals show some 
benefit of n-3 PUFAs in PD.  A combination of uridine and DHA given to rats for 3 days 
before unilateral 6-OHDA lesion increased tyrosine hydroxylase (TH), dopamine and 
synapsin-1 expression on the lesioned side, and decreased amphetamine-induced 
rotation (Cansev et al., 2008).  In a bilateral MPTP rat model of PD, DHA 
supplementation improved motor performance and modulated Akt and Bcl-2 pathways 
(Hacioglu et al., 2012).  In murine studies, mice were given either a control or high n-3 
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PUFA diet for 10 months and then treated with MPTP.  The mice supplemented with n-3 
PUFAs protected against MPTP-induced decrease in dopamine striatal content, TH-
labeled nigral cells, and Nurr1 and DAT mRNA levels (Bousquet et al., 2008).   Another 
MPTP mouse study found that DHA supplementation did not improve motor 
performance, but resulted in reduced dopaminergic neuronal loss and reduced COX2 
activity compared to MPTP-intoxicated controls (Ozsoy et al., 2011a; Ozsoy et al., 
2011b).  DHA supplementation in an MPTP model was also found to increase glial-
derived neurotrophic factor (GDNF) and neurturin (NTN), both important trophic factors 
involved in dopaminergic neuron health (Tanriover et al., 2010).  In primates, a monkey 
MPTP model showed that DHA administration reduced levodopa-induced dyskinesias 
when given either before or after MPTP administration, inviting the prospect of its being 
a potentially effective preventative agent in clinical PD (Samadi et al., 2006).  The 
evidence from these animal studies points to the ability of n-3 PUFAs to modulate 
factors involved in neuroprotection in PD models, suggesting that increased n-3 PUFA 
intake could prevent or attenuate the progress of PD in humans.  
Other studies, however, have found a detrimental effect of PUFAs in PD.  The 
double bonds in PUFAs make them susceptible to lipid peroxidation in pro-oxidative 
environments, and several studies have implicated high n-3 PUFAs with increased 
oxidative damage in PD and PD models.  Neuroprostanes, DHA-derived lipid 
peroxidation products, are increased in the brains of advanced PD patients (Montine et 
al., 2004).  Also, dopamine can react in vitro with fatty acid peroxides to form 6-OHDA, 
providing a potential mechanism for endogenous production of 6-OHDA in the 
pathogenesis of PD (Pezzella et al., 1997).  In one 6-OHDA study in mice, 
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intraperitoneal injection of a DHA ethyl ester resulted in increased the levels of lipid 
peroxidation in the striatum (Kabuto et al., 2009).  In A53T α-synuclein mutant mice, 
DHA supplementation increased accumulation of both soluble and insoluble α-
synuclein, neuritic injury and astrocytosis, and these effects were attenuated by 
decreased dietary DHA content (Yakunin et al., 2012).  In addition, an in vitro 
experiment with oligodendrocytes transfected with A53T α-synuclein supplemented with 
DHA for 3 days before subjection to oxidative stress showed enhanced aggregation of 
α-synuclein (Riedel et al., 2010).  Another recent study found that PUFAs in the brain 
can form neurotoxic adducts with dopamine (Liu et al., 2008).  Since the most toxic of 
the adducts was formed from an n-6 PUFA, the n-6/n-3 ratio in the diet may have an 
effect on development of these adducts and the damage they can cause (see Section 
D.2.1.3).  Despite the potential adverse effects of increased lipid peroxidation and α-
synuclein protein dysregulation which could accompany increased n-3 PUFA intake, the 
evidence for the role of n-3 PUFAs in prevention and treatment of PD remains 
promising, if still inconclusive.  The potential for understanding the mechanisms by 
which n-3 PUFAs contribute to the processes involved in neuroprotection and neuronal 
repair, or alternately to the increased lipid peroxidation found in PD, highlights the 
importance of conducting high-quality clinical and preclinical studies to determine the 
effects of n-3 PUFAs in PD. 
1.8 Stereology and staining in PD 
Morphology is the study of the structure of organisms or their features.  In order 
to accurately assess these physical features, quantitative analytical methods are 
needed, which can be challenging when it comes to microscopic, irregularly shaped 
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objects such as neurons, which are embedded among other types of cells deep within 
the brain.  In order to study neuronal morphology, design-based stereology is the 
quantitative method of choice (Gundersen, 1992; Schmitz and Hof, 2005).  Stereology is 
the study of object properties such as length, surface, area and volume, using a variety 
of sampling and estimation techniques.  Design-based stereology refers to a set of 
sampling parameters that are “defined” before the study, to be independent of the size, 
shape, orientation and distribution of the objects; as opposed to older “method-based” 
stereological techniques in which estimates depended on the geometrical properties of 
the objects of interest (Mayhew and Gundersen, 1996; Boyce et al., 2010b).  Using 
design-based methods that make fewer assumptions about the properties of interest 
reduces bias and results in more robust data than 2D counting methods (de Groot et al., 
2005; Schmitz and Hof, 2005; Boyce et al., 2010a).  Stereology has been particularly 
useful in quantifying large, irregularly shaped biological objects such as neurons, and in 
fact stereology is considered the gold standard in quantification of neuronal morphology 
(Gundersen et al., 1988b; Schmitz and Hof, 2005). 
1.8.1 Sampling methods used in stereology 
Design-based stereology uses systematic random sampling (SRS) to obtain 
unbiased results. This method is systematic because samples are selected at defined 
“systematic” uniform intervals.  A randomized starting point is chosen, and then samples 
are made at uniform intervals.  This principle is demonstrated in Figure 4.  
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Figure 4. 
Simple uniform random versus systematic uniform sampling of a structure. 
Simple uniform random sampling is depicted in the left figure, where the structure is cut 
at independent random positions along its longitudinal axis. Systematic uniform random 
sampling is depicted on the right. The structure is cut at a uniform constant interval (T) 
with a random start (RS), that is, the first cut is positioned uniformly random in the 
interval 0 to T, selected from a random number table or from randomly positioning of the 
organ in an agar block prior to sampling.  Reprinted from Toxicological Pathology 
(Boyce et al., 2010b), with permission from SAGE Publications. 
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Counting objects is performed by placing a randomly placed counting frame 
which ensures that objects will not be re-counted in adjacent regions.  In order to count 
an object, an arbitrarily defined, singly occurring marker for each object must be used. 
For neurons this is usually the nucleus or the nucleolus, since neurons have only one 
nucleus.  Figure 5 demonstrates how the counting frame works: 
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Figure 5.  
The unbiased counting frame ensures that only objects that belong to the area of 
section sampled by the frame are counted. The figure shows a tessellation of nine 
potential sampling sites. The center square is sampled by an unbiased counting frame. 
Objects that “belong” to each of the nine possible sampling squares have a unique 
color, indicated by the color of the small object contained entirely in the respective 
square. The color assigned to the large objects reflects which sampling square they 
“belong to” using the counting rule of the unbiased counting frame: objects completely 
or partly contained in the frame (including those touching the dashed inclusion lines) 
and not touching the exclusion lines or their extensions (thick solid lines) are counted. 
The illustrated profiles represent the unique counting feature that for cells may be either 
nucleoli, nuclei, or cell tops.  Reprinted from Toxicological Pathology (Boyce et al., 
2010b), with permission from SAGE Publications. 
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1.8.2 Stereological probes  
The Optical Fractionator is a commonly used probe used to count objects in 
stereological studies. One major potential source of bias in histological studies is that if 
cells or other objects are cut through, or “capped” during the sectioning process, then 
measuring those sliced profiles could lead to biased conclusions about their properties 
(Boyce et al., 2010b).  The Optical Fractionator avoids this confound by using thick 
sections, and then sampling uniformly spaced counting sites within the X, Y and Z 
planes using SRS.  The researcher can set “guard zones” at the top and bottom of the 
section to ensure that the sampling sites are within the thick section center, avoiding the 
potential to quantify “capped” objects (Gundersen, 1986; Gundersen et al., 1988a; 
Boyce et al., 2010b).  Estimates of the objects sampled with this method are then 
extrapolated by using the fractionator principle, which is based on the assumption that 
by sampling a known fraction of a population, an estimate of the entire population can 
be derived (West et al., 1991; West, 1993).   
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The Nucleator probe is used to quantify the volume of objects in stereological 
studies.  The Nucleator method has been developed to allow computer software to 
calculate the three-dimensional volume of objects such as cells from randomly oriented 
rays placed across the object, and then markers placed along the rays on boundaries of 
the object (Gundersen, 1988; Gundersen et al., 1988a; Mandarim-de-Lacerda, 2003). 
In stereology, the coefficient of error (CE) is used as an index of accuracy of the 
estimation made.  The CE is a computed value that takes into account various sources 
of sampling error, and a number of formulae have been derived to describe this error 
and predict the accuracy of stereological estimates (Gundersen et al., 1999; Boyce et 
al., 2010b).  The CE arbitrarily accepted for most stereological studies is 0.15.  
1.8.3 Staining for stereology 
The technical demands of stereology can present issues in staining for the 
histologist. Whereas normal sections may be very thin (5-10 um), the sections used for 
the Optical Fractionator must be thick (35-60 um).  In addition, it is necessary to be able 
to define the borders of the objects being counted, as well as to visualize the nuclei 
and/or nucleoli for use with the Optical Fractionator and the Nucleator probes.  These 
needs can present a challenge, because it can be difficult to achieve complete staining 
of thick sections.  The issue of visualization of individual structures is especially 
compounded in regions dense with dopaminergic neurons, such as the SN.  As the 
name suggests, this region is already darkly pigmented with neuromelanin, and the TH 
stain used to stain catecholamine neurons also results in darkly stained brown neurons.  
In many studies a thionine or Nissl stain is used to counterstain the neurons and to 
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reveal non-dopaminergic glial neurons, but then this can make it very difficult to 
distinguish the nuclei, as it is easy for the histologist to confuse the counterstained non-
dopaminergic cells with the nuclei.  For these reasons, this study used a newly available 
commercial TH stain combined with a silver nucleolar stain (TH-AgNOR) to determine 
the effects of 6-OHDA partial unilateral intrastriatal lesions on cell number and 
morphology.   AgNOR staining is a silver nitrate preparation that targets chromosomal 
proteins in the nucleolus known as nucleolar organizing regions (NOR).  This stain, 
which has been extensively used by cancer pathologists to assess cell proliferation 
(Trerè, 2000), has recently been exploited for use as a co-stain in dopaminergic 
neurodegeneration studies (Switzer III et al., 2011).   
In combination, the TH and AGNOR stains offer an optimal partnership for 
stereological analysis.  TH immunostaining, which detects tyrosine hydroxylase, the 
rate-limiting enzyme in the pathway to dopamine synthesis, is a common method for 
assessing dopaminergic cells.   Additionally, the AgNOR stain is used by pathologists to 
assess cellular proliferation in tissues.  The AgNOR stain specifically pigments silver-
binding proteins in the NOR’s, resulting in the distinctive dark staining of the nucleoli 
within the cells.  AgNOR staining use as an indicator of the nucleoli in neuroanatomical 
studies has been limited.  One study used AgNOR staining to assess NORs in the 
hypothalamus of aged rats (Begega et al., 1999).  However, our laboratory is the first to 
use AgNOR staining in the SNPC as a method suitable for stereological analysis of the 
dopaminergic neurons in a 6-OHDA model of Parkinson’s disease.  In particular, the 
stain’s features lend themselves to a successful analysis of dopaminergic nucleoli, 
which are often obscured in TH staining alone.  With the TH-AgNOR stain, the 
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histologist is able to clearly see the neuronal outline, dendrites, and axons, with the 
modified TH stain.  Furthermore, the outline of the nucleolus can easily be seen with the 
TH-AgNOR stain, facilitating use with probes such as the Optical Fractionator, and 
making it possible to measure the outline of the nucleolus itself and to determine its 
volume using the Nucleator probe.  Overall, this staining and stereology protocol offers 
promise as a useful tool set with which to analyze morphological changes to 
dopaminergic neurons in PD models.  
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CHAPTER 2 
STATEMENT OF PURPOSE 
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2.1 Objectives 
 Parkinson’s disease (PD) is a chronic progressive neurodegenerative disorder, 
which results in debilitating motor and non-motor symptoms, eventually leading to loss 
of independence and reduced quality of life for the patient. There are currently few 
effective treatments and no cures for PD.  Since the progressive loss of dopaminergic 
function cannot be restored in the late stages of the disease, the best hope for future 
patients is prevention or early intervention.  The early disease process is still poorly 
understood, however, especially the roles environmental or developmental factors such 
as n-3 polyunsaturated fatty acid (n-3 PUFA) consumption.  Deficiencies in n-3 PUFAs 
have been implicated in dopaminergic function and in animal models of PD (Kidd, 2005; 
Cansev et al., 2008; Bousquet et al., 2011; Hacioglu et al., 2012; Eckert et al., 2013), 
although the effects of n-3 PUFAs on the number and morphology of substantia nigra 
pars compacta (SNpc) dopaminergic neurons is still poorly understood.  Apart from the 
effects of diet, changes to dopaminergic morphology also occur in PD and PD models, 
and could be a very useful indicator of disease progression.  Very little is known about 
dopaminergic morphology in the early stages of PD, however, since most of our 
knowledge about dopaminergic morphology in PD comes from post-mortem studies. 
Thus the long-term goals of this study were designed to increase our knowledge about 
the effects of n-3 PUFA deficiency and the unilateral intrastriatal 6-hydroxydopamine (6-
OHDA) neurotoxic lesion on the SNpc dopamine neurons in the early stages of PD. The 
OBJECTIVES of this dissertation were to: 
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1.  Determine the effects of a Low n-3 PUFA diet on the unilateral intrastriatal 6- 
OHDA lesion, which models early to moderate PD. 
2.  Develop a method of quantitating the effects of this 6-OHDA model on 
dopaminergic neuronal and nucleolar morphology. 
3.  Determine the effects of this early PD model on neuronal and nucleolar 
morphology in midbrain dopaminergic subpopulations. 
 
2.2 Rationale for Models and Methods 
2.2.1 Unilateral intrastriatal 6-OHDA neurotoxic lesion 
 The 6-OHDA neurotoxin, a well-accepted method of inducing parkinsonian 
lesions, is very similar in structure to dopamine; and is taken up by the monoamine 
transporters into the terminals, where it is transported back to and selectively destroys 
monoaminergic cells by oxidative mechanisms (Kostrzewa and Jacobowitz, 1974).  
Although the mechanism of neurodegeneration in PD is still unknown, there is evidence 
for the role of oxidative stress in PD (Dauer and Przedborski, 2003). The conditions 
created in our 6-OHDA model, including greatly decreased striatal dopamine 
accompanied by moderate SNpc neuronal loss and motor effects, reflect what has been 
found in early PD (Deumens et al., 2002), making this an appropriate early PD animal 
model.   
 This project employed the unilateral intrastriatal 6-OHDA model, using a single-
site dose of 12.5 µg.  The unilateral intrastriatal 6-OHDA model has been determined to 
be an appropriate 6-OHDA method for modeling early to moderate PD, and this model 
has been previously employed in our laboratory (Bethel-Brown et al., 2010).  We use a 
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unilateral lesion so that the unlesioned hemisphere can serve as a control; and because 
bilateral lesions tend to result in such severe morbidity that the rats can become difficult 
to keep alive for the duration of the study (Schober, 2004).  The single-site single-dose 
intrastriatal route of 6-OHDA infusion was chosen chiefly because the damage inflicted 
to the dopaminergic neurons is less severe than in more extensively destructive models 
such as the SNpc, medial forebrain bundle (MFB) or multiple-site and high-dose 
intrastriatal regimens (Kirik et al., 1998; Deumens et al., 2002).  In addition, the striatum 
provides a larger target during stereotaxic surgery, which results in more consistent 
lesions than attempting to lesion the much smaller SNpc or MFB (Kirik et al., 1998).  In 
addition, the direct trauma of injection into the SNpc could greatly interfere with 
morphological studies in this region.  Overall, this method is a consistently reproducible 
and relevant model of early to moderate PD.  
2.2.2 Changes to dopaminergic neuronal number and morphology quantified by 
stereology and TH-AgNOR staining  
 Losses in dopaminergic number and changes to dopaminergic neuronal 
morphology occur in PD and PD models, and are indicative of neurodegeneration-
induced changes to the neurons (Jackson-Lewis et al., 1995; Gomide et al., 2005; 
Rudow et al., 2008).  Stereological analysis uses random sampling techniques to 
generate unbiased estimates of three-dimensional characteristics of objects from two-
dimensional slides, and is the optimal method for assessing the morphological changes 
induced by neurotoxic lesions and therapeutic interventions (Gundersen et al., 1988a; 
Schmitz and Hof, 2005).  The Optical Fractionator and Nucleator probes have been 
shown to provide more accurate estimates of object number and volume, respectively, 
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than traditional histological quantitation methods (Gundersen et al., 1988a).  Thus we 
chose the Optical Fractionator to quantify the changes to the dopaminergic neuronal 
number. For volumetric quantitation, the Nucleator was used to quantify neuronal 
volume; and in Aims 3 and 4, the Nucleator technique was adapted to a Double 
Nucleator technique by altering the MicroBrightField StereoInvestigator protocol to 
include placement of additional Nucleator markers within each neuron for simultaneous 
neuronal and nucleolar volume measurement.  
 The staining protocol chosen for this project had several advantages over 
traditional tyrosine hydroxylase (TH) thin-section staining with each brain on a separate 
slide.  First, with MultiBrain® technology, up to 16 brains can be mounted on a single 
slide, and the brains are uniformly exposed to mounting and staining conditions.  
Second, with TH-staining with thiamine or Nissl counterstaining in the thick sections 
required by stereology (30-50µm), both over-staining and under-staining can occur.  
The staining can be so dark in areas dense with TH-positive neurons that counting 
individual cells becomes quite difficult.  Furthermore, stereology probes require 
identification of a uniquely occurring single structure, usually the nucleus.  With TH 
over-staining the nuclei can be obscured, and it is difficult to distinguish the nucleolus in 
most cells, making morphological studies of the nucleolus in the SNpc impossible. In 
addition, sometimes the stain will not penetrate into the middle of the thick sections, 
leaving the center neurons under-stained. With the modified tyrosine hydroxylase silver 
nucleolar (TH-AgNOR) stain, special adjustments were made to the staining protocol by 
NeuroScience Associates to account for the requirements of stereology and the 
challenges of staining dopaminergic neurons.  Hydrochloric acid (HCl) was added to 
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improve stain penetration into the tissue, the TH antibody concentration was decreased 
to avoid over-staining of dense dopaminergic neuron populations, and the added 
AgNOR stain pigmented the nucleoli, so that they were clearly distinguishable from the 
neuronal body and the nucleolus in most cases.  Altogether, these adjustments to the 
TH-staining protocol make it an ideal stain for use with stereological studies on 
dopaminergic neurons.  
2.2.3 Rationale for Endpoints Chosen 
2.2.2 Aim 1: The effects of an n-3 PUFA-deficient dietary and breeding protocol on a 
unilateral intrastriatal 6-OHDA lesion model in rats 
 Specific Aim 1 was designed to determine the effects of a dietary, and 
consequently tissue, n-3 PUFA deficiency on outcomes in an established animal model 
of early to moderate PD.  We hypothesized that low dietary n-3 PUFA content 
influences disposition towards PD by altering the functional characteristics of 
nigrostriatal dopaminergic neurons, resulting in increased rotational behavior in n-3 
PUFA deficient rats; and that low dietary n-3 PUFA content alters number and 
morphology of nigrostriatal dopaminergic neurons, rendering them vulnerable to 
increased damage in the unilateral intrastriatal 6-OHDA model of the disease.  A 
previous study in our laboratory had shown a 33% decrease in SNpc neuronal number 
in 2nd litter n-3 PUFA deficient rats, suggesting that a chronic n-3 deficiency could lead 
to either decreased dopaminergic neurogenesis or to decreased ability to maintain 
dopaminergic neurons in adulthood; and that this process might also occur in PD 
(Ahmad et al., 2008).  Thus, we chose to use amphetamine-induced rotational behavior 
assessment and stereological neuronal quantitation techniques to quantify the effects of 
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an n-3 PUFA deficient diet in the unilateral intrastriatal 6-OHDA model of PD.  Although 
no change in SNpc neuronal volume was found in the rats from that study, decreased 
SNpc neuronal volume has been found in Parkinson’s post-mortem studies, and 
decreased neuronal size has been found after 6-OHDA and 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) in rodents (Lee et al., 1996).  Therefore, we predicted that the Low 
n-3 diet might exacerbate the change in volume expected in the lesioned neurons due to 6-
OHDA.   
The Low n-3 PUFA diet protocol used in this project has been used in our 
laboratory to create rats with varying levels of brain phospholipid PUFA composition, 
while keeping all other husbandry parameters the same between the Low n-3 rats and 
controls.  Previous breeding studies in our laboratory have shown that deficient n-3 fatty 
acids in the diet from conception results in a decrease of brain docosahexaenoic acid 
(DHA), and a concurrent increase in the n-6 fatty acid docosapentaenoic acid (DPA), by 
32% and 54%, in first litter and second litter pups, respectively (Ozias et al., 2007).  
Thus, brain DHA content is replaced in the Low n-3 rats with the n-6 PUFA DPA, 
altering the ideal n-6/n-3 PUFA ratio.  Consequent litters do not show marked 
decreases in percent of brain n-3 PUFAs after the second generation, so our study will 
be limited to two litters. The diet is designed to model the high n-6/n3 PUFA ratio 
typically found in Western diets (Simopoulos, 2008) (Table 1).  This diet represents a 
clinically relevant model of n-3 deficiency, which is likely to be present in much of the 
aged population at risk for developing PD.   
 For Aim 1, rats of two subsequent litters were used with the Low n-3 PUFA diet 
breeding protocol to create rats with varying levels of brain n-3 PUFAs.  These rats 
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were then given the unilateral intrastriatal 6-OHDA lesion, and then allowed to recover 
for seven days before d-amphetamine-induced rotational assessment.  D-amphetamine-
induced rotational behavior is a well-established method for validating neurotoxic PD 
model lesions (Schober, 2004; Potashkin et al., 2010).  Since the lesioned rats do not 
display gross motor deficits, especially with mild to moderate neurotoxic lesions, a 
method is required to elicit the functional effects of the loss of striatal dopamine.  
Therefore amphetamine, which is an indirect dopamine agonist, is used to quantitate 
the functional effect of the lesion.  The amphetamine-stimulated rats tend to rotate 
towards the side of the injury after amphetamine administration due to differing amounts 
of striatal dopamine in the intact and the lesioned hemispheres, (Ungerstedt and 
Arbuthnott, 1970).  Rotations were quantified using force-plate rotometry, which 
provides an objective method of counting rotations (Fowler et al., 2001).   
Amphetamine-stimulated rotation is a good way to validate the functional presence of a 
lesion- however; rotational assessment is not very specific in regards to detecting the 
extent of neuronal loss, since rotations often do not correlate to the extent of the lesion 
as determined by loss of TH-positive neurons (Schwarting and Huston, 1996).  
However, since the purpose of our studies was to determine the extent of the SNpc 
lesion using stereology, this test was appropriate for our purposes of confirming a 
functional deficit of the lesion, and for testing the behavioral effects of an n-3 PUFA 
deficiency.  
 After an additional seven days after rotational behavior assessment, the rats 
were sacrificed, and brains were either immediately frozen for later dissection or 
perfused in 4% paraformaldehyde for sectioning and staining stereological analysis.  
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Frozen brains were dissected for quantitation of striatal dopamine by high-performance 
liquid chromatography-electrochemical detection (HPLC-EC) and frontal cortex PUFA 
content by gas chromatography (GC).  The additional seven days was allowed between 
amphetamine-induced rotational assessment and sacrifice to ensure clearance of any 
residual amphetamine [>10 t1/2s, tissue t1/2 = 5-9 hrs for the elimination phase (Kuhn 
and Schanberg, 1978), and to allow for optimal neurodegeneration.  Time- course 
studies have shown that the majority of damage after 6-OHDA occurs within 14 days 
(Przedborski et al., 1995)- thus, this was chosen as an appropriate time point for brain 
fixation and histology and striatal dopamine analysis.  
These results are found in Chapter 4. 
2.2.3 Aim 2: TH-AgNOR staining to determine the effects of a unilateral intrastriatal 6-
hydroxydopamine lesion in the substantia nigra 
 Aim 2 was to develop a method to quantify dopaminergic neuronal morphology 
using stereological techniques combined with TH-AgNOR staining.  Dopaminergic 
neuronal assessment methods are especially needed for quantifying the effects of 
treatments in early PD models, in which subtle changes to neurons can be difficult to 
detect with behavioral assessments and non-stereological neuronal quantitation 
techniques (Schmitz and Hof, 2005).  We hypothesized that the TH-AgNOR staining 
method combined with stereological techniques would be a suitable method to quantify 
dopaminergic neuronal morphology in the rat, and that the TH-AgNOR staining method 
combined with stereology would reveal changes to the SNpc dopaminergic neurons 
induced by the unilateral intrastriatal 6-OHDA neurotoxic lesion. Thus we used this stain 
combined with MicroBrightField StereoInvestigator Optical Fractionator and Nucleator 
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software probes to quantify the SNpc planimetric volume, neuronal number and 
neuronal volume of SNpc dopaminergic neurons after 6-OHDA treatment. 
   
 Many PD studies on neuronal loss or changes in dopaminergic morphology in 
rodent models include quantitation of not only the SNpc, but also of the surrounding 
substantia nigra medialis, substantia nigra lateralis, substantia nigra reticularis, and 
ventral tegmental area (VTA).  While such broad inclusion of dopaminergic regions 
makes for much easier region definition, especially in low-magnification quantitation 
methods such as TH-positive densitometry in which distinguishing the borders of the 
individual neuronal groups can be nearly impossible; these neuronal areas have 
differing functions and neuronal types (Jimenez-Castellanos and Graybiel, 1987; Da 
Cunha et al., 2009; Cho and Fudge, 2010).  Thus grouping some or all them all together 
for counting and morphology assessment can lead to inconsistent results among 
various studies; and to inconclusive clinical relevance if it is unknown which group of 
neurons was affected by a particular lesion or treatment. Thus, we chose to carefully 
define and quantify only the SNpc for two main reasons: 
 
1. The SNpc contains the majority of dopaminergic neurons which project to the 
striatum (Jimenez-Castellanos and Graybiel, 1987), and thus contains the 
population most likely to be affected by a striatal 6-OHDA region and most likely 
to reveal potentially subtle changes induced by a mild to moderate 6-OHDA 
lesion modeling early PD. 
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2. The SNpc contains more densely packed TH-positive neurons than other 
midbrain dopaminergic neuronal groups. Thus, for the purposes of 
demonstrating the optimal advantages of the modified TH-AgNOR staining 
technique, these neurons were the most likely in which we would be able to see 
a clear advantage of the better individual neuronal and nucleolar visualization 
provided by the TH-AgNOR stain. 
 
These results are found in Chapter 5. 
2.2.4 Aim 3: Altered neuronal and nucleolar morphology in substantia nigra dopamine 
neurons following 6-hydroxydopamine lesion in rats 
 Aim 3 was to use and expand the method developed in Aim 2 to quantify and 
characterize 6-OHDA-induced changes in nucleolar morphology.  We hypothesized that 
the unilateral intrastriatal 6-OHDA neurotoxic lesion would alter SNpc dopaminergic 
nucleolar morphology.  We chose to quantify the morphology of the nucleolus because 
it is a key organelle involved in the cell’s response to oxidative stress, which is proposed 
as both a cause and an effect in PD (Dauer and Przedborski, 2003; Hartmann, 2004).  
Since the nucleolus in an important regulator of the cell’s response to oxidative stress, 
and the place of rRNA production and assembly, and an important potential therapeutic 
target (Guarente, 1997; Hetman and Pietrzak, 2012), it is vital that this organelle in the 
early stages of the disease be better understood, and that quantitative methods be 
developed for assessing changes to the nucleolus after lesion induction or treatments.  
Although changes to SNpc neuronal number and neuronal volume have been 
investigated in PD and PD models, little is known about the changes to morphology to 
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the nucleolus in either animal models or in the disease, with only a single known study 
which quantified the volume of the nucleolus in PD brains (Mann and Yates, 1982). 
Using the TH-AgNOR stain and MicroBrightField StereoInvestigator software, we used 
the Optical Fractionator and Double Nucleator probes to quantify the SNpc planimetric 
volume, neuronal number and both the neuronal body and the nucleolar volume in the 
SNpc.  
These results are found in Chapter 6. 
2.2.5 Aim 4: Differentially altered neuronal number and morphology in midbrain 
dopaminergic subregions after a unilateral intrastriatal 6-OHDA lesion 
 Specific Aim 4 was to use the stereological method used in Aim 2 to determine 
effects of 6-OHDA on neuronal number and changes to neuronal and nucleolar volume 
in midbrain dopaminergic subregions. This project especially focused on the VTA and 
RRF, two dopaminergic subregions which are likely involved in the very early 
development of the disease, and could therefore lend insights into the cause and the 
development of a cure for PD.  We hypothesized that the unilateral intrastriatal 6-OHDA 
lesion differentially affects neuronal number and neuronal and nucleolar morphology in 
the SNpc, VTA and retrorubral field (RRF).  The substantia nigra (SN), VTA and RRF, 
corresponding to the A9, A10 and A8 groups of midbrain dopaminergic neurons as 
classified by Dahlstrom and Fuxe, are geographically separate groups of neurons with 
some overlapping projections.  Notably, all are affected in PD (Dahlstrom and Fuxe, 
1964; German et al., 1989; McRitchie et al., 1997; Jellinger, 1999; Rodríguez et al., 
2001).  Most of the mesostriatal dopamine neurons involved in the motor signs of PD 
originate in the SNpc (Jimenez-Castellanos and Graybiel, 1987).  The VTA is the origin 
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of the majority of mesocortical and mesolimbic dopamine neurons, and is implicated in 
the non-motor dopamine-dependent aspects of Parkinson’s such as depression, 
cognitive and affective deficits, which often present up to decades before motor signs 
(Marsden, 1990). The RRF neurons are known to project to both the nigrostriatal and 
mesolimbic systems (Jimenez-Castellanos and Graybiel, 1987).  The RRF is implicated 
in the presence of tremor and in the early-presenting sign of sleep disturbances in 
Parkinson’s (Lai et al., 1999; Kolasiewicz et al., 2012). There are very few studies 
addressing how the morphology of the dopaminergic neurons in these regions are 
differentially affected by PD.  Furthermore, there are no known studies of nucleolar 
morphology in the VTA and RRF in PD models, making this a promising area of 
discovery. 
 The Optical Fractionator and Double Nucleator stereological probes used in Aim 
2 were used in this aim to determine effects of 6-OHDA on neuronal number and 
changes to neuronal and nucleolar volume in the SNpc, VTA and RRF TH-AgNOR-
stained neurons. The SNpc and RRF regions are fairly easy to outline at low 
magnification, but definition of the VTA has presented a challenge to neuroanatomists 
to define (German and Manaye, 1993). The VTA is quite difficult to define because it is 
a large area with irregular borders surrounded by other groups of dopaminergic neurons 
which can be quite difficult to differentiate from those of the VTA.  Thus, we used a 
strictly defined anatomical protocol, defined in the Methods chapter, to outline and 
quantify this region.  
These results are found in Chapter 7. 
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CHAPTER 3 
MATERIALS AND METHODS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
73	  
3.1 Materials and methods  
All experiments were performed in compliance with the NIH Guide for the Care 
and Use of Animals and were approved by the University of Kansas Medical Center 
Institutional Care and Use Committee. 
 
3.2 Animals and husbandry  
 Male Long-Evans rats (90-100 days old) were bred in-house (breeding stock 
obtained from Harlan, Indianapolis, IN).  Rats were housed in a temperature- and 
humidity-controlled animal facility with a 14:10-h light-dark cycle (on at 06:00 h) with ad 
libitum access to water and chow. The control diet was AIN-93G (Teklad, Indianapolis, 
IN), and the n-3 Deficient diet was formulated as described (Table 1).  Adult breeders 
(P70) were allowed to acclimatize in the climate-and temperature controlled facility for at 
least one week before breeding.  Dams were placed on the experimental diets at the 
time of initial mating.  Weaned pups continued on their maternal diet throughout the 
study. Dams were allowed to recover for one week before being mated to produce the 
second litter. Litters were culled to 8 pups on postnatal day 1 and weaned on postnatal 
day 20.  Rats were housed four per cage from weaning until lesion surgery, after which 
they were kept in single housing until euthanized to ensure undisturbed recovery.  
 
3.3 Experimental Diets 
Our laboratory has extensive experience studying the effects of dietary n-3 
polyunsaturated fatty acid (n-3 PUFA) manipulations on behavior and neurochemistry 
(Levant et al., 2006b; Levant et al., 2006a; Levant et al., 2006c; Levant et al., 2007a; 
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Levant et al., 2007b; Ozias et al., 2007; Levant et al., 2008).  The diets are 7% fat by 
weight and vary only in the fatty acid composition.  The Control diet, AIN-93G (Teklad, 
Indianapolis, IN) is made from non-hydrogenated soybean oil (70 g/kg) and contains the 
recommended levels of ALA.  The Low n-3 diet is identical to the Control, except that it 
is formulated with both safflower (66.5 g/kg) and soybean (3.5 g/kg) oils, and contains 
approximately 1% of the ALA of the Control diet (Table 1).  
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Table 1. Diet Composition and Fatty Acid Composition 
Diet Fatty Acid 
Composition (g/kg) Control Low n-3 
Teklad  
Global 2016 
14:00 0.29 1.23 0.16 
16:00 9.84 7.23 6.16 
18:00 6.42 5.84 2.29 
20:00 0.51 0.19 0.14 
22:00 0.33 0.39 0.21 
24:00 ND ND ND 
16:01 ND 0.10 ND 
18:01 13.39 10.99 7.38 
20:1n-9 0.06 0.16 0.28 
18:2n-6 28.68 37.20 17.78 
18:3n-3 (ALA) 5.32 0.54 1.59 
20:2n-6 0.22 0.17 0.41 
20:4n-6 ND 0.62 0.11 
20:5n-3 (EPA) ND ND ND 
22:5n-3 ND ND ND 
22:6n-3 (DHA) ND ND ND 
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3.4 Procedures 
 Rats were subjected to a partial unilateral intrastriatal 6-hydroxydopamine (6-
OHDA) lesion.  D-amphetamine-stimulated rotation was assessed 7 days later.  After an 
additional 7 days to ensure clearance of drug [>10 t1/2s, tissue t1/2 = 5-9 hrs for the 
elimination phase (Kuhn and Schanberg, 1978), rats were euthanized for dopamine 
quantitation or histology.  Separate groups of rats were used for the histological and 
neurochemical end points, but all rats were evaluated for amphetamine-stimulated 
rotation. 
 
3.5 6-OHDA lesions 
 Rats were anesthetized with isoflurane (3%) and secured in a stereotaxic frame. 
After creating a burr hole in the skull over the right striatum (AP+ 1.0 mm, ML+ 2.5 mm 
vs. bregma), a 26-gauge dome-tipped needle attached to a microliter syringe with 
Teflon tubing was lowered into the striatum (5.0 mm from dural surface).  6-OHDA (12.5 
µg administered in a volume of 5.0 µL, at 2.5 µg/µL, in 0.9% saline with 0.1% ascorbic 
acid) was infused at the rate of 0.5 µL/min based on previously published methods 
(Bethel-Brown et al., 2010; Bethel-Brown et al., 2011). The infusion needle was left in 
place for an additional 5 minutes and then slowly withdrawn.  Bone wax was applied to 
the burr hole, and the scalp closed with wound clips.  Buprenex (0.05 mg/kg body 
weight) and ketoprofen (5 mg/kg body weight) were given post-surgery, with follow-up 
doses of ketoprofen for two days, and animals were allowed to recover in single 
housing. 
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3.6 D-amphetamine-stimulated rotations  
 Seven days after surgery, rats were injected with d-amphetamine sulfate (2.5 
mg/kg, sc, in saline) and placed in a rotometer for 60 minutes.  The rotometer is a 26.5 
cm diameter cylinder placed atop a force-sensing actometer surface [see (Fowler et al., 
2001).  D-amphetamine sulfate was injected (2.5 mg/kg in 0.9% saline, S.C.) and 
animals were placed in a rotometer for 60 min.  The rotometer is a force-sensing 
actometer with a 26.5 cm diameter cylindrical chamber (Bethel-Brown et al., 2010).  
Custom software was used to quantify the number of rotations.  
 
3.7 Determination of striatal dopamine content 
 Rats were decapitated, and brains rapidly removed and frozen on dry ice.  Left 
and right caudate-putamen were isolated by freehand dissection on ice and stored at -
80° C.  Concentrations of dopamine were quantified using an isocratic high-
performance liquid chromatography-electrochemical detection (HPLC-EC) system (ESA 
Coulochem III, Chelmsford, MA) coupled to a Coulochem III dual-channel 
electrochemical array detector (E1 + 0.35 mV and E2 − 0.25 mV using a 5011 dual 
analytical cell ESA Model 5100A) as previously described (Levant et al., 2008).  Tissues 
were extracted in 0.3 N perchloric acid.  Analytes were separated using a C18 reverse 
phase column (ESA HR-80 C18, 4.6 mm × 80 mm, 3 µm) with a pH 4.0 citrate-acetate 
mobile phase containing 4.0% methanol and ~0.35 mM 1-octane-sulfonic acid at a flow 
rate of 1.8 ml/min. 3,4-dihydroxy-benzylamine was used as the internal standard.  
Protein concentrations of the extracted tissues were determined by the BCA method 
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(Pierce, Rockford, IL).  Striatal dopamine concentrations were expressed as ng/mg 
protein. 
3.8 Fatty Acid Content Analysis 
  Phospholipids were extracted from frontal cortex, a brain region not required for 
other endpoints according to a protocol previously used in our laboratory (Levant et al., 
2004).  Phospholipids were isolated by thin layer chromatography.  The phospholipid 
band was removed and transmethylated with boron trifluoride methanol to produce fatty 
acid methyl esters, which were then separated on a Varian 3400 gas chromatograph 
(GC) with an SP-2330 capillary column, with helium used as the carrier gas.  Peaks 
were identified by comparison to authentic standards.  Data were expressed as percent 
of total fatty acids on the basis of peak area.  
 
3.9 Histological analysis 
3.9.1 TH-AgNOR staining 
 Rats were deeply anesthetized with pentobarbital and perfused with 0.1M 
phosphate buffered saline (PBS) (pH 7.2), followed by 4% paraformaldehyde in PBS, 
and decapitated.  Skulls were post-fixed at 4° C for at least 7 days, and then transferred 
to PBS.  Brains were extracted and coronal sections (50 µm) were prepared and stained 
by NeuroScience Associates (Knoxville, TN), using MultiBrainTM Technology.  Free-
floating sections were stained with a modified tyrosine hydroxylase plus silver nucleolar 
stain (TH-AgNOR).  Sections were mounted on gelatinized (subbed) glass slides. 
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3.9.2 Stereology  
 Every sixth section containing SNpc was selected for stereological quantitation 
(Bregma −4.70 to −6.30mm).  TH-AgNOR-stained cells were quantified using the 
Microbrightfield Stereoinvestigator software package combined with a Nikon Eclipse 
TE2000-U microscope coupled to a Heidenhein linear encoder unit and a QImaging 
Retiga-2000R color digital video camera.  Guided by an atlas (Paxinos and Watson, 
1998), the SNpc (Bregma -4.80 to -6.30) was outlined in rostrocaudal sections at 4X 
magnification to exclude the parabrachial pigmented nucleus (PBP), substantia nigra 
pars reticulata, SN pars lateralis, the accessory optic tract, SN pars medialis, and the 
VTA.  The VTA was outlined (Bregma -5.20 to -6.80) to exclude the SNpc, SN medialis, 
fasciculus retroflexus, mammillotegmental tract, mammillary peduncle, interfascicular  
nucleus, the rostral line of the nucleus of Raphe, the medial lemniscus, the paranigral 
nucleus, the visual tegmental relay zone, the accessory optic tract, all portions of the 
interpeduncular nucleus, and the RRF.  The PBP was excluded as much as it was 
distinguishable from the boundaries of the VTA (which is difficult in the caudal portions), 
but all sections were photographed and compared for consistent definition of regions.  
The RRF was outlined (Bregma -6.30 to -7.04) to exclude the substantia nigra reticularis 
and the VTA.  The variations in brain positioning in the MultiBrain® embedding process 
provide a randomized sectioning start for each brain quantified.  Cells were counted and 
volumes measured at 100X magnification using the simultaneous application of the 
optical fractionator and a double nucleator method.  The nucleus was used as the 
unique marker for each neuron.  The Double Nucleator was then employed by 
automatic software placement of four randomly oriented crossed rays centered at the 
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counting point, and four discriminately placed markers on the outside borders of each of 
the nucleolus and the outline of the cell body, respectively.  In some neurons the 
nucleolus was visible within the nucleus, but dark staining of the nucleus made it 
impossible to accurately distinguish the borders of the nucleolus for placement of the 
nucleator probe.  These neurons were included in the total cell count, but were not 
included in the volumetric analyses because it was not possible to employ the double 
nucleator technique.  A maximum coefficient of error of 0.15 (m=1) was accepted for all 
results, except for the TH-positive neuronal number values for the RRF in Aim 4, in 
which the CEs ranged from 0.11 to 0.22 (Gundersen et al., 1999).  
 
3.10 Data analysis 
 All data are presented as the mean ± S.E.M.  Outliers identified by Systat on 
initial analysis were discarded.  A significant difference was assumed if P <0.05.  
 For the amphetamine-induced rotational analysis, rats were included in data 
analyses even if they had a very low number of rotations.   
 For Aim 1, brain phospholipid PUFA composition and rotational behavior were 
analyzed by two-way ANOVA with factors of diet and litter (Systat, v.12).  Striatal 
dopamine concentration was analyzed by three-way ANOVA with factors of diet, litter 
and lesion (repeated measure).  Post hoc comparisons were made using 1-way ANOVA 
and the Fisher’s Least Significant Difference test.  The difference in percentages of 
neuronal number and volume change in 2nd litter rats were analyzed by Student’s-t test 
(Instat, v. 3.0).  
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 For Aims 2, 3, and 4, the effects of 6-OHDA between the ipsilateral and 
contralateral hemispheres were tested for statistical significance using paired t-tests 
(SigmaPlot, v.11.0). Within-subject changes in any parameter were expressed as a 
percentage relative to the contralateral side.  
 For Aim 4, the mean percentage changes among the SNpc, VTA and RRF were 
analyzed by repeated-measures one-way ANOVA, and post hoc comparisons were 
made using Student-Newman-Keuls. In the cases of neuronal number and neuronal 
volume, nonparametric repeated measures ANOVA followed by Dunn’s multiple 
comparisons test was used (Instat, v.3.0).  
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CHAPTER 4 
THE EFFECTS OF AN N-3 PUFA-DEFICIENT DIETARY AND BREEDING 
PROTOCOL ON A UNILATERAL INTRASTRIATAL 6-OHDA LESION MODEL IN RATS 
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4. 1 Abstract  
 Rats fed an n-3 polyunsaturated fatty acid (n-3 PUFA)-deficient diet have fewer 
nigrostriatal dopamine neurons (Ahmad et al., 2008), suggesting that low dietary n-3 
PUFAs may increase vulnerability to Parkinson’s disease (PD).  In view of this potential 
increased vulnerability, the effects of a neurotoxic lesion PD model were examined in n-
3 PUFA-deficient rats.  The effects of partial unilateral striatal 6-hydroxydopamine (6-
OHDA) lesions were determined in male Long-Evans rats with two levels of decrease in 
brain phospholipid DHA content (36% and 42%) produced using an n-3 PUFA-deficient 
diet and breeding protocols.  A functional effect of the lesion was assessed 7 days post-
surgery by measuring d-amphetamine (2.5 mg/kg, s.c.)-induced rotational behavior and 
striatal dopamine content.  In rats with a 42% decrease in brain docosahexaenoic acid 
(DHA), the neuronal number and neuronal volume of tyrosine-hydroxylase silver 
nucleolar (TH-AgNOR)-stained substantia nigra (SN) neurons were determined by 
stereological analysis.  Consistent with the loss of dopamine neurons after 6-OHDA 
infusion, amphetamine induced rotation towards the lesioned side, and striatal 
dopamine was depleted by more than 90% in all treatment groups (P<0.001), although 
diet had no effect on these parameters.  The 6-OHDA lesion induced a decrease in TH-
positive ipsilateral SN neuronal volume (51% ± 10% for Low n-3 rats and 45% ± 5% for 
Control rats, P<0.001), but no significant change in ipsilateral neuronal volume in either 
diet.  There was no effect of diet on TH-AgNOR-stained dopaminergic neuronal number 
or volume.  While this finding suggests that the effect of 6-OHDA was similar in both diet 
groups, further studies need to be pursued in order to establish whether there is a 
threshold effect of DHA deficiency in prevention of 6-OHDA-induced neurotoxic effects. 
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4.2 Introduction  
Parkinson’s disease (PD) is a debilitating neurodegenerative disease 
characterized by the loss of striatal dopamine and consequent clinical signs of tremor, 
rigidity and bradykinesia.  Although the etiology of the majority of PD cases is still not 
known, evidence strongly points to several potentially modifiable contributors to 
neurodegenerative diseases such as PD, including oxidative stress and 
neuroinflammation (Jenner, 2003; Griffin, 2006; Dutta et al., 2008; Gao and Hong, 2008; 
Orr and Bazinet, 2008a; Amor et al., 2010; Kones, 2010).  Dietary deficiency of 
polyunsaturated fatty acids (PUFAs) is a potential contributing factor to the development 
of neurodegenerative diseases, including PD.  N-3 PUFAs such as docosahexaenoic 
acid (DHA) are crucial to brain composition and optimal function (Willatts et al., 1998; 
Birch et al., 2000), and have been implicated in the development and sequelae of 
numerous diseases in humans, including neurodegenerative diseases (Youdim et al., 
2000; Orr and Bazinet, 2008a; Bazan et al., 2011).  
Dietary n-3 PUFA deficiency is pervasive in Western society, and likely impacts a 
variety of human health outcomes.  DHA and the n-6 PUFA arachidonic acid (AA) must 
be consumed in the diet, or their essential fatty acid precursors α-linolenic acid (ALA) 
and linoleic acid (LA) must be provided.  In humans, most of the DHA in the brain is 
accumulated in late gestation and early childhood through the mother’s dietary 
consumption and breast milk, with lifelong turnover (Clandinin et al., 1980a; Clandinin et 
al., 1980b; Hadley et al., 2009).  In rats, accretion of brain DHA occurs primarily during 
the last three days of gestation through weaning (Kishimoto et al., 1965; Green and 
Yavin, 1996).  Western diets are very low in n-3 fatty acids, and have an n-6/n-3 as high 
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as 16.7/1 (Simopoulos, 2003).  A very high n-6/n-3 ratio has been implicated in a variety 
of human diseases such as coronary artery disease, hypertension, diabetes, arthritis, 
osteoporosis, autoimmune disorders, cancer and mental health (Simopoulos, 2008).  
Low dietary n-6/n-3 ratios have been shown to favorably alter LDL status, improve 
cardiovascular health, have anti-proliferation effects in colorectal cancer, decrease the 
risk of breast cancer, and decrease inflammation in rheumatoid arthritis and asthma 
(Haworth and Levy, 2007; Calder and Yaqoob, 2009; Fetterman and Zdanowicz, 2009; 
Hartwich et al., 2009; Lavie et al., 2009).  Thus the high n-6/n-3 PUFA ratio found in 
Western diets may be the harbinger of a variety of complicated health effects that will 
greatly impact the aging population.  
Indeed, PUFAs have already been implicated in neurodegenerative diseases, 
including PD.  Although there is a lack of conclusive clinical evidence for the role of n-3 
PUFA’S in PD, the Rotterdam study concluded that a high dietary intake of unsaturated 
fatty acids may be protective against PD (de Lau et al., 2005).  Apart from motor 
improvements, n-3 PUFAs have known benefits in several affective disorders and may 
be especially beneficial in the non-motor aspects of PD such as depression.  In one 
recent study, consumption of fish oil improved depressive symptoms in PD patients, 
when taken either with or without antidepressants (da Silva et al., 2008).  Although the 
difficulty of completing large-scale clinical trials due to confounds and inter-study 
variations has not established a clear link between n-3 PUFAs and PD, PD models have 
shown promising evidence that n-3 PUFAs play an important role in dopaminergic 
neuronal maintenance and the modulation of stressors similar to those seen in PD.  In 
PD, DHA supplementation has improved a variety of outcomes, such as decreased L-
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DOPA dyskinesia (Samadi et al., 2006), decreased loss of dopaminergic neurons , and 
decreased striatal dopamine depletion (Bousquet et al., 2011).  Overall, more studies 
are needed to fully understand the role of PUFAs in PD. 
In this study, the effects of a dietary n-3 PUFA deficiency in the unilateral 
intrastriatal 6-hydroxydopamine model of PD in rats were determined using a breeding 
model that produced different levels of DHA deficiency with two consecutive litters from 
the same dams.  Previous breeding studies in our laboratory have shown that a 
decrease in n-3 fatty acids in the diet results in a decrease of brain DHA of 32% and 
54%, in first litter and second litter pups, respectively (Ozias et al., 2007).  Thus brain 
DHA content is replaced in the Low n-3 rats with the n-6 PUFA DPA, altering the ideal 
n-6/n-3 PUFA ratio.  Consequent litters do not show marked decreases in percent of 
brain n-3 PUFAs after the second litter (Levant et al., 2006a), so this study was 
restricted to two litters.  
The unilateral intrastriatal 6-hydroxydopamine (6-OHDA) PD model employs 6-
OHDA, a neurotoxin resembling dopamine, which is taken up by monoamine 
transporters and causes neurodegeneration by oxidative mechanisms (Kostrzewa and 
Jacobowitz, 1974; Glinka et al., 1997).  This method is especially relevant for modeling 
the early stages on PD, in which neuroprotectants and dietary interventions might be 
especially crucial. To determine the effects of an n-3 PUFA deficiency in this model, we 
assessed brain PUFA composition, amphetamine-induced rotational behavior and 
striatal dopamine content in both 1st and 2nd litter rats.  Morphological changes to 
substantia nigra pars compact (SNpc) neurons as quantified by stereological techniques 
and the tyrosine hydroxylase silver nucleolar (TH-AgNOR) staining method were 
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assessed only in 2nd litter rats, which exhibited the greatest diet-induced change in brain 
phospholipid fatty acid composition. 
4.3 Results 
4.3.1 Effects of diet and breeding protocol on growth 
The mean weight of both the Low n-3 and Control 2nd litter rats at sacrifice (70-
100 days) was increased compared to 1st litter animals (P<0.001 by ANOVA), but there 
was no effect of the diet on weight.  
4.3.2 Effects of diet, breeding protocol and 6-OHDA lesion on brain phospholipid fatty 
acid composition 
1st litter rats raised on the Low n-3 diet had an 36% decrease in brain DHA 
phospholipid content compared to those raised on the Control diet, and 2nd litter Low n-3 
rats had an 42% decrease in brain DHA compared to Control rats, although the 
difference between 1st and 2nd litter Low n-3 brain DHA was not significant (Fig. 1).  The 
loss in 1st litter rats is greater than expected with previous studies in our laboratory, in 
which DHA losses of approximately 32% and 55% were found in 1st and 2nd litters, 
respectively (Ozias et al., 2007).  Furthermore, the 2nd litter rats did not achieve as high 
a level of DHA loss as in previous studies, which may be the reason why the 
morphological changes to DHA-deficient dopaminergic neurons observed in a previous 
study in our laboratory (Ahmad et al., 2008) were not replicated.  There were 
compensatory increases in the Low n-3 rats of the n-6 fatty acid docosapentaenoic acid 
[(n-6) DPA, 22:5(n-6)] compared to the Control rats (p<0.001 by ANOVA), and DPA was 
increased in the 2nd litter compared to the 1st (P<0.001 by ANOVA).  There was no 
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effect of diet or litter on levels of arachidonic acid [20:4(n-6)], in concordance with 
previous studies (Galli et al., 1971).  
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Figure 1.   
Effects of diet and litter on brain total phospholipid fatty acid composition.  Data 
are presented as the mean ± SEM (n = 6-11).  *P<0.001 by ANOVA and Fisher’s LSD 
test  
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4.3.3 Effects of diet, breeding protocol, and 6-OHDA lesion on striatal dopamine 
concentration 
 The dopamine levels measured in the hemispheres contralateral to the lesion 
were comparable to those found in previous studies (Kilts et al., 1981; Widerlöv et al., 
1982; Davis et al., 2010; Levant et al., 2011).  6-OHDA lesion resulted in decreased 
dopamine concentrations in the ipsilateral dopamine concentrations all rats in all groups 
(vs. contralateral concentration, P<0.001 by paired t-test, n = 9-11).  There was a mean 
striatal dopamine depletion of the ipsilateral side compared to the contralateral of 91 ± 
26% in 1st Litter Control rats, 95 ± 30% in 1st Litter Low n-3 rats, 95 ± 30% in 2nd Litter 
Control rats, and 91 ± 26% in 2nd Litter Low n-3 rats.  There was no effect of diet or 
litter on percentage of striatal dopamine loss, as determined by ANOVA (Fig. 2).  
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Figure 2.   
Effects of diet, breeding protocol and unilateral intrastriatal 6-OHDA lesion on 
striatal dopamine.  There was no effect as determined by ANOVA of diet or litter on 
percentage of striatal dopamine loss (n= 9-11). 
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4.3.4 Effects of diet and breeding protocol on amphetamine-induced rotational behavior 
The mean total number of d-amphetamine-stimulated rotations completed by 
lesioned rats during the 60-minute observation period was 124 ± 26 in the 1st litter 
Control rats, 157 ± 32 in the 1st litter Low n-3, 153 ± 30 in the 2nd litter Control rats and 
128 ± 22 in 2nd litter Low n-3 rats, indicating a functional dopaminergic deficit in the 
ipsilateral striatum.  The numbers of recorded rotations in the 60-min recording period 
ranged from 2 to 641 in 1st litter Low n-3 rats, from 1 to 426 in 1st litter Control rats, from 
8 to 358 in 2nd litter Low n-3 rats, and from 4 to 464 in 2nd litter Control rats. There was 
no effect of either diet or litter on the mean total numbers of amphetamine-stimulated 
rotations as determined by ANOVA (Figure 4).  
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Figure 3. 
 
Effects of diet and breeding protocol on amphetamine-induced rotational 
behavior. There was no effect of either diet or litter on mean total amphetamine-
stimulated rotations as determined by ANOVA (n = 20-21).  
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4.3.5 Effects of diet and lesion on TH-positive SNpc neuronal number in 2nd Litter rats 
In 2nd litter rats, which had the greatest decrease in brain DHA content achieved 
in this study, the mean number of SNpc TH-positive neurons on the intact side (12,872 
± 469 in Control rats and 12,545 ± 371 in Low n-3 rats) was similar to findings in 
previous stereological studies (Kirik et al., 1998; Lindner et al., 1999; Carvalho and 
Nikkhah, 2001; Debeir et al., 2005; Gomide et al., 2005; Ahmad et al., 2008; Eriksen et 
al., 2009).  The estimated numbers of contralateral TH-positive SNpc neurons in 
individual rats ranged from 10,336 to 13,686 in Low n-3 rats and from 11,087 to 14,500 
in Control rats.  The estimated numbers of ipsilateral TH-positive SNpc neurons ranged 
from 4,446 to 11,149 in Low n-3 rats and from 3,257 to 11,099 in Control rats.  All rats 
had reduced numbers of TH-positive SNpc neurons after 6-OHDA lesion, and both diets 
showed decreased number of TH-positive cells in the ipsilateral SNpc compared to the 
contralateral SNpc (P<0.001 by paired t-test).  The losses of TH-positive SNpc neurons 
ranged from 19% to 57% in Low n-3 rats, and from 7% to 75% in Control rats. The 
mean within-subject decrease in TH-positive neuron number between the ipsilateral and 
contralateral SNpc was 51% ± 10% for Low n-3 rats and 45% ± 5% for Control rats.  
There was no difference between the diets on mean percent loss of neurons on the 
ipsilateral side (t-test, P>0.05). (Figure 4)  
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Figure 4.   
Effects of diet on TH-positive SNpc neuron number. There was no effect of diet on 
percent neuronal loss after 6-OHDA (t-test, P>0.05, n = 7-8). 
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4.3.6 Effects of diet and lesion on TH-AgNOR positive neuronal volume in 2nd Litter rats 
The mean neuronal volume of SNpc TH-positive neurons on the intact side 
(3,444 ± 118 µm3 in Control rats and 3,037 ± 129 µm3in Low n-3 rats) was comparable 
to findings in previous stereological studies (Gomide et al., 2005; Healy-Stoffel et al., 
2012).  Five of 7 Control and 5 of 8 Low n-3 rats exhibited decreased average neuronal 
body volume after 6-OHDA lesion.  The estimated volumes of contralateral TH-positive 
SNpc neurons ranged from 2,905 to 4,103 µm3 in Low n-3 rats and from 3,206 to 4,109 
µm3 in Control rats.  The mean estimated volumes of ipsilateral TH-positive SNpc 
neurons ranged from 2,581 to 3169 µm3 in Low n-3 rats and from 2,489 to 3513 µm3 in 
Control rats.  The change in TH-positive SNpc neuron volume ranged from +5% to -23% 
in Low n-3 rats, and from +3% to -39% in Control rats. There was a mean within-subject 
decrease in neuronal body volume of 11 ± 6% in Low n-3 rats and 7 ± 4% in Control 
rats, although neither decrease was significant (paired t-test, P>0.05).  There was no 
difference between the diets on mean percent loss of neuronal volume on the ipsilateral 
side (t-test, P>0.05). (Figure 5)  
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Figure 5.   
Effects of diet on TH-positive SNpc neuron volume. There was no effect of diet on 
the percent neuronal body volume loss after 6-OHDA (t-test, P>0.05, n = 7-8). 
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4.4 Discussion 
 In this aim, a diet and breeding protocol employing a Low n-3 diet from 
conception was used to achieve differing levels of n-3 PUFA brain composition in rats.  
Although the maternal diets remain consistent throughout the study, the Low n-3 
cohort’s maternal DHA stores are depleted after the 1st litter and further diminished after 
the 2nd litter; thus the dams have less available DHA to pass on to their nursing pups 
(Jumpsen et al., 1997; Ozias et al., 2007).  Thus, differing levels of brain DHA depletion 
were expected, with a greater depletion expected in the 2nd litter rats.  Brain DHA was 
decreased 36% in 1st litter, and 45% in 2nd litter rats, although the difference between 
the litters was not significant.  The level of DHA depletion in the 1st Litter Low n-3 rats 
was greater than expected.  However, the 2nd litter levels of DHA depletion were 
comparable to, but not as great as, the 54% loss in a previous study from our laboratory 
(Ozias et al., 2007).  Thus, the rats prepared for this study did not generate a “DHA 
dose-response” that would have facilitated assessment of several levels of brain DHA 
content on the effects of 6-OHDA lesion.  Nevertheless, the study does represent a 
valid assessment of the effects of low n-3 PUFAs on rats with approximately 40% of the 
normal brain phospholipid n-3 PUFA depletion on neuronal number and volume in a 
mild to moderate 6-OHDA PD lesion model.  As such, this study provides an informative 
starting point from which to design future studies in order to determine a threshold of 
effects for n-3 PUFA depletion in early PD models. 
 To validate the lesion and to determine the effects of brain PUFA content on 
motor behavior after striatal depletion by intrastriatal 6-OHDA, d-amphetamine-induced 
rotational behavior was assessed by force-plate rotometry.  There was no effect of diet 
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or litter on d-amphetamine-induced rotations.  The total numbers of rotations for a 60 
min. period are comparable to previous studies (Lee et al., 1996; Roedter et al., 2001; 
Bethel-Brown et al., 2010).  The lack of an effect of differing levels of brain and dietary 
n-3 PUFAs on rotational behavior may be explained in the context of a recent study in 
which DHA supplementation in a mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) model reduced the loss of TH-positive SN neurons, but there was no 
improvement of motor activity (Ozsoy et al., 2011a).  This suggests that even when the 
DHA exerts a neuroprotective effect on cells, there may be a threshold effect before 
functional improvements are observed.  Contralateral striatal compensation could also 
have occurred, since projections are known to sprout from the contralateral side in 
lesion models (Finkelstein et al., 2000), and our relatively mild lesion may not be 
enough to elicit subtle effects induced by n-3 PUFA deficiency that a more severe lesion 
could.  Overall, in our study rotational behavior was successful for lesion validation 
purposes, although more sensitive behavioral assessments may be needed in future 
studies to show differences caused by diet.   
 Furthermore, there was no difference in the number of neurons between the 
Control and Low n-3 contralateral SNpc.  This is in contrast to a recent study performed 
in our laboratory, which found that intact rats (not 6-OHDA lesioned) fed a low n-3 
PUFA diet, which produced a decrease in brain DHA of 54% in other rats using the 
same breeding protocol (Ozias et al., 2007), had 33% fewer SNpc TH-positive neurons 
(Ahmad et al., 2008), as well as another recent study which found fewer SN 
dopaminergic neurons in rats fed an n-3 PUFA deficient diet from conception (Cardoso 
et al., 2012).  Although these stereology results do not support our hypothesis that there 
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would be differences in neuronal number between the Control and Low n-3 rats, 
differences in the study designs offer an explanation for these findings.  The previous 
study in our laboratory was performed in unlesioned rats.  Although using the 
contralateral side of the lesion as the control to compare changes in morphology is a 
common and well-accepted method among 6-OHDA studies (Lee et al., 1996; Kirik et 
al., 1998; Roedter et al., 2001; Deumens et al., 2002; Gomide et al., 2005), it could 
produce different results than using unlesioned rats as the control.  Crossed fibers from 
ipsilateral striatum have been found to project to the contralateral side, and the 
contralateral side is slightly affected after unilateral 6-OHDA lesion (Cheng et al., 1998; 
Finkelstein et al., 2000).  This can allow the loss of ipsilateral neurons to be 
underestimated when using the contralateral side as a control.  However, staining 
conditions can vary considerably between individual animals, so using separate 
unlesioned animals can introduce additional bias, making within-subject comparisons 
between the contralateral and ipsilateral sides an attractive alternative.  In addition, 
observing the changes that occur between the contralateral and ipsilateral sides may be 
most relevant to what is occurring in PD, since motor signs usually present unilaterally.  
In summary, although unlesioned control animals present their own biases, in future 
studies quantifying dopaminergic neurons from unlesioned animals would help confirm 
whether the neuronal deficits caused in the previous studies in unlesioned rats were 
replicable, or whether it is something about the lesion itself that changes the expected 
proportions of SNpc neurons between the Control and Low n-3 rats. 
 Although the 6-OHDA lesion decreased both the SNpc number and the neuronal 
volume in the ipsilateral SNpc in both the Control and Low n-3 rats, the change elicited 
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by the 6-OHDA lesion to neuronal volume was not significant in either Control or Low n-
3 2nd litter rats, and there was no difference between the diet groups in the percent 
decrease in either neuronal number or neuronal volume.  Several potential mechanisms 
could be contributing to the lack of an effect of diet on the SNpc neurons after a mild to 
moderate 6-OHDA lesion.  Even if the Control diet rats initially did have more SNpc 
neurons than the Low n-3 rats, the DHA-sufficient Control neurons may have been more 
susceptible to oxidative damage than their Low n-3 counterparts, and thus any potential 
advantage in initial neuronal number could have been masked by increased neuronal 
loss in the Control rats.  Despite the many studies demonstrating beneficial effects of 
DHA, others suggest that in high oxidation states, the increased capacity for lipid 
peroxidation provided by a PUFA-rich environment can lead to increased oxidative 
damage (Montine et al., 2004; Kabuto et al., 2009; Yakunin et al., 2012).  Thus, in the 
high oxidative stress environment induced in the SNpc dopaminergic neurons by 
intrastriatal 6-OHDA infusion, a mild DHA deficiency such as that found in our rat model 
may in fact be beneficial in preventing the oxidative-stress-induced loss of neurons on 
the both the lesioned and the contralateral side, which contains a small percentage of 
crossed fibers from the ipsilateral side (Finkelstein et al., 2000) by providing fewer 
targets for lipid peroxidation (Yakunin et al., 2012).  Alternatively, the fact that there was 
no discernible protective effect of DHA deficiency in the Low n-3 rats may support the 
theory that at some neurotoxic threshold, any neuroprotective benefit of n-3 PUFAs may 
be overwhelmed.  Obviously, further studies are needed to establish the threshold of 
neuroprotection against 6-OHDA in our n-3 PUFA deficiency rat model.   
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 Other studies have found decreased loss of TH-positive neurons in PD models 
after n-3 PUFA supplementation (Bousquet et al., 2008; Cansev et al., 2008; Ozsoy et 
al., 2011a).  Thus it is likely that n-3 PUFA consumption or brain DHA content does play 
some role in the development or prevention of PD, and this hypothesis deserves the 
dedication of further studies.  In this project, however, we created a relatively mild n-3 
PUFA deficiency meant to model the Western diet, combined with a moderate loss of 
SNpc neurons intended to mimic early PD.  Thus, our rats may not have experienced 
the degree of neuronal insult necessary to demonstrate any potential differences in 
response to 6-OHDA caused by a moderately n-3 PUFA-deficient diet.  In short, this 
project, in attempting to best model the conditions found in pre-clinical PD and a 
standard Western diet, may be suffering from inconclusive results because subtle 
changes caused by a mild deficiency in an early disease cannot be detected by 
rotational behavior or stereology.   
4.5 Conclusions 
Overall, this study was informative, yet inconclusive.  This study successfully 
determined the effects of low n-3 PUFAs on neuronal number and volume in a mild to 
moderate 6-OHDA PD lesion model.  However, based on our results, it can only be 
concluded that low n-3 PUFAs from conception have no effect on SNpc dopaminergic 
number and morphology at the particular level of dietary n-3 PUFA depletion and 6-
OHDA dose and route of administration employed in this study.  In order to definitively 
say that the Low n-3 diet has no effect on the behavior or neuronal number and 
morphology in the unilateral intrastriatal 6-OHDA lesion model, we would need to do 
further studies to replicate the stereological findings previously obtained in our 
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laboratory on unlesioned Low n-3 rats.  In addition, it would be informative to expand 
the lesion procedures to include a range of doses, and well as to experiment with 
varying doses of dietary n-3 PUFAs, to test whether our lack of findings was an indicator 
that there truly is no effect of the Low n-3 diet on the endpoints chosen, or whether 
different endpoints or if more severe neuronal stress elicited by an n-3 PUFA deficiency 
or a more severe 6-OHDA model is necessary to be able to discern any differences 
using our quantitative techniques.  
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CHAPTER 5 
TYROSINE HYDROXYLASE-SILVER NUCLEOLAR STAINING TO DETERMINE THE 
EFFECTS OF A UNILATERAL INTRASTRIATAL 6-HYDROXYDOPAMINE LESION IN 
THE SUBSTANTIA NIGRA 
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5.1 Abstract 
 Neurotoxic lesions of the nigrostriatal pathway model the deficits found in 
Parkinson’s disease (PD).  This study used stereology and a novel staining method to 
examine the effects of a partial unilateral striatal 6-hydroxydopamine (6-OHDA) lesion 
on substantia nigra pars compacta dopamine neuron number and morphology in rats.  
Adult male Long-Evans rats were subjected to unilateral lesion of the substantia nigra 
pars compacta (SNpc) by intrastriatal microinjection of 6-OHDA (12.5 µg).  Lesions 
were verified by d-amphetamine-stimulated rotation (2.5 mg/kg, sc) by force-plate 
rotometry 7 days post-surgery.  Seven days after rotation testing, rats were euthanized, 
and brains were prepared for either histology (n = 12) or determination of striatal 
dopamine content by HPLC-EC (n =20).  Brains prepared for histology were stained for 
tyrosine hydroxylase silver nucleolar (TH-AgNOR) staining using a modified protocol 
developed for stereological assessment.  The AgNOR counterstain allowed for precise 
definition of the nucleolus of the cells, facilitating both counting and qualitative 
morphometry of TH-positive neurons.  Stereological quantitation determined a 54% 
decrease in TH-positive neuron number (P<0.01), and a 14% decrease in neuron 
volume (P<0.05) on the lesioned side.  Striatal dopamine concentration was decreased 
by 92% (P<0.01), suggesting that striatal dopamine analysis may overestimate the 
numbers of SNpc neurons lost. These findings demonstrate that combined use of TH 
and AgNOR staining provides improved characterization of 6-OHDA-induced pathology.  
Furthermore, the data suggest that decreased neuronal volume as well as number 
contributes to the functional deficits observed after unilateral intrastriatal 6-OHDA 
lesion.   
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5.2 Introduction 
Parkinson’s disease (PD) is a chronic neurodegenerative disorder marked by 
loss of nigrostriatal dopamine neurons, resulting in clinical signs when about 80% of 
striatal dopamine is depleted (Calne and Langston, 1983).  Current treatments are 
largely palliative, emphasizing the urgent need for preventative and disease-modifying 
treatments.  However, the development of such early-stage treatments is fraught with 
challenges.  The relationships between the causative factors of PD and the effects of 
neuroprotective treatments are still unclear (Ybot-Gorrin et al., 2011), and a better 
understanding of neuronal morphology is needed to elucidate the mechanisms of 
neurodegenerative disease (Przedborski et al., 2003). Thus the importance of early- to 
moderate-stage PD models is vital to advancing the treatment of the disease.    
 The partial unilateral intrastriatal 6-hydroxydopamine (6-OHDA) model is a 
clinically-relevant model of early-stage PD (Kirik et al., 1998; Deumens et al., 2002). 
This technique is widely used as an investigational tool for both screening potential 
therapeutics and for understanding the underlying mechanisms of early PD.   Although 
rotational behavior and striatal dopamine concentration are routinely quantified after 
neurotoxic lesions to verify a functional dopaminergic deficit, advanced histological 
analysis is needed to assess the effects of the lesion and potential treatments on 
morphologic changes to the dopaminergic neurons.  Histological analysis of partial 6-
OHDA lesions in the substantia nigra pars compacta (SNpc) is challenging, however, 
because moderate degenerative changes to neuron morphology can be difficult to 
quantify.  Stereological analysis using tyrosine hydroxylase (TH) staining of dopamine 
neurons has been used to study the morphological changes in several animal models of 
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PD, but the morphometric outcomes vary according to study.  The variation in the 
results of PD model morphology studies has been attributed to the varying lesion, 
staining and quantitation methods used (Stark and Pakkenberg, 2004); and while a 
certain amount of inter-study variation is unavoidable, a clear understanding of the 
morphology of dopaminergic neurons has undoubtedly been clouded by the inconsistent 
findings in the literature.  
Darkly pigmented TH antibody immunostaining can mask morphological markers 
such as the nucleolus and individual neuronal body outlines in regions thickly populated 
with TH-positive neurons.  With the goal of better understanding the effects of 6-OHDA 
on dopaminergic morphology, this study used stereological methods and a newly 
available commercial TH stain combined with a silver nucleolar (AgNOR) stain to 
determine the effects of 6-OHDA partial unilateral intrastriatal lesions on cell number 
and morphology.   AgNOR staining is a silver nitrate preparation that targets 
chromosomal proteins in the nucleolus known as nucleolar organizing regions (NORs).  
This stain, which has been extensively used by cancer pathologists to assess cell 
proliferation (Trerè, 2000), has recently been exploited for use as a co-stain in 
dopaminergic neurodegeneration studies (Switzer III et al., 2011).  We will show that the 
combined use of TH and AgNOR staining provides improved characterization of 6-
OHDA-induced pathology by facilitating the identification and quantification of neuronal 
structures used in stereology.  In addition, our findings suggest that decreased neuronal 
volume as well as decreased neuronal number contributes to the functional deficits 
observed after unilateral 6-OHDA lesion.
108	  
5.3 Results 
5.3.1. Amphetamine-stimulated rotation 
The mean number of amphetamine-stimulated rotations completed by lesioned 
rats during the 60-minute observation period was 145 ± 24 (n = 31), indicating a 
functional dopaminergic deficit in the ipsilateral striatum.  
5.3.2. Striatal dopamine concentrations 
Dopamine concentration was decreased between the ipsilateral and contralateral 
striata of all rats subjected to 6-OHDA lesion, with a mean within-subject decrease in 
striatal dopamine of 92 ± 2% (P<0.01) (Figure 2). The dopamine levels measured in the 
unlesioned hemispheres were comparable to those found in previous studies (Kilts et 
al., 1981; Widerlöv et al., 1982; Davis et al., 2010; Levant et al., 2011). 
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Figure 1.   
Anatomical definition of regions of interest. Representative photomicrographs (4X) 
of digital tracings of the boundaries of the SNpc in contralateral and ipsilateral brain 
through 6 coronal sections of a single animal. Tracings shown are dorsal to ventral from 
the top to the bottom of the figure.  TH-AgNOR-stained number and neuronal body 
volume were assessed within these boundaries. Tracings were produced using 
MicroBrightField’s Stereoinvestigator software, and sections were aligned to facilitate 
comparison.   
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Figure 2.   
Effects of unilateral intrastriatal 6-OHDA lesion on striatal dopamine. All rats had 
decreased striatal dopamine content in the ipsilateral striatum compared to the 
contralateral striatum.  The mean within-subject decrease in dopamine concentration 
between the ipsilateral and contralateral striata was 92 ± 2%.  *P<0.01 by paired t-test 
(n = 12). 
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5.3.3. Stereological analysis of SNpc TH-AgNOR-stained neurons 
Low-and high-power photomicrographs demonstrate the effects of the lesion 
using AgNOR staining or TH-thionine counterstain (Figure 3).  Neurodegeneration of 
the 6-OHDA-lesioned SNpc was evident at low magnification (Figure 3A-3D).  High-
power magnification illuminates the advantages of using a combined modified TH and 
AgNOR staining protocol.  The neuronal bodies were more clearly delineated in the 
AgNOR-stained sections than with the TH-thionine counterstain, allowing for more 
precise marking of the cell borders using the nucleator tool for volume calculations.  The 
reduced TH antibody concentration used in the TH-AgNOR protocol results in reduced 
background darkening and staining of debris.  In addition, the lack of thionine 
counterstain prevented further background clutter and facilitated a clear view of 
individual neuronal bodies and axons (Figures 3G and 3H vs. 3E and 3F).  Most 
importantly, the addition of the AgNOR stain resulted in a darkly pigmented and clearly 
distinguishable nucleolus (Figure 3G and 3H). This selectivity in staining facilitated the 
use of the nucleolus within the nucleus as both a unique singly occurring cell landmark 
for counting with the optical fractionator, and as a center point for positioning crossed 
measurement rays using the Nucleator software marking tool in Stereoinvestigator.  In 
the few instances in which the nucleus of the cell, but not the nucleolus, was visible, the 
rays were placed centered on the nucleus. 
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Figure 3.  
Effects of unilateral intrastriatal 6-OHDA lesion on TH-thionine- and TH-AgNOR-
staining in the SNpc.  A. TH-thionine contralateral, 4X. B. TH-thionine ipsilateral, 4X. 
C. TH-AgNOR contralateral, 4X. D. TH-AgNOR ipsilateral, 4X. E. TH-thionine 
contralateral, 100X. F. TH-thionine ipsilateral, 100X. G. TH-AgNOR contralateral, 100X. 
H. TH-AgNOR ipsilateral, 100X. Representative images are shown and are all from the 
same animal. Scale bars are 300 µm and 10 µm for the 100X and 4X images, 
respectively. 
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5.3.3.1. TH-AgNOR-stained SNpc region volume 
Eleven of 12 rats exhibited a smaller regional volume of the ipsilateral SNpc 
compared to the contralateral SNpc (Fig. 4).  The regional volume of the SNpc for 
individual rats ranged from 3.9 to 5.3 mm3 on the contralateral side, and from 2.6 to 4.5 
mm3 on the ipsilateral side. The within-subject percentage decrease neurons ranged 
from 10% to 36%. The mean within-subject decrease in volume of the SNpc region 
between the ipsilateral and contralateral SNpc was 20 ± 3% (P<0.05) as measured by 
planimetry.  
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Figure 4.   
Effects of unilateral intrastriatal 6-OHDA lesion on SNpc regional volume. Eleven 
of 12 rats exhibited a smaller regional volume in the ipsilateral SNpc compared to the 
contralateral SNpc assessed by planimetry. The mean within-subject decrease in 
regional volume between the ipsilateral and contralateral SNpc was 20 ± 3%.  *P<0.05 
by paired t-test (n = 12). 
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5.3.3.2. TH-AgNOR-stained SNpc neuron number 
The mean number of SNpc TH-positive neurons on the contralateral side (13,133 
± 361) was comparable to the range of findings in previous stereological studies using 
traditional TH staining (Kirik et al., 1998; Lindner et al., 1999; Carvalho and Nikkhah, 
2001; Debeir et al., 2005; Gomide et al., 2005; Ahmad et al., 2008; Eriksen et al., 2009).  
The estimated number of TH-positive SNpc neurons for each rat ranged from 11,087 to 
15,389 on the contralateral side, and from 3,257 to 10,398 on the ipsilateral side.  All 
rats showed a decrease in the number of TH-positive cells in the ipsilateral SNpc 
compared to the contralateral SNpc (Fig. 5).  The within-subject percentage decrease 
neurons ranged from 21% to 75%. The mean within-subject decrease in TH-positive 
neuron number between the ipsilateral and contralateral SNpc was 54% ± 5% (P<0.01).  
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Figure 5.   
Effects of unilateral intrastriatal 6-OHDA lesion on TH-AgNOR-stained neuron 
number in the SNpc.  All rats exhibited a decrease in neuronal number in the ipsilateral 
SNpc compared to the contralateral SNpc with a mean within-subject decrease in 
neuron number between the ipsilateral and contralateral SNpc of 54 ± 5%. *P<0.01 by 
paired t-test (n = 12).  
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5.3.3.3 TH-AgNOR-stained SNpc neuron volume  
Nine of 12 rats exhibited a smaller average neuronal body volume in the 
ipsilateral SNpc compared to the contralateral SNpc.  The mean estimated neuronal 
volume of TH-AgNOR-positive SNpc neurons for individual rats ranged from (3,188 to 
4109 µm3) on the contralateral side, and from (2,489 to 4,110 µm3) on the ipsilateral 
side.  The within-subject percentage change of neuronal volume ranged from (9% 
increase to 39% loss). The mean within-subject decrease was 14 ± 3% (P<0.05) 
(Figure 6A). Figure 6B shows the change in the number of neurons in various size 
categories between ipsilateral and contralateral SNpc.  
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Figure 6.  
Effects of unilateral intrastriatal 6-OHDA lesion on TH-AgNOR-stained neuronal 
body volume. (A)  Effects on average neuronal cell body volume. Nine of 12 rats 
exhibited a smaller average neuronal body volume in the ipsilateral SNpc compared to 
the contralateral SNpc.  The mean within-subject decrease in average neuronal body 
volume between the ipsilateral and contralateral SNpc was 14 ± 3%. *P<0.05 by paired 
t-test (n = 12). (B) Effects on frequency distribution of neuronal volume. *P<0.05 by 
paired t-test (n = 12), (C) Effect on percent loss in the number of cells in each size 
category between the ipsilateral and contralateral SNpc.  
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5.4 Discussion 
  The 6-OHDA toxin, a structural analog of dopamine, is transported by the 
monoamine transporter into catecholaminergic cells, leading to their destruction by 
oxidative mechanisms (Kostrzewa and Jacobowitz, 1974; Glinka et al., 1997).  Although 
lacking the Lewy bodies and the progressive course of clinical PD, the 6-OHDA lesion 
nonetheless produces marked degeneration of targeted dopaminergic neurons, 
providing a functional PD model quantifiable by characteristic behavioral changes, 
dopamine depletion and histological observations (Ungerstedt and Arbuthnott, 1970; 
Kirik et al., 1998). 
The partial unilateral intrastriatal 6-OHDA model, with its relatively moderate loss 
of SNpc TH-positive neurons, is particularly appropriate as an early-stage PD model 
(Kirik et al., 1998; Deumens et al., 2002; Bethel-Brown et al., 2010).  The importance of 
early PD models is underscored by our existing knowledge about the destruction of 
pigmented SN neurons long before onset of the clinical disease in humans.  Estimates 
hold that patients with the earliest detectable clinical signs have already lost about 50% 
of their pigmented SN neurons (Marsden, 1990).  Furthermore, pigmented SN neurons 
are also lost as a part of natural aging (Rudow et al., 2008), and although the degree of 
loss is still debated, this natural attrition adds another layer of complexity to the 
investigation of early PD.  Differences in the degree of dopaminergic degeneration 
among the existing studies of the partial unilateral intrastriatal 6-OHDA model have 
been attributed to the differences in lesion site, histology methods, toxin dose, and to 
biologic variability (Kirik et al., 1998; Deumens et al., 2002; Stark and Pakkenberg, 
2004). Thus, the capacity for accurate, accessible morphometry of the neuronal 
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populations at risk in this Parkinson’s model is important for the advancement of 
Parkinson’s research. 
 Stereological analysis, with its use of random sampling techniques and 
generation of unbiased estimates of three-dimensional characteristics, is the optimal 
toolkit for assessing the morphological changes induced by neurotoxic lesions and 
therapeutic interventions (Gundersen et al., 1988a; Schmitz and Hof, 2005).  Stereology 
comes with its own set of challenges, however, especially pertaining to its requirement 
of staining thick tissue sections, which can be difficult for stains to penetrate.  An 
additional challenge is the necessary definition of specific morphological landmarks like 
the nucleus and nucleolus, which can be easily obscured by improper staining. This is 
especially important in dense, mostly homogenous populations of a darkly-staining cell 
type, such as TH-positive SNpc neurons.  In particular, the nucleus and nucleolus can 
be difficult to distinguish from other darkly stained structures within the cell.  Since the 
nucleus and the nucleolus are unique anatomical markers useful in stereological 
quantitation, improved staining methods such as the TH-AgNOR protocol are needed to 
be able to specifically identify these structures in TH-positive tissues.  
 AgNOR staining offers a versatile tool in specific identification of the nucleolus in 
TH-stained preparations.  The nucleolus is localized around chromosomal segments 
known as NORs, which contain ribosomal RNA (rRNA)-encoding genes.  NORs also 
contain acidic AgNOR proteins.  Because the quantity of AgNOR proteins and cell 
proliferation rate are related, AgNOR staining has been extensively used as a tool by 
cancer pathologists to characterize a variety of cancer types (Derenzini et al., 2000; 
Trerè, 2000; Derenzini et al., 2004).  The highly specific nucleolar staining achieved with 
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this method lends it to other applications in which visualization of the nucleolus is 
desirable, especially to stereological study of neural tissues. 
The present findings demonstrate that the modified TH-AgNOR staining protocol 
offered a number of qualitative advantages observed during the histopathological 
analysis (Figure 3). Enhanced stain penetration facilitated by a hydrochloric acid (HCl) 
permeabilization step in the modified TH-staining protocol was combined with less 
background staining of fibers and debris with the reduced concentration of TH antibody. 
This enabled better visualization and potentially resulted in more accurate counting of 
both the ipsilateral and contralateral SNpc than has been possible in previous studies.  
The TH-AgNOR staining advantage may be more marked in lesioned tissue, where a 
higher degree of cell destruction and accumulation of debris makes identification of 
individual neurons especially challenging.  Since technical variations are a likely 
explanation for the discrepancies between neuronal morphometry findings in the 
literature, this modified TH-AgNOR staining protocol should prove to be a beneficial tool 
in the modern characterization of classic dopaminergic neurotoxin models.  It may be 
anticipated that its use will lead to a fuller understanding of the affected neurons, and 
importantly, the underlying functional changes related to morphology.   
The data also clearly demonstrate that unilateral intrastriatal 6-OHDA lesions 
result in decreased SNpc regional volume and cell loss (Figures 3-5) in addition to 
amphetamine-stimulated rotation and the depletion of striatal dopamine (Figure 2)    
Compared to the near-complete destruction of both SNpc neurons and striatal 
dopamine in medial forebrain bundle (MFB) or SNpc lesions, the degree of neuron and 
dopamine loss is more variable in intrastriatal 6-OHDA lesions, dependent on the site 
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and dose of the toxin administration (Kirik et al., 1998) .  However, our study found a 
greater disparity between percent depletion in SNpc neurons (54%) and striatal 
dopamine (92%) than is typical of the literature (Deumens et al., 2002). Striatal 
dopamine concentration is rarely measured in histological 6-OHDA studies, because it 
requires a separate set of animals for dopamine analysis; however, other studies have 
found decreases in striatal dopamine content and nigral dopamine neuron number that 
were more similar that those observed in this study.   Of note, a stereological study 
using a bilateral  6-OHDA infusion (12.5µg)  found a 79% dopaminergic SN neuron loss 
associated with a 77% striatal dopamine loss quantified by high-performance liquid 
chromatography-electrochemical detection (HPLC-EC) (Lindner et al., 1999). Similarly, 
a non-stereological study of unilateral 6-OHDA lesions (12 ug) that quantified a 
subsection of the SNpc, found a 47% TH-positive cell loss [SN and ventral tegmental 
area (VTA)] accompanied by a 54% dopamine content loss measured by 
radioenzymatic immunocytochemistry (Lee et al., 1996).  In contrast to these studies, 
our lesion resulted in a larger decrease in striatal dopamine content relative to cell loss.  
Thus, our results suggest that even severe unilateral striatal dopamine depletion may 
reflect a relatively modest loss of SNpc dopamine neurons, underscoring the 
importance of using stereological techniques to assess the effects of the toxin on cell 
number and morphology.   
Although only a few studies have examined both changes in dopamine cell 
number and striatal dopamine content, a number of studies have examined changes in 
SN dopaminergic cell number after 6-OHDA lesion using both non-stereological and 
stereological methods.  Non-stereological studies indicate a loss of SNpc neurons after 
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6-OHDA lesions (for review, see: (Deumens et al., 2002); however, two-dimensional 
methods for counting cells have inherent bias that can result in inaccurate cell counts 
(Sterio, 1984; West, 1993).  Stereological studies also demonstrate a loss of SN 
dopaminergic neurons after unilateral striatal 6-OHDA studies.   We found a 20% 
decrease in SNpc regional volume and a 54% depletion of SNpc TH-positive neurons 
after a single-site moderate 6-OHDA dose of 12.5 µg (Figures 4 and 5). This finding 
complements two recent stereological studies that found a 33% TH-positive cell loss in 
the SN with an 8.75 µg dose, and a 33% loss with an 8 µg dose (Debeir et al., 2005; 
Gomide et al., 2005).  Taken together, these stereological results support a dose-
response effect of 6-OHDA dose on the number of SNpc TH-positive neurons.  
Even when using stereology to reduce bias, studies must be compared carefully.  
Differences in lesion sites and in region definition can produce varying results. For 
example, Kirik et al. (Kirik et al., 1998) used a total 20 µg dose produced a loss of 
neurons in the SN (including the pars reticulata and lateralis) of approximately 50%, 
although the percentage of loss varied depending on the lesion location within the 
striatum and the number of sites lesioned, with as much as 70% loss with a pre-terminal 
three-site injection of 7 µg per site.  Increasing the total terminal dose to 28-30 µg 
resulted in a 60-76% loss, depending on the number of sites lesioned.  Similarly, 
another study that used a total of 28 µg over 4 striatal injection sites found a 60% loss of 
SNpc neurons (Carvalho and Nikkhah, 2001).  In the context of the available literature 
overall, we observed a large loss of neurons based on the total dose of 6-OHDA. Given 
the high striatal dopamine loss, however, the degree of SNpc loss is less surprising.  
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In addition to yielding enhanced data on changes in cell number after lesion, 
stereological methods can quantify subtle changes in cell morphology.  In this study, the 
addition of AgNOR staining to the standard TH staining protocol resulted in clearly 
defined nucleolar bodies, which could be used as foci for using the nucleator tool to 
determine cell body volume.  We found a 14% reduction in neuronal body volume in 6-
OHDA lesioned rats, indicating that volume is a quantifiable morphological characteristic 
related to toxicity and subsequent neurodegeneration (Figure 6A).  Another study using 
stereology to quantify the effects of a unilateral striatal 6-OHDA lesion on cell volume 
found no difference between lesioned and intact SNpc TH-positive neurons (Gomide et 
al., 2005).  While the time from lesion to sacrifice (14 days) was the same in both 
studies, the dose used by Gomide et al. (8 µg) was lower than that used in this study 
(12.5 µg), indicating that the observed difference in volume changes may be  dose-
related. 
The dopaminergic cells in the rat SNpc are medium-sized neurons that are about 
11 x 20 µm in size, although individual neurons vary (Paxinos, 1995).  The observation 
of both decreased neuronal number and volume then raises the question: is the 
decreased volume truly due to atrophy, or is the shift in the mean volume a selective 
loss of the larger neurons?  Both hypertrophy and atrophy of SNpc dopaminergic 
neurons have been observed in PD brains (Rudow et al., 2008), and atrophy of the 
SNpc dopaminergic neurons has been observed after intrastriatal 6-OHDA injection 
(Sauer and Oertel, 1994; Lee et al., 1996). The frequency histogram of the distribution 
of the absolute number of TH-positive SNpc neurons by size category shows a clear 
post-lesion shift toward smaller neuronal volumes, and there was a lower percent loss in 
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the smallest size category of neurons (Figures 6B and 6C).  Studies of the frequency 
distributions of the neurons in demonstrating atrophy are informative yet inconclusive, 
as they cannot rule out the preferential loss of large SNpc neurons.  In fact, there is 
evidence that the subdivisions of the SNpc populated with mostly large neurons are also 
those most affected by neurotoxic lesions and by PD (Rodríguez et al., 2001).  
However, another analysis of the size frequency distribution of absolute number of 
neurons when a range of doses were administered showed a small increase in the 
numbers of smaller cells with the smallest dose of toxin, suggestive of an atrophic 
response rather than a strictly selective loss of large neurons (Lee et al., 1996).  It is 
also possible that a combination of atrophic development and preferential loss of large 
dopaminergic neurons occurs in neurotoxic-induced degeneration, as well as in the 
clinical disease.  Although more research is needed to better characterize the effects of 
6-OHDA lesions on dopaminergic neuronal volume, our study contributes to the current 
understanding of toxin-induced morphology changes and offers an improved method for 
further investigation.  Overall, the addition of the AgNOR stain to a modified TH staining 
protocol resulted in facilitated identification of the nucleolus and better visualization of 
the neuronal bodies, and thus the likelihood of improved quantitation. 
 
5.5 Conclusions 
 In conclusion, we find that TH-AgNOR staining facilitates stereological analysis of 
the effects of 6-OHDA lesions on the SNpc of rats when compared to standard TH-
thionine staining.  Using this staining protocol combined with stereological analysis to 
determine the effects of a unilateral intrastriatal 6-OHDA lesion revealed a moderate 
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loss of SNpc TH-positive neurons despite severe striatal dopamine depletion.  In 
addition, volumetric measurements confirmed SNpc TH-positive neuronal atrophy 14 
days post-lesion, suggesting that 6-OHDA induces morphological changes to SN 
neurons relevant to those found in the PD literature (Rudow et al., 2008). These findings 
confirm the utility of this staining protocol, and suggest the utility of this method in 
further investigation of PD lesion models.  Furthermore, these findings suggest that 
decreased neuronal volume as well as number contributes to the functional deficits 
observed after unilateral 6-OHDA lesion, and may also play a role in PD.  
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CHAPTER 6 
ALTERED NUCLEOLAR MORPHOLOGY IN SUBSTANTIA NIGRA DOPAMINE 
NEURONS FOLLOWING 6-HYDROXYDOPAMINE LESION IN RATS 
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6.1 Abstract 
 The nucleolus, the site of ribosomal ribonucleic acid (rRNA) transcription and 
assembly, is an important player in the cellular response to stress.  Altered nucleolar 
function and morphology, including decreased nucleolar volume, has been observed in 
Parkinson’s disease (PD); thus the nucleolus represents a potential indicator of 
neurodegeneration in the disease.  This study determined the effects of a partial 
unilateral intrastriatal 6-hydroxydopamine (6-OHDA) lesion, which models the 
dopaminergic loss found in PD, on the nucleoli of dopaminergic cells in the substantia 
nigra pars compacta (SNpc).  Adult male Long-Evans rats underwent unilateral 
intrastriatal infusion of 6-OHDA (12.5 µg).  Lesions were verified by amphetamine-
stimulated rotation 7 days later, and rats were euthanized 14 days after infusion.  
Coronal sections (50 µm) were stained with tyrosine hydroxylase silver nucleolar (TH-
AgNOR) staining using MultiBrain Technology (NeuroScience Associates), which 
resulted in clearly defined nucleoli and neuronal outlines.  Stereological methods were 
used to compare dopaminergic morphology between lesioned and intact hemispheres in 
each rat.  In cells exhibiting a definable nucleolus, nucleolar volume was decreased by 
16% on the ipsilateral side.  The ipsilateral SNpc also exhibited an 18% decrease in 
SNpc planimetric volume, a 46% decrease in total TH-positive neuron number, and an 
11% decrease in neuronal body volume (all P<0.05 by paired t-test).  These findings 
suggest that the 6-OHDA lesion alters nucleolar morphology and that these changes 
are similar to those occurring in PD.  	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6.2 Introduction  
The nucleolus is a likely participant in the neurodegenerative process of 
Parkinson’s disease (PD).  In addition to ribosomal RNA (rRNA) transcription and 
assembly, the nucleolus is involved in directing the cellular response to stress (Boulon 
et al., 2010), thus implicating it in the process of neurodegeneration.  Notably, altered 
postmortem nucleolar size and nucleolar damage have been observed in PD, as well as 
in several other neurodegenerative diseases (Mann and Yates, 1982; Rieker et al., 
2011; Hetman and Pietrzak, 2012).  Despite the importance of the nucleolus in neuronal 
function, the exact mechanisms of its dysfunction in degenerating neurons are still 
poorly understood, justifying the need for better knowledge of the roles of this influential 
organelle in neurodegenerative disease. 
 The partial unilateral intrastriatal 6-hydroxydopamine (6-OHDA) model of PD 
destroys SNpc neurons by neurotoxic oxidative stress mechanisms (Kostrzewa and 
Jacobowitz, 1974; Glinka et al., 1997).  In contrast to more extensive dopaminergic 
ablation models, this method causes moderate substantia nigra pars compacta (SNpc) 
neuronal loss resembling that found in early Parkinson’s (Kostrzewa and Jacobowitz, 
1974; Glinka et al., 1997; Kirik et al., 1998; Deumens et al., 2002; Bethel-Brown et al., 
2010).  In addition to decreases in neuronal number, morphological changes to 
dopaminergic neurons and their nucleoli after 6-OHDA may also reflect the processes 
occurring in PD (Lee et al., 1996; Gomide et al., 2005; Hetman and Pietrzak, 2012).  
Nucleolar function has been associated with nucleolar size; (Boulon et al., 2010) hence 
a decrease in nucleolar volume in the lesioned SNpc could reflect a loss of nucleolar 
function after 6-OHDA lesion, and thereby model the processes involved in PD.  
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Design-based stereology is a well-established method for obtaining robust data, and is 
extensively used to determine neuronal number and morphology of the SNpc in PD and 
in animal models (Kirik et al., 1998; Finkelstein et al., 2000; Carvalho and Nikkhah, 
2001; Schmitz and Hof, 2005; Ahmad et al., 2008; Rudow et al., 2008; Eriksen et al., 
2009).  Accordingly, this study employed the tyrosine hydroxylase-silver nucleolar (TH-
AgNOR stain), which combines tyrosine hydroxylase (TH) staining for 
catecholaminergic neurons with silver-binding nucleolar (AgNOR) staining (Healy-Stoffel 
et al., 2012), and stereological analysis techniques to determine the effects of a partial 
unilateral 6-OHDA model on the SNpc TH-positive neuronal and nucleolar morphology 
in adult male Long-Evans rats.  
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6.3 Results 
6.3.1 Amphetamine-stimulated rotation 
The mean number of amphetamine-stimulated rotations completed by lesioned 
rats during the 60-min observation period was 154 ± 47.  The relationship between 
rotation and percent of SNpc neuronal was poorly correlated (r2 = 0.135). 
6.3.2 Stereological Analysis 
Low-and high-power photomicrographs show the morphology of the ipsilateral 
and contralateral SNpc TH-positive neurons.  Low (4X) magnification demonstrates the 
loss of TH-positive neurons typical of neurodegeneration of the lesioned SNpc (Figure 
1A and B).  High-power (100X) magnification (Figure 1C and D) shows the outlines of 
nucleolar bodies, which are heavily pigmented compared to the surrounding cytoplasm. 
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Figure 1.  
 
High-power and low-power micrographs of TH-AgNOR stained sections of 
contralateral and ipsilateral substantia nigra.  4X images of TH-AgNOR-stained 
sections of contralateral and ipsilateral SN qualitatively show depletion of the lesioned 
dopaminergic regions (1A and B). 100X images show the outlines of the neurons and 
the AgNOR-stained nucleoli (1C and D).  Representative sections from the same rat are 
shown.  Abbreviations: SNL- substantia nigra lateralis, SNpc- substantia nigra pars 
compacta, VTA- ventral tegmental area 
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Figure 2.  
  
The Double Nucleator technique.  Markers are placed on the nucleolus center and 
where the nucleator rays intersect with the borders of the nucleolus and the neuronal 
body outline.   
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6.3.3 TH-AgNOR-stained SNpc region volume   
Regional planimetric volume of the ipsilateral SNpc was smaller in all rats 
compared to the contralateral SNpc (Figure 3A).  The planimetric volume ranged from 
3.7 to 4.9 mm3 on the contralateral side, and from 2.9 to 4.5 mm3 on the ipsilateral side. 
The within-subject percentage of volume decrease ranged from 7% to 28%. The mean 
within-subject decrease in planimetric volume between the ipsilateral and contralateral 
SNpc was 18 ± 2% (P<0.05).  
 
6.3.4 TH-AgNOR-stained SNpc neuron number   
The mean total number of TH-positive SNpc neurons was 4631 ± 355 on the 
ipsilateral and 9062 ± 781 on the contralateral sides (fig. 3B), which is comparable with 
other stereological studies (Kirik et al., 1998; Carvalho and Nikkhah, 2001; Gomide et 
al., 2005; Ahmad et al., 2008; Eriksen et al., 2009).  The number of TH-positive SNpc 
neurons ranged from 5,177 to 12,369 on the contralateral side, and from 3,442 to 7,289 
on the ipsilateral side.  All rats showed a decrease in the number of TH-positive cells in 
the ipsilateral SNpc compared to the contralateral SNpc.  The within-subject percentage 
decrease neurons ranged from 18% to 68%. The mean within-subject decrease was 
46% ± 5% (P<0.05).  
 
6.3.5 TH-AgNOR-stained SNpc neuron volume   
Average neuronal body volume was smaller in all rats in the ipsilateral SNpc 
compared to the contralateral SNpc (Figure 3C). The mean volume of SNpc TH-
AgNOR positive neurons on the contralateral side (3,722 ± 60 µm3) was comparable to 
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the range of findings in other stereological studies (Gomide et al., 2005; Ahmad et al., 
2008).  The neuronal volume of TH-AgNOR-positive SNpc neurons ranged from 3,331 
to 3,961 µm3 on the contralateral side, and from 2,263 to 3,700 µm3 on the ipsilateral 
side.  The within-subject percentage loss of neuronal volume ranged from 4% to 40%. 
There was a mean within-subject decrease of 11 ± 3% (P<0.05).  
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Figure 3.  
  
Effects of unilateral intrastriatal 6-OHDA lesion on TH-AgNOR-stained planimetric 
volume (A), neuron number (B) and neuron volume (C) in the SNpc.  All rats 
showed decreased SNpc planimetric volume between the ipsilateral and contralateral 
hemispheres. The mean within-subject decrease was 18 ± 2% (P<0.05 by paired t-test, 
n = 11).  All rats showed decreased neuronal number between the ipsilateral and 
contralateral SNpc. The mean within-subject decrease was 46% ± 5% (P<0.05 by 
paired t-test, n = 11).  All rats showed decreased neuronal volume between the 
ipsilateral and contralateral SNpc. The mean within-subject decrease was 11± 3% 
(P<0.05 by paired t-test, n = 11).  
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6.3.6 TH-AgNOR-stained SNpc nucleolar volume   
Average nucleolar volume was smaller in all rats in the ipsilateral SNpc 
compared to the contralateral SNpc.  The mean nucleolar volume of TH-AgNOR-
positive SNpc neurons in individual rats ranged from 20 to 32 µm3 on the contralateral 
side, and from 16 to 29 µm3 on the ipsilateral side.  The within-subject percentage 
decrease of nucleolar volume ranged from 5% to 32%. There was a mean within-
subject decrease of 16 ± 2% (P<0.05) (Figure 4A).  However, the ratio of nucleolar 
volume to neuronal volume between the ipsilateral and contralateral SNpc was smaller 
in only 6 of the 11 rats and there no significant difference between sides (Figure 4B).  
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Figure 4.  
  
Effects of unilateral intrastriatal 6-OHDA lesion on TH-AgNOR-stained nucleolar 
volume in the SNpc.  All rats showed decreased nucleolar volume between the 
ipsilateral and contralateral SNpc (4A). The mean within-subject decrease was 16 ± 2% 
(P<0.05 by paired t-test, n = 11). The ratio of nucleolar volume to neuronal volume in 
the ipsilateral SNpc was smaller in only 6 of the 11 rats the contralateral SNpc and there 
was no significant difference between sides (4B).  
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6.4 Discussion 
  This study determined the effects of unilateral 6-OHDA neurotoxic lesion on 
SNpc neuronal number, soma volume and nucleolar morphology using stereology and 
TH-AgNOR staining.  A functional dopaminergic deficit was confirmed in the ipsilateral 
striatum by mean amphetamine-stimulated rotations.  The single-site injection of 6-
OHDA (12.5 µg) resulted in an 18% decrease in the planimetric volume of the TH-
positive ipsilateral SN and a 46% depletion of SNpc TH-positive neurons (Figures 3A 
and 3B).  Furthermore, the appearance of clinical signs in PD has been associated with 
SNpc neuronal losses of around 50% (Marsden, 1990); thus, cell loss of this magnitude 
reflects a clinically relevant model of moderate PD.  Neuronal volume loss was 11% 
with a corresponding 16% decrease in nucleolar volume on the ipsilateral side.  Overall, 
these findings suggest that the partial unilateral 6-OHDA lesion achieved a moderate 
depletion of SNpc neurons comparable to the threshold findings in parkinsonian human 
brains.  
 Using the TH-AgNOR stain, the present data show a 16% decrease in nucleolar 
volume accompanied by an 11% decrease in neuronal body volume (Figure 3C).  
These decreases in nucleolar and neuronal size support morphological findings 
observed in postmortem PD brains (Mann and Yates, 1982; Rudow et al., 2008).  This 
supports the validity of the 6-OHDA lesioned rat as model of the early stages of 
parkinsonian neurodegeneration, at least with respect to these parameters. 
 Altered morphology is an informative tool in documenting the changes caused 
by the neurodegenerative process to neuronal and nucleoli volume.  Quantitation of 
morphological changes is an important first step in establishing differences between 
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neurons, which can then be further explored with complementary functional or 
biochemical assays to determine the mechanisms of change.  The volumetric changes 
that occurred in this study could be due to either neurodegeneration on the ipsilateral 
side, or to compensation-related hypertrophy on the contralateral side, since striatal 
sprouting after unilateral brain lesions has been proposed as a compensatory 
mechanism (Cheng et al., 1998; Finkelstein et al., 2000).  In future studies, it would be 
interesting to determine the neuronal and nucleolar volume in additional unlesioned rats 
for comparison; however, another study using a unilateral intrastriatal 6-OHDA (8µg) 
and solvent-injected control animals using stereological analysis found no difference in 
contralateral TH-positive SNpc soma volumes between the 6-OHDA- and solvent-
injected animals (Gomide et al., 2005).  Nucleolar size is associated with nucleolar 
activity (Boulon et al., 2010), thus the 16% change in nucleolar volume in the ipsilateral 
hemisphere (Figure 4A) may reflect a change in nucleolar function and provide a 
valuable index of neuronal damage.  Other changes to nucleolar morphology, such as 
nucleolar segregation and disruption, are associated with various cellular stressors, 
including DNA damage, hypoxia, viral infection, and nutrient stress (Boulon et al., 2010).  
Likewise, the stressors potentially involved in the etiology of PD could also cause 
altered nucleolar morphology.  Altered nucleolar morphology has been reported in 
clinical PD, with the volume of nucleoli decreased in post-mortem PD brains by 16% 
(Mann and Yates, 1982).  Since neuronal and nucleolar function are closely interrelated, 
however, it may be more relevant to consider neuronal and nucleolar volume together 
than separately.  Indeed, in our study there was no difference in the percentage of the 
nucleolus to total neuronal volume in the ipsilateral and contralateral SNpc (Figure 4B), 
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suggesting a concomitant decrease of both neuronal body and nucleolus that may 
indicate their interdependent morphology.  Although the morphological relationship 
between the nucleolar and neuronal body volumes in clinical PD is not currently known, 
stereological assessment of neuronal and nucleolar volumes in postmortem brains from 
Alzheimer’s patients showed both neuronal and nucleolar atrophy in the CA1 region of 
the hippocampus (Iacono et al., 2008), implicating decreased nucleolar volume in 
neurodegenerative disease.  
How nucleolar morphology reflects the neurodegeneration in PD is still uncertain, 
although there are several potential mechanisms for nucleolar damage and consequent 
morphology changes in PD.  Greater nucleolar damage to postmortem PD neurons, 
assessed by loss of nucleolar integrity, has been found relative to controls (Rieker et al., 
2011).  Oxidative damage to RNA has been a suspected factor in a number of  
neurodegenerative diseases, including PD (Kong and Lin, 2010), and may play a role in 
nucleolar damage.  For example, in mice, 1,2,3,6-tetrahydro-1-methyl-4-phenylpyridine 
hydrochloride (MPTP) treatment induced nucleolar damage marked by nucleophosmin 
staining localization to the cytoplasm and inhibited mammalian target of rapamycin 
(mTOR) signaling, a regulator of rRNA synthesis. (Rieker et al., 2011).  The 
transcription initiation factor 1A (TIF-1A) regulates the nucleolus-specific RNA 
polymerase 1 (Pol1), and TIF-1A ablation in mouse embryonic fibroblasts results in 
nucleolar disruption and in upregulation of tumor-suppressing protein p53 (Yuan et al., 
2005).  Adult mice with selective dopaminergic neuron ablation of TIF-1A demonstrated 
progressive loss of SN neurons and locomotor deficits (Rieker et al., 2011).  Nucleolar 
damage in PD could also be precipitated by DNA damage, as the DNA-topoisomerase-
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2 inhibitor etoposide inhibited Pol1 and induced nucleolar stress indicated by staining 
for B23/nucleophosmin (Pietrzak et al., 2011).  Future studies must determine 
specifically how nucleolar damage, and corresponding nucleolar morphology changes, 
contribute to the pathophysiology of PD and whether nucleolar morphology may prove 
useful as an indicator of disease progression.  
 
6.5 Conclusions 
In conclusion, TH-AgNOR staining combined with stereological assessment 
indicated altered nucleolar morphology of SNpc dopaminergic neurons in rats after a 
partial unilateral intrastriatal 6-OHDA.  The observed decreased nucleolar volume 
suggests that this organelle plays a critical role in neurodegenerative processes and 
possibly also in the early clinical course of the PD.  
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CHAPTER 7 
DIFFERENTIALLY ALTERED NEURONAL NUMBER AND MORPHOLOGY IN 
MIDBRAIN DOPAMINERGIC SUBREGIONS AFTER A UNILATERAL INTRASTRIATAL           
6-OHDA LESION 
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7.1 Abstract 
 The nucleolus is an important player in the cellular response to stress, and 
changes in nucleolar morphology may be an indicator of neuronal response to the 
neurodegeneration caused by Parkinson’s disease (PD).  Although nucleolar 
morphology is altered in substantia nigra (A9 dopamine neurons) in PD, it is not known 
whether the nucleoli of the A8, A9 and A10 dopamine subgroups are differentially 
affected in PD.  This study determined the effects of a partial unilateral intrastriatal 6-
hydroxydopamine (6-OHDA) lesion model of PD on the nucleoli of dopaminergic cells in 
the A8, A9 and A10 neurons.  Adult male rats underwent unilateral intrastriatal infusion 
of 6-OHDA (12.5 µg).  Lesions were verified by amphetamine-stimulated rotation 7 days 
post-surgery, and rats were euthanized 14 days after infusion and brains stained with a 
TH-AgNOR protocol (NeuroScience Associates).  Dopaminergic morphology in the 
lesioned and intact hemispheres in each rat was quantified with stereology.  Nucleolar 
volume was decreased by 22% on the ipsilateral side in the A9 neurons, 24% in the 
A10, and 26% in the A8 (all P<0.05 by paired t-test).  In addition, the lesion decreased 
dopaminergic regional planimetric volume, neuronal number and density, and neuronal 
body volume in the ipsilateral side in all subgroups (P<0.05 by paired t-test for all 
endpoints, except for no change in A8 density).  Furthermore, dopaminergic regional 
planimetric volume, neuronal number and density, and neuronal body volume varied 
among the subgroups (P<0.05 by repeated-measures ANOVA).  These findings suggest 
that although the 6-OHDA lesion did not differentially alter nucleolar morphology in the 
subgroups, the nucleolus of all three regions demonstrated morphological changes after 
6-OHDA, which could prove useful in assessing PD treatments.   
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7.2 Introduction  
Parkinson’s disease (PD), a chronic progressive neurodegenerative disorder 
characterized by loss of dopamine, is best known for its motor symptoms of tremor, 
bradykinesia and rigidity. However, PD also features a variety of non-motor symptoms 
in which dopaminergic loss may play a role, such as depression, dementia, sleep 
disturbances and anosmia; and these non-motor signs often manifest years before the 
onset of motor signs (Becker et al., 2002; Claassen et al., 2010).  Thus, unraveling the 
etiology of the early non-motor signs of PD may be the key to developing preventive 
treatments and early disease interventions.  
The substantia nigra pars compacta (SNpc), ventral tegmental area (VTA) and 
retrorubral field (RRF) midbrain regions roughly corresponding to the A9, A10 and A8 
groups of dopamine neurons, respectively, are responsible for the various motor and 
non-motor deficits in PD are differentially affected both in the disease and in PD models 
(Deutch et al., 1986; German et al., 1989; Hirsch et al., 1989; German et al., 1992; 
German and Manaye, 1993; Rodríguez et al., 2001), although the reasons for their 
differential susceptibility are still unclear.  
The nucleolus, the site of ribosomal RNA (rRNA) synthesis, has great influence 
on the response of cells to stress and injury, and is a promising target for developing 
and assessing new treatments and therapeutics, especially in the early stages of PD.  
Thus, different midbrain dopamine neuron subpopulations may react differently to the 
processes involved in PD, and changes to nucleolar morphology may reveal new 
information that can lend insight into the pathophysiology of the disease.   
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The 6-hydroxydopamine (6-OHDA) neurotoxic lesion is a well-accepted animal 
model for PD, and has a demonstrated effect on the SNpc nucleolus and differential 
effects on different subregions. The 6-OHDA neurotoxin structurally resembles 
dopamine, and causes oxidative damage and cell death when taken up into the 
catecholamine neurons (Kostrzewa and Jacobowitz, 1974).  The partial unilateral 
intrastriatal 6-OHDA model is relevant to model early Parkinson’s, since it results in a 
more moderate loss of midbrain dopamine neurons than more extensive lesions (Kirik et 
al., 1998).  Previous work from our laboratory showed that unilateral intrastriatal 6-
OHDA infusion resulted in decreased SNpc neuronal number and neuronal and 
nucleolar volume (Healy-Stoffel et al., 2012). This study will determine the effects of a 
single-site intrastriatal unilateral 6-OHDA lesion on the numbers and neuronal 
morphology of the A8, A9 and A10 groups of dopaminergic neurons in rats, using 
stereological analysis and the tyrosine hydroxylase silver nucleolar (TH-AgNOR) 
staining method previously described (Healy-Stoffel et al., 2012). 
 
7.3 Results  
7.3.1 Stereological analysis of TH-AgNOR-stained neurons 
Low-and high-power photomicrographs show the morphology of the ipsilateral 
and contralateral SNpc, VTA and RRF TH-AgNOR-stained neurons.  Low (4X) 
magnification demonstrates the loss of TH-positive neurons following 6-OHDA-induced 
neurodegeneration (Figure 1).  High-power (100X) magnification (Figure 2) shows the 
outlines of nucleolar bodies within neurons in the SNpc, VTA and RRF. The nucleoli are 
heavily pigmented with the AgNOR stain compared to the surrounding cytoplasm. 
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Figure 1.   
 
Low-power micrographs of TH-AgNOR stained sections of contralateral and 
ipsilateral SNpc, VTA and RRF.  4X images of TH-AgNOR-stained sections of 
contralateral and ipsilateral SN qualitatively show depletion of the contralateral SNpc (A 
and C), ipsilateral SNpc (B and D), contralateral VTA (A, C and E), ipsilateral VTA (B, D 
and F), contralateral RRF (E) and ipsilateral RRF (F). Representative sections from the 
same rat are shown.  Size bar = 300 µm.  Abbreviations: SNL- substantia nigra lateralis, 
SNpc- substantia nigra pars compacta, VTA- ventral tegmental area, RRF- retrorubral 
field 
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Figure 2.  
 
High-power micrographs of TH-AgNOR stained sections of contralateral and 
ipsilateral SNpc, VTA and RRF. 100X images show the outlines of the neurons and 
the AgNOR-stained nucleoli in contralateral SNpc (A), ipsilateral SNpc (B), contralateral 
VTA (C), ipsilateral VTA (D), contralateral RRF (E) and ipsilateral RRF (F).  
Representative sections from the same rat are shown.  Size bar = 10 µm.  
Abbreviations: SNL- substantia nigra lateralis, SNpc- substantia nigra pars compacta, 
VTA- ventral tegmental area, RRF- retrorubral field 
7.3.2 TH-AgNOR-stained region planimetric volume 
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The ipsilateral SNpc was smaller in 9 out of 10 rats compared to the contralateral 
SNpc, the ipsilateral VTA was smaller in 8 out of 10 rats compared to the contralateral 
VTA, and the ipsilateral RRF was decreased in all rats compared to the contralateral 
RRF.  The estimated planimetric volumes for individual rats ranged from 3.7 to 4.9 mm3 
in contralateral SNpc and from 2.7 to 4.5 mm3 in ipsilateral SNpc; from 7.2 to 11.5 mm3 
in contralateral VTA and from 6.9 to 11.8 mm3 in ipsilateral VTA; and from 3.2 to 5.5 
mm3 in contralateral RRF and from 1.9 to 4.5 mm3 in ipsilateral RRF.  The mean within-
subject percent loss in planimetric volume between the ipsilateral and contralateral 
hemispheres was 20 ± 3% in the SNpc (P<0.001), 8 ± 2 % in the VTA (P<0.01), and 20 
± 5 % in the RRF (P<0.05) (Figure 3).  The SNpc and RRF demonstrated greater 
planimetric volume loss than the VTA (P<0.05) (Table 1).  
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Table 1. Changes to TH-AgNOR-stained neurons and nucleoli in the SNpc, VTA 
and RRF after a unilateral intrastriatal 6-OHDA lesion 
 
Data are presented at the mean ± SEM.   
‡ P<0.5 vs. contralateral side by paired t-test.# P<0.5 vs. SNpc  by nonparametric repeated measures ANOVA 
followed by Dunn’s multiple comparisons test. 
* P<0.5 vs. VTA  by repeated measures ANOVA followed by Student-Newman-Keuls or nonparametric repeated 
measures ANOVA followed by Dunn’s multiple comparisons test. 
† P<0.5 vs. RRF by repeated measures ANOVA followed by Student-Newman-Keuls. 
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Figure 3. 
 
Effects of unilateral intrastriatal 6-OHDA on planimetric regional volume. Nine out 
of 10 rats showed decreased SNpc planimetric volume between the ipsilateral and 
contralateral hemispheres. Eight out of 10 rats showed decreased VTA planimetric 
volume between the ipsilateral and contralateral hemispheres. All rats showed 
decreased RRF planimetric volume between the ipsilateral and contralateral 
hemispheres.  
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7.3.3 TH-AgNOR-stained neuron number 
 All rats had decreased ipsilateral TH-positive neuronal numbers compared to the 
contralateral SNpc and VTA, and 8 out of 10 rats had decreased TH-positive neuronal 
numbers compared to the contralateral RRF (Figure 4).  The estimated TH-positive 
neuron numbers in individual rats ranged from 3,890 to 16,177 in contralateral SNpc 
and from 3,877 to 9,422 in ipsilateral SNpc; from 13,477 to 19,862 in contralateral VTA 
and from 9,494 to 13,818 in ipsilateral VTA; and from 1,205 to 4,164 in contralateral 
RRF and from 1,055 to 3,335 in ipsilateral RRF.  The mean within-subject percent loss 
in TH-positive neuron number between the ipsilateral and contralateral hemispheres 
was 46 ± 6% in the SNpc (P<0.001), 28 ± 3% in the VTA (P<0.001), and 28 ± 11% in 
the RRF (P<0.05).  The SNpc demonstrated an increased percentage of TH-positive 
neuron number loss compared to the VTA (P<0.05) (Table 1).  
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Figure 4.  
 
Effects of unilateral intrastriatal 6-OHDA on TH-positive neuron number.  All rats 
(n=10) showed decreased SNpc neuron number between the ipsilateral and 
contralateral hemispheres. All rats showed decreased VTA neuron number between the 
ipsilateral and contralateral hemispheres. Eight out of 10 rats showed decreased RRF 
neuron number between the ipsilateral and contralateral hemispheres.  
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7.3.4 TH-AgNOR-stained density 
All rats had decreased ipsilateral TH-positive neuronal density compared to the 
contralateral SNpc and the contralateral VTA, and 8 out of 10 rats had decreased TH-
positive neuronal density compared to the contralateral RRF (Figure 5). The estimated 
TH-positive neuron density for individual rats ranged from 1,045 to 3,412 neurons/mm3 
in contralateral SNpc and from 960 to 2,213 neurons/mm3 in ipsilateral SNpc; from 
1,233 to 2,193 neurons/mm3 in contralateral VTA and from 1,125 to 1,613 neurons/mm3 
in ipsilateral VTA; and from 303 to 739 neurons/mm3 in contralateral RRF and from 440 
to 1,016 neurons/mm3 in ipsilateral RRF.  The mean within-subject percent loss in TH-
positive neuronal density between the ipsilateral and contralateral hemispheres was 33 
± 6 % in the SNpc (P<0.001), 22 ± 3% in the VTA (P<0.001), and 11.1 ± 10.0% in the 
RRF.  The SNpc demonstrated an increased percentage of TH-positive neuron number 
loss compared to the RRF (P<0.05). Mean TH-positive neuronal density of the 
ipsilateral RRF was unchanged compared to the contralateral side (Table 1).   
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Figure 5.  
 
Effects of unilateral intrastriatal 6-OHDA on TH-positive neuronal density.  All rats 
(n=10) showed decreased SNpc neuronal density between the ipsilateral and 
contralateral hemispheres.  All rats showed decreased VTA neuronal density between 
the ipsilateral and contralateral hemispheres.  Eight out of 10 rats showed decreased 
RRF neuronal density between the ipsilateral and contralateral hemispheres.  
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7.3.5 TH-AgNOR-stained neuron volume  
Eight out of 10 rats had decreased TH-positive neuronal volume compared to the 
contralateral SNpc, 9 out of 10 rats had decreased TH-positive neuronal volume 
compared to the contralateral VTA, and all rats had decreased TH-positive neuronal 
volume compared to the contralateral RRF (Fig. 6).  The mean TH-positive neuron 
volumes for individual rats ranged from 3,327 to 4,104 µm3 in contralateral SNpc and 
from 2,216 to 4,161 µm3 in ipsilateral SNpc; from 2,206 to 3,377 µm3 in contralateral 
VTA and from 1,733 to 2,985 µm3 in ipsilateral VTA; and from 3,522 to 5,065 µm3 in 
contralateral RRF and from 2,374 to 3,849 µm3 in ipsilateral RRF.  The mean within-
subject percent loss in TH-positive neuronal volume between the ipsilateral and 
contralateral hemispheres was 13 ± 4% in the SNpc (P<0.05), 21 ± 5% in the VTA 
(P<0.05), and 24 ± 4% in the RRF (P<0.001).  The VTA demonstrated an increased 
percentage TH-positive neuronal volume loss compared to the SNpc (P<0.05).  The 
RRF demonstrated an increased TH-positive percentage neuronal volume loss 
compared to the SNpc (P<0.001) (Table 1).  
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Figure 6.  
 
Effects of unilateral intrastriatal 6-OHDA on TH-AgNOR-positive neuronal volume. 
Eight out of 10 rats showed decreased SNpc neuronal volume between the ipsilateral 
and contralateral hemispheres. Nine out of 10 showed decreased VTA neuronal volume 
between the ipsilateral and contralateral hemispheres. Nine out of 10 rats showed 
decreased RRF neuronal volume between the ipsilateral and contralateral hemispheres.  
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7.3.6 TH-AgNOR-stained nucleolar volume  
All rats had decreased TH-positive SNpc, VTA and RRF nucleolar volume 
compared to the contralateral hemisphere (Figure 7). The mean TH-positive neuron 
volumes for individual rats ranged from 20 to 29 µm3 in contralateral SNpc and from 16 
to 24 µm3 in ipsilateral SNpc; from 15 to 37 µm3 in contralateral VTA and from 12 to 18 
µm3 in ipsilateral VTA; and from 20 to 27 µm3 in contralateral RRF and from 13 to 20 
µm3 in ipsilateral RRF.  The mean within-subject decrease in TH-positive nucleolar 
volume between the ipsilateral and contralateral was 22 ± 3% in the SNpc (P<0.001), 24 
± 6% in the VTA (P<0.001), and 26 ± 4% in the RRF (P<0.001).  There was no 
significant difference among the percentage of loss in TH-positive nucleolar volume 
among the SNpc, VTA or RRF (Table 1).   
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Figure 7.  
 
Effects of unilateral intrastriatal 6-OHDA on TH-AgNOR-positive nucleolar 
volume.  All rats (n = 10) showed decreased SNpc nucleolar volume between the 
ipsilateral and contralateral hemispheres. All rats showed decreased VTA nucleolar 
volume between the ipsilateral and contralateral hemispheres. Nine out of 10 rats 
showed decreased RRF nucleolar volume between the ipsilateral and contralateral 
hemispheres.  
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7.4 Discussion 
This study determined the effects of a unilateral intrastriatal 6-OHDA lesion on 
differential susceptibility of neuronal number and morphology in the A8, A9 and A10 
dopamine neuron groups in rats.  The SN, VTA and RRF, corresponding to the A9, A10 
and A8 groups of midbrain dopaminergic neurons, respectively, are geographically 
separate groups of neurons that have some overlap in their projections, and are all 
three regions are affected in PD.  The substantia nigra, especially the pars compacta 
portion, is the main site for the origin of the mesostriatal dopamine neurons involved in 
motor disorders like PD, Huntington’s disease and progressive supranuclear palsy; and 
its role in PD is well documented (German et al., 1989; Damier et al., 1999; Eriksen et 
al., 2009).  The VTA is the origin of the majority of mesocortical and mesolimbic 
dopamine projections, and is involved in cognition, motivation, addiction, emotion and 
reward, and in PD, the VTA is implicated in the non-motor dopamine-dependent aspects 
of PD such as depression, cognitive and affective deficits (Lieberman, 2006; Sillitoe and 
Vogel, 2008; Da Cunha et al., 2009; Blonder and Slevin, 2011).  The role of the RRF is 
the least understood of these regions, although its neurons are known to project to the 
nigrostriatal, mesocortical and mesolimbic systems (Deutch et al., 1988; Arts et al., 
1996; François et al., 1999; Cho and Fudge, 2010).  In rats, A8 neurons innervate the 
striatum, the amygdala and other regions, implicating these regions in modulation of 
both motor and limbic circuits (Jimenez-Castellanos and Graybiel, 1987). There is 
known cell loss in the RRF in both post-mortem PD brains and in and Parkinson’s 
animal models, and the RRF is implicated in the presence of tremor, orofacial motor 
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dysfunction, and in sleep and visual disturbances in PD and PD models (Spooren et al., 
1993a; Jellinger, 1999; Lai et al., 1999; Aarsland et al., 2005; Kolasiewicz et al., 2012).   
Although there have been many studies on the projections, circuitry and function in 
these three dopaminergic regions, there are few studies addressing how the 
morphology of the dopaminergic neurons in these regions are differentially affected by 
PD, making this a promising area of investigation using modern histological and 
stereology tools.  
6-OHDA enters the cells by monoamine transporter uptake, and causes 
neurodegeneration of monoaminergic neurons by oxidative mechanisms (Kostrzewa 
and Jacobowitz, 1974).  This model is relevant to early PD because it causes less 
extensive SNpc neuron loss and milder behavioral deficits than those found in more 
severe lesion methods (Deumens et al., 2002).  Of course, intrastriatal 6-OHDA differs 
from PD in that the toxin is administered directly into the striatum, whereas the origins of 
neurodegeneration in PD are still unknown.  In respect to the A8, A9 and A10 
dopaminergic subregions, differential neurotoxicity could be expected simply based on 
the reduced numbers of projections to the striatum from the A8 and A10 regions 
compared to the A9 neurons of the SNpc (Jimenez-Castellanos and Graybiel, 1987; 
German et al., 1988), and the intrastriatal route of toxin administration could cause 
disproportional loss of A9 neurons to that found in PD.  However, similar patterns of 
dopaminergic neuron loss to those in this study have been found after both 
intraventricular administration of 6-OHDA in the rat and intraperitoneal injection of 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse (German et al., 1996; 
Rodríguez et al., 2001), suggesting that the route of 6-OHDA infusion may not greatly 
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affect the proportion of cell loss.  Most importantly, the pattern of dopamine cell loss 
induced by 6-OHDA reflects the losses found in post-mortem parkinsonian brains, 
reinforcing the likelihood that the same processes may be occurring in both 6-OHDA 
neurotoxicity and in PD; and making the intrastriatal 6-OHDA lesion a potentially useful 
model of all the dopaminergic neuron populations affected in PD.  
The unilateral intrastriatal 6-OHDA lesion administered in this study induced a 
20% loss of region volume loss in the SN, an 8% loss in the VTA, and a 20% loss in the 
RRF.  Most studies do not report changes in the regional volume of dopaminergic 
subnuclei, but decreases in region volume have been reported in the SN and the VTA in 
PD (McRitchie et al., 1997; Kashihara et al., 2011; Ziegler et al., 2013). However, one 
stereological study on the volume of the RRF in PD found no change in region volume 
in diseased patients (McRitchie et al., 1997).  Our planimetric volume findings were 
interesting because the degree of volume loss found in the VTA was less than that in 
the SN and RRF, which reflects the pattern of neuronal loss found in these regions in 
animal studies (German et al., 1988; German et al., 1996; Rodríguez et al., 2001).  This 
suggests that a loss of regional volume is associated with the degree of neuronal loss in 
PD models; and although these findings conflict with what has been found in PD, the 
scarcity of robust stereological studies in this area warrant further investigation into the 
differential vulnerability of dopaminergic neuronal group regional volumes.  
Furthermore, the unilateral intrastriatal 6-OHDA lesion resulted in a neuronal density 
(neurons/mm3) loss of 33% in the SN, 22% in the VTA, and 11% (not significant) in the 
RRF.  Losses of neuronal density have been reported in PD in the SN and the VTA, 
although no change was found in neuronal density in the RRF (Jellinger, 1991; German 
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and Manaye, 1993; McRitchie et al., 1997).  Our findings reflect the results found in PD 
studies, and furthermore are comparable to the findings in a recent stereological 
unilateral 6-OHDA lesion study in rats (8 µg), which found a 25% loss of neuronal 
density in the SN, and a 32% loss in the VTA (Gomide et al., 2005).  While neuronal 
density is related to both the regional volume and to the neuronal number, it indicates 
that the regional volume loss is due to a loss of neurons, and not simply due to 
degeneration of TH-pigmented axons and dendrites.  More anatomical studies of the 
midbrain dopaminergic neurons should report the region volume and neuronal density 
findings, in order to furnish a more complete understanding of the neuronal losses 
occurring in PD. 
Single-site unilateral intrastriatal administration of 6-OHDA induced a 46% loss of 
TH-positive neurons in the SNpc, a 28% loss in the VTA, and a 28% loss in the RRF.  
The SNpc has the most projections to the striatum, and is the most affected in PD lesion 
models (German et al., 1988; Hirsch et al., 1988; German et al., 1996; Rodríguez et al., 
2001).  The percentage of SNpc neurons lost in this study is comparable to others’ 
findings in moderate PD models (Lee et al., 1996; Rodríguez et al., 2001), although in 
more extensive lesion models the loss of SNpc dopaminergic neurons is much greater 
and resembles the levels of SN neuronal loss found in PD post-mortem studies (Kirik et 
al., 1998; Deumens et al., 2002).  In post-mortem PD brains, most of which are at an 
advanced stage of neuronal loss, SNpc neurons are decreased by 70% or more (Hirsch 
et al., 1988).  The VTA chiefly projects to the mesolimbic and mesocortical 
dopaminergic pathways (Oades and Halliday, 1987; van Domburg and ten Donkelaar, 
1991), and studies in the VTA show that it is usually less vulnerable than the SN and 
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similarly affected to the A8 neurons in PD, and the least vulnerable region in PD models 
(Uhl et al., 1985; German et al., 1988; Hirsch et al., 1988; Hirsch, 1994; German et al., 
1996; Rodríguez et al., 2001).  Consistent with the design of our lesion as a model of 
early stage PD, we found a smaller loss of neurons in all of these neuronal groups than 
is typically found in PD post-mortem studies, which are assumed to be in the late stages 
of the disease.  Our results complement the findings of another study of dopaminergic 
neuronal loss after 6-OHDA administration, in which a 300 µg intraventricular infusion 
induced losses of 50-80% in the A9 group, and 30-50% losses in the A8 and A10 
groups (Rodríguez et al., 2001).  Interestingly, even in more severe lesion models and 
in PD, the ultimate levels of neuronal loss in the A8 and A10 groups peak at around 
70% for the A8 RRF neurons in most studies, and around 60% for the A10 VTA neurons 
(Uhl et al., 1985; German et al., 1988; Hirsch et al., 1988; German et al., 1996; 
Rodríguez et al., 2001).  This could indicate that although the A8 and A10 groups may 
be ultimately less susceptible in end-stage loss of numbers, they may be more sensitive 
to early loss of neurons.   Even if the VTA and RRF ultimately lose a smaller percentage 
of their numbers, they may still be more vulnerable to a loss of function than their SNpc 
counterparts, and may thus be responsible for the early non-motor signs of Parkinson’s.  
An important thing to keep in mind when comparing rodent models with post-mortem 
PD studies is that rodents have a lower proportion of A9 and a higher proportion of A10 
dopaminergic neurons relative to primates, although the proportions of A8 neurons are 
similar (German and Manaye, 1993); therefore susceptibility to PD-modeling lesions 
may be different.  This is especially relevant for analysis of motor signs which manifest 
after a critical threshold of dopamine loss is reached as is thought to occur in PD 
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(Marsden, 1990).  However, rodent studies still provide a meaningful and practical way 
to model the disease and assess treatments.  In fact, the rodents’ greater proportions of 
the A10 neurons implicated in the non-motor signs of Parkinson’s may make them more 
sensitive to insults in these neurons, and thus better models for learning about the early 
disease process.     
Changes to neuronal volume can be an indicator of altered neuronal function, 
and therefore potentially useful indicators of the changes induced by 
neurodegeneration.  In this study, 6-OHDA induced a TH-positive neuronal body volume 
loss of 13% in the SNpc, 21% in the VTA and 24% in the RRF.  The fact that the SNpc 
neurons in this study were relatively resistant to change in volume compared to those of 
the VTA and RRF is especially intriguing when considered in the context of the 
increased SNpc dopaminergic neuron loss compared to the VTA and RRF.  This may 
indicate that the ipsilateral RRF and VTA neurons are either more susceptible to 
decreased volume in early stages of the disease, or that there is relatively greater 
hypertrophy on the contralateral side- either of which could be indicators that these 
lesser-understood dopamine subpopulations may play an important role in the early 
disease process.  Alternatively, the ipsilateral SNpc neurons could be relatively 
hypertrophied in comparison to those of the VTA and RRF in order to compensate for 
the greater degree of neuronal loss in the SNpc.  The results of studies of the effects of 
PD on neuronal volume in the SN have been mixed (Rudow et al., 2008); but recent 
studies using stereological analysis have found that neuronal volume is decreased in 
Parkinson’s subjects, and that these findings are in contrast to hypertrophy of SN 
neurons found in normal aging (Rudow et al., 2008).  In the VTA, dopaminergic 
166	  
neuronal size was decreased in PD (McRitchie et al., 1997), as well as in a mouse 
chronic MPTP and probenecid model of PD.  In the chronic MPTP and probenecid 
model, the morphological sequelae of the neuroprotective effects of exercise were 
determined, and the MPTP-induced losses in the volume of VTA neurons were restored 
after 18 weeks of exercise.  This indicates that the morphology of VTA neurons is an 
effective indicator of neuronal response to neuroprotective treatments (Ahmad et al., 
2009a).  In the RRF, neuronal volume studies are lacking, but decreased A8 neuronal 
diameter was observed after intraventricular 6-OHDA in rats (Rodríguez et al., 2001).  
Because altered neuronal volume is associated with neurodegeneration (Iacono et al., 
2008; Rudow et al., 2008), it is a potentially useful endpoint for assessing damage 
induced by PD.  It has been proposed that neurons may undergo hypertrophy in initial 
reaction to stress, compensating for decreased function, and then may atrophy as the 
insult overwhelms the cell’s ability to function, resulting in ultimate degeneration (Rudow 
et al., 2008).  Of course, a limitation of post-mortem histology studies is the inability to 
determine whether the decreased volume is due to neuronal atrophy or to preferential 
loss of larger neurons.  In addition, in unilateral lesion studies, as well as in early PD, 
which usually presents with unilateral clinical motor signs (Hoehn and Yahr, 1967); the 
difference in neuronal size between the ipsilateral and contralateral sides could be due 
to relative compensatory hypertrophy of the intact neurons as discussed in detail in Aim 
3.  However, the ability to quantify that volumetric changes are occurring in a model of 
early PD presents a very useful tool for assessing early treatments and interventions, 
since neuronal size changes can be a sign of cellular dysfunction (Janson et al., 1991; 
Smith et al., 1999; Rudow et al., 2008).  
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 In addition to the changes to neuronal volume, the 6-OHDA lesion resulted in a 
nucleolar volume loss of 22% in the SNpc, a 22% loss in the VTA, and a 25% loss in the 
RRF.  A 16% decrease in nucleolar volume has also been observed in post-mortem PD 
brains (Mann and Yates, 1982).  Although studies on the effects of PD to the nucleolar 
volume are lacking in the VTA and RRF, it is interesting that in the present study, the 
nucleolar volume is decreased in both the VTA and the RRF, suggesting that alterations 
to nucleolar morphology in these regions may also be present in PD.  Although the 6-
OHDA lesion did not differentially alter nucleolar morphology in the SNpc, VTA and 
RRF, the A8 and A10 neurons, which are often less affected than the SN in PD, 
demonstrated similar nucleolar morphology changes to the SN.  This suggests that A8 
and A10 nucleolar morphology may be particularly susceptible to changes even early in 
PD, and could therefore be a useful assessment tool for developing and assessing early 
PD therapies.  Although histological snapshots of nucleolar volume are subject to the 
same limitations that are discussed above regarding neuronal volume, the nucleolus 
plays important role in the cellular response to the oxidative stressors implicated in PD, 
and it is likely that morphological changes to the nucleolus reflect the presence of 
neurodegeneration.  Thus nucleolar morphology studies offer promise as an important 
evaluation tool in early treatment assessment, in addition to their potential to lend 
insights to the etiology of the disease.  
The metabolism and protein expression of dopaminergic neuron subpopulations 
are known to be different, providing an explanation for the differential susceptibility in 
PD. Of course, the differences in the number of striatal projections from each region 
likely influence each subpopulation’s role in PD, but there are other potential factors 
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influencing subregion susceptibility.  For example, the dopamine transporter (DAT) is 
differentially expressed in dopaminergic subpopulations; thus it has been proposed that 
the neuronal subgroups have differential metabolism of dopamine, which may contribute 
to their susceptibility in PD (Gibb and Lees, 1991; Blanchard et al., 1994).  In support of 
this theory, the tissue content of melanin, a metabolite of tyrosine used an indicator of 
dopamine turnover, is differentially altered in dopaminergic subregions in Parkinson’s 
(Gibb, 1992). In addition, the protein calbindin is differentially expressed in 
dopaminergic subregions, being present in the less-affected dopaminergic regions in 
PD and therefore may be associated with neuroprotection (Gibb, 1992).  As the site of 
rRNA transcription, the nucleolus likely plays an important role in directing these factors 
in the differential susceptibility of dopaminergic neurons to PD, although further studies 
are needed to determine whether nucleolar changes in morphology are associated with 
changes in protein expression and metabolism; and whether these changes are a cause 
or an effect of Parkinson’ pathology.  In addition, the damage in PD is associated with 
oxidative damage, and the nucleolus is a key responder to oxidative stressors in the cell 
(Boulon et al., 2010; Hetman and Pietrzak, 2012). Thus the nucleoli in the midbrain 
dopaminergic subpopulations may play an important role in the differential response of 
these neurons to oxidative insult in PD.  Further studies are needed to determine the 
roles of the nucleolus in the differential effects of PD on midbrain dopaminergic 
subpopulations, but determining the changes to neuronal morphology is an important 
part of the discovery process.  
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7.4 Conclusions 
In conclusion, TH-AgNOR staining combined with stereological assessment 
indicated altered morphology of SNpc, VTA and RRF dopaminergic neurons in rats after 
a partial unilateral intrastriatal 6-OHDA.  The observed decreased nucleolar volume 
suggests that this organelle is differentially affected in the dopaminergic subpopulations, 
and elucidating the mechanisms of the differential susceptibility of dopaminergic 
neurons may lead to new insights into the pathophysiology of PD, as well as 
contributing to the development of diagnostics and treatments. 
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CHAPTER 8 
CONCLUSIONS AND FUTURE DIRECTIONS 
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8.1 Project Significance 
8.1.1 Introduction  
 Although we are approaching the 200th anniversary of the 1817 publication of 
James Parkinson’s An Essay on the Shaking Palsy describing the disease that would 
bear his name (Parkinson, 2002), there is still no cure for the progressive and 
debilitating neurodegenerative disorder of Parkinson’s disease (PD).  A major obstacle 
to advancements of treatments for the disease may be that much of our knowledge 
about PD comes from late-stage clinical assessment or post-mortem pathological 
studies.  Likewise, many animal models of PD have also focused on reproducing a 
severe loss of dopamine similar to that found in clinical PD (Deumens et al., 2002).  
However, in severe PD and PD models, too much damage may already have occurred 
to be able to assess the effects of neuroprotective treatments and preventative 
interventions. Thus it is crucial to the advancement of the treatment of PD that we learn 
about the pathological processes occurring in the early stages of the neurodegeneration 
caused by PD.  
 Although the etiology of idiopathic PD is still unknown, a number of 
environmental factors, including n-3 polyunsaturated fatty acid (n-3 PUFA) intake have 
been proposed to contribute to susceptibility to PD. Thus the first way in which this 
dissertation aimed to increase knowledge of early PD was to determine the effects of a 
Low n-3 PUFA diet on functional and neuronal morphology effects in the well-
established unilateral intrastriatal 6-hydroxydopamine (6-OHDA) rat model of PD.  The 
effect of an n-3 PUFA-deficient diet has been linked to human health throughout the 
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lifespan, including advanced age (Swanson et al., 2012).  Discoveries linking PUFA 
composition and the development of neurodegenerative disorders have the potential to 
change food regulation policies, the food industry, and standards of care in how nutrition 
is provided throughout life, thus this project has important long-term potential impact.   
 This project also elucidated the aspects of the pathobiological changes likely to 
be occurring in early PD was by determining the effects on dopaminergic number and 
neuronal and nucleolar morphology in the unilateral intrastriatal 6-OHDA model of early 
to moderate PD.  Because neuronal structure and function are interrelated, changes to 
neurons determined by morphology can be informative of disease processes and 
effects of treatments.  Changes to dopaminergic neuronal morphology occur in PD and 
PD models, and may be a useful index of the degree of disease progression and level 
of response to preventative and therapeutic treatments, as well as leading to better 
understanding of the processes occurring at the neuronal level in early PD.   
 In order to better treat and to cure PD, its etiology and the early stages of the 
disease need to be better understood, so that interventions take place before the 
damage becomes irreversible and untreatable.  This dissertation contributed to the body 
of knowledge of the effects of an early to moderate model of PD on the dopaminergic 
neurons involved in early PD, and future projects can be built on the studies performed 
in this dissertation to further expand our knowledge of the mechanisms of PD.  
8.1.2 Challenges in studying early PD  
In general, early PD presents a number of inherent challenges to the clinical or 
basic science researcher.  The most difficult problem to overcome may be the issue of 
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early detection of the development of the disease. The dopaminergic system is 
remarkable in its ability to compensate until quite a high threshold of damage has been 
reached.  It has been estimated that PD patients may first present with motor 
dysfunction when approximately 80% of the striatal dopamine has already been 
depleted (Calne and Langston, 1983).  Thus even if there is a stage at which clinicians 
can intervene and prevent PD, it is likely that patients presenting at such a late stage 
are beyond the threshold of intervention.  Since the motor deficits are a relatively late 
manifestation of dopaminergic deficit, earlier diagnostic signs need to be pursued, such 
as the affective, cognitive and sleep disturbances attributed to ventral tegmental area 
(VTA) and retrorubral field (RRF) function, in addition to more sensitive detection of 
substantia nigra pars compacta (SNpc)-derived motor deficits.   
 Because animal studies can be designed to control for the factors of aging and 
comorbidity, they provide a promising resource to better understand the etiology of PD 
and its early effects on neurons.  However, an additional challenge in detecting the early 
signs of PD in animal models is that they are of a nature that is often difficult to assess 
in animals. There is much debate on the best ways to detect and assess PD-relevant 
behavioral endpoints in animal models, and non-motor effects such as depression, 
cognitive changes and sleep disturbances are even more challenging to quantify 
(Potashkin et al., 2010; Rana et al., 2013).  For this reason, less subjective endpoints 
such as assessment of neuronal morphology are highly desirable for studying the 
effects of early PD models on dopaminergic neurons.   
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8.2 The effects of an n-3 PUFA-deficient dietary and breeding protocol on a 
unilateral intrastriatal 6-OHDA lesion model in rats 
8.2.1 Outcome of this project 
 In Aim 1, a diet and breeding protocol employing a Low n-3 diet from conception 
was used to achieve differing levels of n-3 PUFA brain composition in rats, and the 
effects of the diet on a unilateral intrastriatal 6-OHDA rat model of mild to moderate PD. 
There was no effect of diet on either amphetamine-stimulated rotational behavior or 
striatal dopamine depletion in either 1st or 2nd litter rats; or in SNpc dopaminergic 
neuronal number or morphology as quantified in 2nd litter rats by tyrosine hydroxylase 
silver nucleolar (TH-AgNOR) staining and stereological analysis.  These findings were 
in contrast to a previous study from our laboratory, which found a 33% decrease in TH-
positive SNpc neuronal number in unlesioned 2nd litter rats fed the Low n-3 diet.  In 
future studies, quantifying dopaminergic neurons from unlesioned animals would help 
confirm whether the neuronal deficits caused in the previous studies in unlesioned rats 
were replicable, or whether aspects of the 6-OHDA lesion changed the expected 
proportions of SNpc neurons between the Control and Low n-3 rats. 
8.2.2 Future studies of the effects of a Low n-3 PUFA diet and breeding protocol on the 
6-OHDA PD lesion model in rats 
 Future studies for determining the effects of Low n-3 PUFAs on early PD involve 
several approaches to determine the threshold of a potential effect of n-3 PUFAs in a 
mild to moderate PD model.  One potential reason there was no effect of diet on the 
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lesion is that the relatively mild lesion model we used may not have caused a threshold 
of neurotoxicity needed to reveal the protective effects of the n-3 PUFA deficient diet.  In 
addition, our moderate n-3 PUFA deficiency may not have created drastic n-3 PUFA 
deficits that may be needed to show a preferentially detrimental effect in 6-OHDA 
neurotoxicity.  Further studies are needed to fully understand the threshold of detectable 
effects caused by n-3 PUFA deficiency in models of early PD. Since there was no effect 
of differing dietary or brain DHA content in this study, in future studies it would be useful 
to use a range of DHA content in diets to establish a dose-responsive effect on the 
endpoints.  In addition, it would be interesting to introduce several different doses of 6-
OHDA, to see if there is a dose-response effect to the toxin, and whether n-3 PUFA 
status affects that.  Furthermore, since behavioral tests are sometimes unable to detect 
subtle differences between neuronal damage between treatment groups, it would be 
interesting to perform biochemical assays to gain more knowledge of what is occurring 
between the Control and Low n-3 brains.  Some informative endpoints to include would 
be measuring lipid peroxidation or DA-specific neurotoxic adducts (see Introduction), or 
to look at indicators of dopaminergic function like DAT, vesicular monoamine 
transporter, or TH expression, which serve as indirect indicators of dopamine function.  
In addition, even if our model created conditions too mild to find an effect in behavior or 
neuronal stereological analysis, the Low n-3 diet may be affecting PUFA-influenced 
factors implicated in the development and maintenance of dopaminergic neurons, such 
as Nurr1, and RXR (see Section 1.7.4.1 for more details).  Assessment of these factors 
in future studies will yield a more comprehensive perspective of the processes occurring 
in our PD model.  
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8.3 TH-AgNOR staining to determine the effects of a unilateral intrastriatal 6-
OHDA lesion in the substantia nigra 
8.3.1 Outcome of this project 
 In Aim 2, a method was developed using stereological techniques and the TH-
AgNOR staining method to quantify neuronal number and volume in the SNpc of adult 
Long-Evans rats after unilateral intrastriatal 6-OHDA lesion.  This was accomplished by 
using a modified TH-AgNOR staining method combined with stereological techniques, 
which enabled better visualization and potentially more accurate counting of the SNpc 
than has been possible in previous studies.  In the past, many studies have not 
quantified individual TH-positive neurons or quantified neuronal morphology, instead 
relying on biased 2D counting techniques to estimate changes to the neurons.  Our 
novel neuronal quantitation method using a combination of TH-AgNOR staining and 
stereological techniques overcame several obstacles that have previously stood 
between the researcher and easy, efficient quantitation of TH-positive neuronal number 
and morphology.  Stereological studies using traditional TH-only staining protocols 
developed for thin-section staining can result in over-staining and can obscure the 
nucleus, which is a necessary unique marker for the neuron as required by many 
stereological protocols.  With the modified TH-AgNOR stain, staining modifications were 
implemented by NeuroScience Associates to address both the requirements of 
stereology and the challenges of staining dopaminergic neurons.  Hydrochloric acid 
(HCl) was added to improve stain penetration into the tissue, the TH antibody 
concentration was decreased to avoid over-staining of dense dopaminergic neuron 
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populations, and the added AgNOR stain pigmented the nucleoli, so that they were 
visually distinct from the neuronal body and the nucleolus in most cases.  Furthermore, 
this method revealed new findings about the changes to SNpc dopaminergic neuronal 
morphology after a unilateral intrastriatal 6-OHDA lesion.  In Aim 2, a 20% decrease in 
SNpc regional volume and a 54% depletion of SNpc TH-positive neurons was 
determined after a single-site 12.5 µg 6-OHDA infusion.  There was also a 11% 
reduction in neuronal body volume in 6-OHDA lesioned rats, indicating that volume is a 
quantifiable morphological characteristic related to toxicity and subsequent 
neurodegeneration.  Our findings contributed to the SNpc morphological literature, and 
supported recent studies about changes to SNpc neuronal number and volume in PD 
(Rudow et al., 2008; Eriksen et al., 2009). This method, by making it much easier to 
determine individual cells and place markers on individual structures, improves the 
accessibility stereological studies in the SNpc for the average researcher.  This could 
result in greater numbers of higher-quality studies in the future literature, and 
consequently a better understanding of the neurodegenerative process in PD.  
 
8.4 Altered neuronal and nucleolar morphology in dopamine neurons following 6-
OHDA lesion in rats 
8.4.1 Outcome of this project 
 In this study, the unilateral intrastriatal 6-OHDA lesion caused decreased 
neuronal volume and nucleolar volume in the SNpc neurons in Aims 1,2 and 3, and in 
the SNpc, VTA and RRF in Aim 4.  The changes to neuronal and nucleolar volume 
found in this dissertation project indicate that the 6-OHDA toxin is causing an effect to 
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the neurons that is likely similar to what is occurring to the neurons in PD.  Although 
there is a lack of stereological nucleolar morphology studies in the VTA and the RRF, 
our findings in the 6-OHDA rat model support the findings in the SNpc in post mortem 
PD brains (Mann and Yates, 1982).  Our findings underscore the importance of 
understanding the morphological effects of PD models on dopamine neurons, and pave 
the way for future studies in this area.   
 
8.4.2 Determining morphological changes to dopamine neurons.   
 Morphology is a very useful tool that tells us about the physical characteristics of 
the neurons and allows us to compare them between the “normal” and diseases states.  
Morphological studies have been especially invaluable in neurodegenerative disease 
studies in humans because they allow determination of changes wrought by the disease 
process within the limits of only having a fixed post-mortem brain with which to study.  
The morphological findings in human subjects can be compared to complementary 
findings in animal disease models, and those morphological findings in animals can be 
correlated to other objectively determined behavioral, biochemical and anatomical 
analysis endpoints to extrapolate the mechanisms of the disease in humans from the 
findings in the animal models.  Since this dissertation has established an effective 
staining and stereological analysis method for quantification of dopaminergic neurons, 
and validated its ability to detect differences induced in dopaminergic neurons after a 
mild to moderate 6-OHDA lesion, the obvious next step is to expand the use of this 
method to determine the dysfunction of dopamine neurons in other studies in animals 
and in humans.  
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8.4.3 General challenges in future morphology studies of dopaminergic neurons 
 In designing future morphological experiments on midbrain dopaminergic 
neurons, there are a number of challenges to be considered.  First, although the A8, A9 
and A10 dopamine neurons are classified by their geographical location and their 
proposed function based on the majority of their projections, in reality these anatomical 
distinctions may be fairly arbitrary, since the projections and consequent functions have 
some overlap (Deutch et al., 1988; German and Manaye, 1993; Ferreira et al., 2008; Da 
Cunha et al., 2009; Hosp et al., 2011) (see Section 1.5 for a detailed description of 
dopaminergic subgroups).  The complexity of the connections in the midbrain 
dopaminergic system, paired with the fact that the borders of the regions can be very 
difficult to distinguish based on relative anatomical landmarks, means that accurate, 
standard and consistent regional definition is crucially important to meaningful and 
robust morphological studies in both animal models and in humans.  
 In addition, the dopaminergic neurons affected in PD are not exempt from the 
complex and potentially confounding effects of natural aging and comorbid conditions 
on neuronal morphology. In order to understand how the neurons are different in PD, 
we need to know more about what happens to neuronal morphology in natural aging, as 
well as in other diseases. While there have been a number of studies on SNpc neuronal 
morphology in aging in both humans and in animals (Carvey et al., 2006b; Rudow et al., 
2008), the effects of aging on neuronal morphology in other dopaminergic subregions 
remain largely unknown.  Also, since PD patients often have other comorbidities 
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common to advanced age, such as vascular disease and diabetes, these factors should 
be considered when designing clinical trials and conducting post-mortem studies.  
8.4.4 Future studies of dopaminergic neuronal and nucleolar volume 
 The studies performed in this dissertation project found that a unilateral 
intrastriatal 6-OHDA lesion alters neuronal and nucleolar volume in the SN, VTA and in 
the RRF dopaminergic neurons in the rat, although the exact mechanisms causing the 
change remain to be determined.  Changes to neuronal volume, whether hypertrophy or 
atrophy, signal a functional response of the neurons to a stimulus or stressor.  It has 
been proposed that in normal aging, the dopaminergic SN neurons decrease in number 
but hypertrophy in size, in order to compensate for reduced numbers (Rudow et al., 
2008).  In PD, however, the SN neurons have been found to be smaller in volume 
(Iacono et al., 2009), which suggest several possible explanations.  Either the larger SN 
neurons are selectively susceptible, or the neurons are atrophied in response to the 
stressors in PD overwhelming the neurons’ capability to maintain their size. Likewise, 
changes to nucleolar size are associated with nucleolar function, including increased 
rRNA transcription (Boulon et al., 2010), but how the nucleolar size or volume is related 
to the continuum of progressive neurodegenerative changes is still unknown.  In future 
studies, the staining and stereological methods employed here could be used to 
characterize the neuronal and nucleolar morphology neurons in post-mortem human 
studies including both mild and severe PD cases, and in animal PD model studies to 
characterize the effects of various doses of 6-OHDA at multiple time points.  In addition, 
it will be important to determine stereologically assessed nucleolar morphology in 
unlesioned control animals as well as in normal aging, to be able to compare the normal 
181	  
nucleolar morphology to the changes throughout the course of the disease.  Finally, 
although morphology is an invaluable tool in assessing the changes that have occurred 
to the neurons as a result of PD or a PD model lesion, morphological studies alone 
cannot establish causality of the changes.  Thus, in future studies it would be 
informative to include additional animals designated for analysis of biochemical 
endpoints informative of neuronal maintenance and survival status and nucleolar 
function.  Some relevant endpoints for assessment would be dopaminergic neuronal 
survival and maintenance factors like brain-derived neurotrophic factor and Nurr1; or 
nucleolar assessment endpoints like nucleophosmin nucleolar integrity staining.   
 
8.5 Differentially altered neuronal number and morphology in midbrain 
dopaminergic subregions after a unilateral intrastriatal 6-OHDA Lesion 
8.5.1 Outcome and relevance of this project 
 This dissertation project determined that the TH-positive neuronal number and 
TH-AgNOR-positive neuronal volume and nucleolar volume were differentially affected 
in different dopaminergic subregions in a unilateral intrastriatal 6-OHDA model of the rat 
(see Chapter 7). Notably, this study was the first to our knowledge to determine that the 
neuronal and nucleolar volume of the dopaminergic neurons was decreased in the VTA 
and the RRF after unilateral intrastriatal 6-OHDA lesion.  These novel findings are 
exciting because the implications of the functional differences of these regions in PD 
have recently come into focus as a potential source of insight into the etiology of the 
early and non-motor aspects of the disease. Importantly, how the morphology of these 
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regions is differentially affected may yield more knowledge about the pathogenesis of 
PD and lead to assessment methods for treatments and neuroprotective interventions.   
 
8.5.2 General challenges in future studies of dopaminergic subregions 
 The current study has considerably added to our knowledge about the different 
dopaminergic subregions in early PD.  However, in order for these studies to be 
confirmed as reflective of what is occurring in PD, we need to know more about the 
roles that these different regions play in early PD.  Although the role of the SN and its 
impact on motor effects has been extensively characterized in PD and in animal 
models, little is yet known about the roles of other dopaminergic neuronal populations in 
PD.  In general, if PD studies include any histological analysis of dopaminergic regions 
or neurons, it is usually in only the SN.  Future studies in humans and in animal PD 
models need to include other dopaminergic subregions in addition to the SN, so we can 
understand how the morphology of the dopamine neurons is affected during the course 
of the disease in comparison with the SN.    
8.5.3 Future directions in animal PD models 
 This dissertation project established the differential effects of a unilateral 
intrastriatal 6-OHDA lesion on the neuronal number and neuronal and nucleolar 
morphology in TH-AgNOR-strained neurons in the SNpc, VTA and RRF.  In the future, it 
would be interesting to use the TH-AgNOR staining method and our PD model to 
determine the neuronal morphology of dopaminergic neurons in the SN, VTA and RRF 
in unlesioned control animals, aged controls, and with varied doses of 6-OHDA to gain a 
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more comprehensive understanding of the differential effects of the lesion on the 
dopaminergic subpopulations.  
 In addition, it would be interesting to establish the effects of the Low n-3 PUFA 
diet used in Aim 1 on other dopaminergic brain regions, such as the VTA and the RRF, 
after 6-OHDA lesion. Since n-3 PUFAs have been implicated in the development and 
maintenance of the SNpc dopaminergic neurons, it stands to reason that they may also 
be crucial to optimal function of other dopaminergic neuronal subtypes.  A previous 
study in our laboratory found the VTA in unlesioned rats fed the Low n-3 diet to have a 
TH-positive neuronal loss of about 34% (Ahmad et al., 2008).  However, few studies 
have determined the effects of n-3 PUFA status on the maintenance of survival of VTA 
and RRF neurons either in intact rats or in PD models.  Since the neurons in these 
regions are implicated in early PD, at which point dietary interventions might be able to 
elicit the most benefit, it is important to know more about how PUFA status affects these 
neurons.  
 
8.5.4 Future directions in post-mortem PD brains 
 There is currently a dearth of comparative stereological studies of the midbrain 
dopaminergic subpopulations in humans, and such studies in the VTA and RRF of PD 
patients are particularly lacking. Complementary high-quality stereological 
morphological studies of the neurons in dopaminergic subpopulations affected by PD 
are a crucial next step in validating the relevance of the progress being made our 
knowledge of dopaminergic morphology in animal models of PD.  While the novel TH-
AgNOR staining protocol used in this dissertation project will undoubtedly improve the 
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quality and ease of execution of stereological studies in human PD post-mortem brains, 
challenges may arise regarding differences in the tissue quality and preparation (i.e. 
perfusion in paraformaldehyde vs. immersion fixation) between the animal PD model 
specimens and post-mortem PD brains.  In addition, in future studies of the 
dopaminergic subpopulations in humans, it is especially important that the stage of both 
clinical and neuropathological disease advancement be determined so that the 
morphological effects of the disease on the neurons throughout the course of PD may 
be determined.  
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